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Abstract 
Colorectal cancer is the 4
th
 most common cancer in the UK and the second commonest cause 
of cancer death. Whilst mortality rates from colorectal cancer haven fallen over the last 2 
decades, around 40% of those diagnosed with colorectal cancer will die from their disease. 
Surgery currently remains the only chance of cure. Around 10% of patients present as an 
emergency with perforation, obstruction or bleeding. Outcomes from these emergency 
operations are substantially worse than from elective procedures.   
The presence of a systemic inflammatory response pre-operatively is now widely recognised 
as a predictor of disease progression and poor outcomes, both long and short term, regardless 
of tumour stage in those with colorectal cancer. Numerous scoring systems that measure 
various components of the systemic inflammatory response have been documented, the most 
commonly used are the modified Glasgow Prognostic Score (mGPS) and the Neutrophil-
Lymphocyte Ratio (NLR). The NLR has the advantage of using 2 components of the 
differential white cell count, which is routinely measured in surgical and oncological practice, 
whereas CRP is less commonly routinely measured. However, studies utilising the NLR have 
used a variety of thresholds, making comparison of the results from study to study difficult. 
Whether one of the components of the NLR is more important than the other remains to be 
seen and indeed whether there is a more optimal score that utilises the white cell count is not 
clear. To date no work has examined similar scoring systems in the post-operative period. 
The present thesis aims to examine the impact of the innate immune response, through such 
systemic inflammation based scoring systems, on patients undergoing surgery for colorectal 
cancer. Furthermore, it analyses the nature of the inflammatory response in the post-operative 
period in order to ascertain whether similar scoring systems may be of clinical utility. 
Chapter 1 provides an overview of colorectal cancer, its presentation and treatment and its 
known determinants of outcomes. Furthermore, the immune response to injury and post-
operative inflammatory response are discussed. Chapter 2 documents a survey of clinicians 
who have an interest in systemic inflammation. The survey asks the participants whether they 
routinely measure systemic inflammation, to what purpose and which scoring system they 
prefer. Unsurprisingly, the majority of participants use these scoring systems for research 
purposes only with an even split in terms of which scoring system they prefer to use. Their 
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use in clinical practice remains small but their use in some oncological studies may signify a 
step towards their incorporation into clinical practice in the future.   
Chapter 3 presents data from a cohort of patients whom have undergone surgery for 
colorectal cancer with pre-operative differential white cell counts in order to determine 
whether any of the white cell count components are important in determining long term 
outcomes. Only the neutrophil count was independently associated with poor long term 
survival in patients undergoing surgery for colorectal cancer. These results highlight the 
importance of both the neutrophil count and the innate immune system in outcomes in 
patients with colorectal cancer. 
In chapter 4, a cohort of colorectal cancer patients and a cohort of patients with cancer were 
utilised in order to determine whether a pre-operative systemic inflammation based score 
using the neutrophil and platelet count was capable of predicting survival in these patients. 
This was based on the fact that recent in-vitro work had suggested that a critical checkpoint 
early in the inflammatory process involved the interaction between neutrophils and activated 
platelets. The subsequent score – the neutrophil platelet score (NPS)- was shown to be 
capable of predicting survival, independent of TNM stage, in patients with colorectal cancer 
and had prognostic value in patients with a variety of other tumours. 
Chapter 5 describes a systematic review of studies analysing the effect of various surgical 
procedures on markers of the systemic inflammatory response. Only CRP and IL-6 were 
found to represent the degree of surgical trauma and invasiveness of the procedure. This work 
provides a framework for analysing the post-operative SIR and how it is affected by surgery 
and peri-operative programmes such as ERAS that are reported to improve length of stay and 
sort term outcomes following surgery for colorectal cancer. 
It was of interest in the previous chapter that white cell count did not reflect the degree of 
surgical trauma. Whether individual white cell components act differently and represent the 
degree of surgical trauma was unclear. Chapter 6 sought to clarify this by analysing, in a 
cohort of patients undergoing surgery for colorectal cancer, the differential white cell count 
and whether it reflected the magnitude of injury and short term outcomes. Only the neutrophil 
count reflected the magnitude of trauma and development of infective complications. 
However, it remains inferior to other well established markers such as CRP.      
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Whilst the pre-operative systemic inflammatory response is a well-recognised determinant of 
both long term outcomes and short term outcomes such as infective complications, little work 
has focussed on the post-operative systemic inflammatory response. In chapter 7, the 
possibility of the post-operative systemic inflammatory response also being capable of 
predicting both short and long term outcomes was explored in a cohort of patients whom had 
undergone surgery for colorectal cancer. A score using the combination of post-operative 
CRP and albumin was created and called the post-operative Glasgow Prognostic Score 
(poGPS). In this cohort of patients, this score predicted the development of infective 
complications and also long term survival. Given that these results would indicate that a 
reduction in the post-operative systemic inflammatory response would improve outcomes, the 
clinicopathological factors that may alter this post-operative systemic inflammatory response 
should be investigated as some of these may be modifiable and may therefore improve 
outcomes following surgery for colorectal cancer. 
ERAS programmes have changed perioperative management and are reported to be beneficial 
in reducing length of hospital stay and post-operative complications. It is purposed that this is 
due to the reduction on the surgical stress response. However it is unclear which of the 
components of an ERAS programme are responsible for this reduction in the systemic 
inflammatory response. Chapter 8 describes a systematic review analysing studies of the 
various ERAS components and whether there is objective evidence of a reduction in the SIR, 
evidenced by a reduction in either CRP or IL-6. Only laparoscopic surgery was reported to 
reduce the SIR in these studies, all the remaining components had either little or no evidence 
of a reduction in the SIR. Further work is required to ascertain whether any of the other 
components also reduce the SIR. This will hopefully allow streamlining of the ERAS process 
in order to improve outcomes.  
Specific clinicopathological factors that may alter the post-operative systemic inflammatory 
response are examined in chapter 9. Common clinicopathological factors were examined 
using the poGPS to ascertain which factors resulted in increased poGPS scores. In those 
patients undergoing elective surgery, year of operation, ASA grade, pre-operative systemic 
inflammation, and tumour site were associated with increased poGPS scores. These findings 
may have important clinical consequences as whilst factors such as ASA grade and BMI are 
not readily modifiable in the short time frame between diagnosis and surgery, pre-operative 
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inflammation could potentially be targeted with anti-inflammatory medication. However, 
more work is required to identify the specific agent and the timing of its delivery. 
In chapter 10, a cohort of patients undergoing surgery for colorectal cancer in whom there 
was prescription information available. Patients prescribed aspirin or statin were identified 
and their post-operative inflammatory response and short term outcomes were compared to 
those not prescribed aspirin or statins. In 446 patients, neither aspirin nor statin prescription 
was associated with a reduction in the post-operative systemic inflammatory response. 
Therefore, it would appear that these medications will not be useful in moderating the 
systemic inflammatory response following surgery. However, further work is required to 
identify which medications will be of benefit and should take the format of a randomised 
controlled trial. 
Chapter 11 provides a summary of the main findings of this thesis, discussed their 
implications and provides some discussion surrounding future work in this field.                      
 
  
5 
 
Table of Contents 
Abstract ...................................................................................................................................... 1 
List of Tables ............................................................................................................................. 9 
List of Figures .......................................................................................................................... 12 
Acknowledgement ................................................................................................................... 14 
Author’s Declaration ................................................................................................................ 15 
Publications .............................................................................................................................. 16 
Presentations ............................................................................................................................ 18 
Dedication ................................................................................................................................ 20 
Definitions/Abbreviations ........................................................................................................ 21 
1 Introduction ...................................................................................................................... 24 
1.1 Epidemiology of Colorectal Cancer .......................................................................... 24 
1.2 Colorectal Cancer Carcinogenesis Pathways ............................................................ 26 
1.2.1 Adenoma-Carcinoma Sequence ......................................................................... 26 
1.2.2 Microsatellite Instability .................................................................................... 27 
1.2.3 Hypermethylation .............................................................................................. 27 
1.3 Aetiology of Colorectal Cancer................................................................................. 28 
1.3.1 Sporadic Colorectal Cancer ............................................................................... 28 
1.3.2 Hereditary Colorectal Cancer ............................................................................ 32 
1.4 Clinical Presentation ................................................................................................. 34 
1.4.1 Symptomatic Primary Disease ........................................................................... 34 
1.4.2 Bowel Screening Programme ............................................................................ 34 
1.4.3 Metastatic Disease ............................................................................................. 35 
1.5 Investigations and Diagnosis ..................................................................................... 37 
1.5.1 Blood Tests ........................................................................................................ 37 
1.5.2 Endoscopic Evaluation....................................................................................... 37 
1.5.3 Computed Tomography ..................................................................................... 38 
1.5.4 Magnetic Resonance Imaging ............................................................................ 38 
1.5.5 Staging of Colorectal Cancer ............................................................................. 38 
1.5.6 Multi-disciplinary Team Meetings .................................................................... 40 
1.6 Management of Colorectal Cancer ............................................................................ 41 
1.6.1 Surgery ............................................................................................................... 41 
1.6.2 Enhanced Recovery after Surgery (ERAS)........................................................ 43 
1.6.3 Neoadjuvant Therapy ......................................................................................... 43 
1.6.4 Adjuvant Therapy .............................................................................................. 43 
1.6.5 Palliative Therapy .............................................................................................. 44 
6 
 
1.7 Prognostic Factors ..................................................................................................... 45 
1.7.1 Duke’s Classification ......................................................................................... 45 
1.7.2 TNM Classification ............................................................................................ 45 
1.7.3 Grade of Tumour................................................................................................ 46 
1.7.4 Venous Invasion................................................................................................. 46 
1.7.5 Perineural Invasion ............................................................................................ 47 
1.7.6 Peritoneal Involvement ...................................................................................... 47 
1.7.7 Tumour Perforation ............................................................................................ 47 
1.7.8 Margin Involvement........................................................................................... 47 
1.7.9 Petersen Index .................................................................................................... 48 
1.7.10 Lymph Node Ratio ............................................................................................. 48 
1.7.11 Tumour Necrosis ................................................................................................ 48 
1.8 Inflammation and Cancer .......................................................................................... 49 
1.8.1 Host Response .................................................................................................... 49 
1.8.2 The Tumour Microenvironment ........................................................................ 51 
1.8.3 The Local Inflammatory Response .................................................................... 52 
1.8.4 The Systemic Inflammatory Response .............................................................. 53 
1.8.5 Systemic Inflammation Based Prognostic Scores.............................................. 55 
1.9 The Physiological Response to Surgery .................................................................... 57 
1.9.1 The Surgical Stress Response ............................................................................ 57 
1.9.2 The Role of Enhanced Recovery after Surgery (ERAS) ................................... 58 
1.9.3 Complications Following Surgery for Colorectal Cancer ................................. 59 
1.10 Aims of Thesis ....................................................................................................... 61 
2 A survey of attitudes towards the clinical application of systemic inflammation based 
prognostic scores in cancer ...................................................................................................... 62 
2.1 Introduction ............................................................................................................... 62 
2.2 Methods ..................................................................................................................... 64 
2.3 Results ....................................................................................................................... 65 
2.4 Discussion ................................................................................................................. 67 
3 Neutrophil count is the most important prognostic component of the differential white 
cell count in patients undergoing elective surgery for colorectal cancer ................................. 78 
3.1 Introduction ............................................................................................................... 78 
3.2 Methods ..................................................................................................................... 79 
3.2.1 Patients ............................................................................................................... 79 
3.2.2 Statistical Analysis ............................................................................................. 79 
3.3 Results ....................................................................................................................... 80 
3.4 Discussion ................................................................................................................. 82 
7 
 
4 The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal 
cancer and a variety of common cancers ................................................................................. 91 
4.1 Introduction ............................................................................................................... 91 
4.2 Methods ..................................................................................................................... 92 
4.2.1 Patients ............................................................................................................... 92 
4.2.2 Statistical Analysis ............................................................................................. 93 
4.3 Results ....................................................................................................................... 94 
4.4 Discussion ................................................................................................................. 97 
5 Routine Clinical Markers of the Magnitude of the Systemic Inflammatory Response 
Following Elective Surgery: A Systematic Review............................................................... 108 
5.1 Introduction ............................................................................................................. 108 
5.2 Methods ................................................................................................................... 110 
5.3 Results ..................................................................................................................... 111 
5.3.1 Study Selection Process ................................................................................... 111 
5.3.2 Markers of the Systemic Inflammatory Response ........................................... 111 
5.4 Discussion ............................................................................................................... 115 
6 Comparison of the components of a white cell count and acute phase proteins as markers 
of the magnitude of injury and the development of infective complications following elective 
surgery for colorectal cancer .................................................................................................. 134 
6.1 Introduction ............................................................................................................. 134 
6.2 Methods ................................................................................................................... 135 
6.2.1 Patients ............................................................................................................. 135 
6.2.2 Statistical Analysis ........................................................................................... 136 
6.3 Results ..................................................................................................................... 137 
6.4 Discussion ............................................................................................................... 139 
7 A post-operative systemic inflammation score predicts short and long term outcomes in 
patients undergoing surgery for colorectal cancer ................................................................. 153 
7.1 Introduction ............................................................................................................. 153 
7.2 Methods ................................................................................................................... 155 
7.2.1 Patients ............................................................................................................. 155 
7.2.2 Statistical Analysis ........................................................................................... 156 
7.3 Results ..................................................................................................................... 157 
7.3.1 Test Cohort....................................................................................................... 157 
7.3.2 Validation Cohort............................................................................................. 157 
7.3.3 Overall Cohort ................................................................................................. 158 
7.4 Discussion ............................................................................................................... 159 
8 Enhanced Recovery after Surgery (ERAS); which components, if any, impact on the 
systemic inflammatory response following colorectal surgery? – A systematic review ....... 173 
8 
 
8.1 Introduction ............................................................................................................. 173 
8.2 Methods ................................................................................................................... 175 
8.3 Results ..................................................................................................................... 177 
8.3.1 Assessment of included study validity ............................................................. 177 
8.3.2 Enhanced Recovery after Surgery (ERAS) protocols ...................................... 177 
8.4 Discussion ............................................................................................................... 185 
9 Clinicopathological determinants of an elevated systemic inflammatory response 
following elective potentially curative resection for colorectal cancer ................................. 195 
9.1 Introduction ............................................................................................................. 195 
9.2 Methods ................................................................................................................... 197 
9.2.1 Patients ............................................................................................................. 197 
9.2.2 Statistical Analysis ........................................................................................... 198 
9.3 Results ..................................................................................................................... 199 
9.4 Discussion ............................................................................................................... 201 
10 Pre-operative aspirin and statin prescription and the post-operative systemic 
inflammatory response following surgery for colorectal cancer ........................................... 209 
10.1 Introduction ......................................................................................................... 209 
10.2 Methods ............................................................................................................... 211 
10.2.1 Patients ............................................................................................................. 211 
10.2.2 Statistical Analysis ........................................................................................... 211 
10.3 Results ................................................................................................................. 213 
10.4 Discussion ............................................................................................................ 215 
11 Conclusions .................................................................................................................... 223 
11.1 Future Research ................................................................................................... 231 
References .............................................................................................................................. 234 
 
 
  
9 
 
List of Tables 
Table 1.1 TNM staging system for colorectal cancer .................................................... 39 
Table 1.2 Dukes stage and 5-year survival in patients with colorectal cancer ............. 45 
Table 1.3 Comparison of TNM Staging and Dukes Classification ................................ 46 
Table 2.1 Survey of systemic inflammation based prognostic scores in cancer ............ 71 
Table 3.1 Clinicopathological characteristics, components of the differential white cell 
count and survival in patient undergoing elective resection for colorectal 
cancer ............................................................................................................. 84 
Table 3.2  Multivariate analysis of clinicopathological factors and components of 
differential white cell count following elective, potentially curative surgery for 
colorectal cancer ........................................................................................... 85 
Table 3.3  Clinicopathological characteristics, components of the differential white cell 
count and survival in patients undergoing elective resection for node negative 
colon cancer ................................................................................................... 86 
Table 4.1 The neutrophil-platelet score (NPS) .............................................................. 99 
Table 4.2 The relationship between Neutrophil-Platelet Score (NPS) and 
clinicopathological characteristics in patients with colorectal cancer ....... 100 
Table 4.3 The relationship between the NPS and 5 year cancer-specific survival in 
patients undergoing curative resection of colorectal cancer ...................... 101 
Table 4.4 The relationship between NPS and 5 year overall survival in patients 
undergoing curative resection of colorectal cancer .................................... 103 
Table 4.5 The relationship between NPS and patient demographics in an incidentally 
sampled cohort of patients with cancer ....................................................... 105 
Table 5.1 The timing and magnitude of cortisol concentrations following elective surgery
...................................................................................................................... 122 
Table 5.2 The timing and magnitude of interleukin-6 (IL-6) concentrations following 
elective surgery ............................................................................................ 124 
Table 5.3 The timing and magnitude of white cell count (WCC) concentrations following 
elective surgery ............................................................................................ 128 
Table 5.4 The timing and magnitude of C-reactive protein (CRP) concentrations 
following elective surgery ............................................................................ 130 
Table 6.1 Clinicopathological characteristics of patients undergoing elective resection 
for colorectal cancer .................................................................................... 142 
10 
 
Table 6.2 Changes in the concentrations of components of the differential white cell count 
and acute phase proteins in patients undergoing elective surgery for colorectal 
cancer ........................................................................................................... 143 
Table 6.3 Components of the differential white cell count and acute phase proteins in 
patients developing no complications and infective complications following 
open and laparoscopic surgery for colorectal cancer ................................. 146 
Table 6.4 Correlations between the neutrophil count and CRP concentrations on post-
operative days 1-4 ........................................................................................ 148 
Table 6.5 Correlations between neutrophil count and albumin concentrations on post-
operative days 1-4 ........................................................................................ 148 
Table 7.1 The pre-operative modified Glasgow Prognostic Score (mGPS) and the post-
operative Glasgow Prognostic Score (poGPS)............................................ 162 
Table 7.2 Comparison of clinicopathological characteristics in both the test and 
validation cohort .......................................................................................... 163 
Table 7.3 The clinical characteristics, pre-operative systemic inflammation and post-
operative complications in the test cohort ................................................... 164 
Table 7.4 Clinical characteristics and post-operative complications of patients 
undergoing resection for colon cancer in test cohort .................................. 166 
Table 7.5 Clinical characteristics and post-operative complications of patients 
undergoing resection of colorectal cancer in the validation cohort ............ 168 
Table 7.6 The day 3 and day 4 poGPS and the development of post-operative 
complications in patients undergoing resection for colorectal cancer in both 
test and validation cohorts ........................................................................... 170 
Table 7.7 The relationship between clinicopathological factors and the pre- and post-
operative systemic inflammatory response in patients undergoing resection for 
colorectal cancer ......................................................................................... 171 
Table 7.8 The relationship between clinicopathological factors and pre- and post-
operative systemic inflammatory response in patients undergoing resection for 
colon cancer ................................................................................................. 172 
Table 8.1 Components of Enhanced Recovery after Surgery – ERAS Group 
Recommendations ........................................................................................ 188 
Table 8.2 Summary of included studies for each ERAS component and the marker of the 
systemic inflammatory response analysed ................................................... 191 
11 
 
Table 9.1 Clinicopathological characteristics of patients undergoing elective, potentially 
curative resection for colorectal cancer ...................................................... 204 
Table 9.2 Relationship between clinicopathological characteristics and day 3 & 4 poGPS 
in patients undergoing elective, potentially curative surgery for colorectal 
cancer ........................................................................................................... 205 
Table 9.3 Binary logistic regression of clinicopathological factors associated with low 
poGPS (poGPS 0) versus high poGPS (poGPS 2) on post-operative day 3.207 
Table 9.4 Binary logistic regression of clinicopathological factors associated with low 
poGPS (poGPS 0) versus high poGPS (poGPS 2) on post-operative day 4.208 
Table 10.1 Clinicopathological characteristics of patients undergoing surgery for 
colorectal cancer ......................................................................................... 217 
Table 10.2 The relationship between aspirin and statin use, the post-operative systemic 
inflammatory response and post-operative complications in patients 
undergoing potentially curative resection of stage I-III colorectal cancer . 219 
Table 10.3 The relationship between aspirin and statin use, the post-operative systemic 
inflammatory response and post-operative complications in patients 
undergoing curative resection of stage I-III colorectal cancer with an mGPS ≥1
...................................................................................................................... 220 
Table 10.4 The relationship between aspirin and statin use, clinicopathological 
characteristics and the day 3 poGPS in patients undergoing potentially curative 
resection of stage I-III colorectal cancer ..................................................... 221 
Table 10.5 The relationship between aspirin and statin use, clinicopathological 
characteristics and the day 4 poGPS in patients undergoing potentially curative 
resection of stage I-III colorectal cancer ..................................................... 222 
 
12 
 
List of Figures 
Figure 1.1 The 20 Most Common Cancers in the UK 2014 ............................................ 24 
Figure 1.2 Adenoma–carcinoma sequence model for chromosomal instability in colorectal 
cancer ............................................................................................................. 26 
Figure 1.3 Therapeutic Targeting of the Hallmarks of Cancer ....................................... 31 
Figure 1.4 Overview of the Scottish National Bowel Screening Programme ................. 35 
Figure 2.1 Responses to survey question 1. ..................................................................... 72 
Figure 2.2 Responses to survey question 3. ..................................................................... 73 
Figure 2.3 Responses to survey question 4. ..................................................................... 74 
Figure 2.4 Responses to survey question 5. ..................................................................... 75 
Figure 2.5 Responses to survey question 7. ..................................................................... 76 
Figure 2.6 Responses to survey questions 8 and 9. ......................................................... 77 
Figure 3.1 Kaplan Meier plots of TNM stage and components of the differential WCC and 
cancer-specific survival in total cohort ......................................................... 87 
Figure 3.2 The relationship between the neutrophil count and the NLR (rs = 0.633, p < 
0.001) in patients undergoing elective surgery for colorectal cancer with node 
negative disease ............................................................................................. 88 
Figure 3.3 The relationship between the lymphocyte count and the NLR (rs = 0.689, 
p<0.001) in patients undergoing elective surgery for colorectal cancer with 
node negative disease .................................................................................... 89 
Figure 3.4 Kaplan Meier plot of optimised Glasgow Prognostic Score (oGPS) and cancer 
specific survival in total cohort...................................................................... 90 
Figure 4.1 The relationship between NPS and cancer-specific survival in all patients in the 
GIOS cohort. ................................................................................................ 106 
Figure 4.2 The relationship between the NPS and cancer-specific survival in each tumour 
site. ............................................................................................................... 107 
Figure 5.1 Flow chart demonstrating the process used for study selection .................. 121 
Figure 6.1 The magnitude of the neutrophil count, CRP and albumin in both open and 
laparoscopic elective colorectal cancer resection ....................................... 149 
Figure 6.2 The magnitude of the neutrophil count, CRP and albumin in patients developing 
infective complications and no complications following elective colorectal 
cancer resection ........................................................................................... 150 
13 
 
Figure 6.3 (a) ROC curve of the day 3 neutrophil count and development of infective 
complications and (b) ROC curve of the day 3 CRP and the development of 
infective complications................................................................................. 151 
Figure 6.4 (a) ROC curve of the day 4 neutrophil count and development of infective 
complications and (b) ROC curve of the day 4 CRP and the development of 
infective complications................................................................................. 152 
Figure 8.1 PRISMA flowchart demonstrating study selection ...................................... 190 
Figure 8.2 Cochrane risk of bias summary ................................................................... 194 
 
  
14 
 
Acknowledgement 
I am grateful to the following people for their continual encouragement, support and guidance 
throughout my research both on a day to day basis whilst based in the department of 
academic surgery and also in writing and completing my thesis: 
- Professor Donald McMillan (Academic Unit of Surgery, University of Glasgow, 
Glasgow Royal Infirmary) 
- Professor Paul Horgan (Academic Unit of Surgery, University of Glasgow, Glasgow 
Royal Infirmary) 
- Mr Campbell Roxburgh (Academic Unit of Surgery, University of Glasgow, Glasgow 
Royal Infirmary) 
- The consultant colorectal surgeons at Glasgow Royal Infirmary 
  
15 
 
Author’s Declaration 
The work presented in this thesis was undertaken during a period of research between 2013 
and 2015 in the Academic Unit of Surgery at Glasgow Royal Infirmary. The work has been 
completed whilst working as a Specialty Registrar in General Surgery in the West of 
Scotland.  
 
I declare that the work presented in this thesis was undertaken by myself, except where 
indicated below:  
 Creation of survey questions and survey concept by Mr Campbell Roxburgh (Chapter 
2) 
 Assistance with data collection by Ms Michelle Ramanathan, Mr James Park and Mr 
Stephen McSorley  
 Analysis of data from database of patients with a range of common cancers and their 
pre-operative blood test results by Mr Michael Proctor  
 Collection of aspirin and statin usage data by Shoukee Ng (Chapter 10) 
  
16 
 
Publications 
The work presented in this thesis has resulted in following publications: 
1. A survey of attitudes towards the clinical application of systemic inflammation based 
prognostic scores in cancer.                            
Watt DG, Roxburgh CS, White M, Chan JZ, Horgan PG, McMillan DC.                   
Med of Inflamm 2015; 2015:842070. 
2. Neutrophil count is the most important prognostic component of the differential white 
cell count in patients undergoing elective surgery for colorectal cancer.                       
Watt DG, Martin JC, Park JH, Horgan PG, McMillan DC.                                  
Am J Surg 2015; 210 (1): 24-30. 
3. The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal 
cancer and a variety of common cancers.                       
Watt DG, Proctor MJ, Park JH, Horgan PG, McMillan DC.                       
PLOS One 2015; 10 (11): e0142159. 
4. Routine clinical markers of the systemic inflammatory response after elective 
operation: a systematic review.                 
Watt DG, Horgan PG, McMillan DC.              
Surgery 2015; 157 (2): 362-380. 
5. A Postoperative Systemic Inflammation Score Predicts Short- and Long-Term 
Outcomes in Patients Undergoing Surgery for Colorectal Cancer.                             
Watt DG, McSorley ST, Park JH, Horgan PG and McMillan DC.                                         
Ann Surg Oncol 2017; 24(4): 1100-1109 
6. Enhanced Recovery After Surgery: Which components, if any, impact on the systemic 
inflammatory response following colorectal surgery? A systematic review 
Watt DG, McSorley ST, Horgan PG, McMillan DC.                                
Medicine (Baltimore) 2015; 94 (36): e1286. 
17 
 
7. Clinicopathological Determinants of an Elevated Systemic Inflammatory Response 
Following Elective Potentially Curative Resection for Colorectal Cancer. 
Watt DG, Ramanathan ML, McSorley ST, Walley K, Park JH, Horgan PG, McMillan 
DC.                             
Ann Surg Oncol 2017; 24 (9): 2588-2594. 
 
8. Comment on “Prognostic performance of inflammation-based prognostic indices in 
patients with resectable colorectal liver metastases.”                      
Watt DG, Horgan PG, McMillan DC.                    
Med Oncol 2015; 32 (5): 1-2. 
9. Re: Meta-analysis of the predictive value of C-reactive protein for infectious 
complications in abdominal surgery.                        
Watt DG, McSorley ST, Horgan PG, McMillan DC.                         
BJS – Your views 2015: 102 (6) 
 
 
 
  
18 
 
Presentations 
The work presented in this thesis has resulted in the following presentations: 
1. Neutrophil count is the most important prognostic component of the differential white 
cell count in patients undergoing elective surgery for colorectal cancer.                   
National Cancer Research Institute Conference, Liverpool, UK. 2014 (Poster 
Presentation) 
2. Pre- and post-operative inflammatory response to predict survival in patients 
undergoing potentially curative resection for colorectal cancer.                           
American Society of Clinical Oncology GI Symposium, San Francisco, USA. 2015 
(Poster Presentation) 
3. The relationship between red cell distribution width (RDW), markers of systemic 
inflammation and survival in patients undergoing curative surgery for colorectal 
cancer.                         
American Society of Clinical Oncology GI Symposium, San Francisco, USA. 2015 
(Poster Presentation) 
4. The validation of C-reactive protein and albumin as predictors of post-operative 
infective complications and their clinical utility in patients with colorectal cancer.                        
Digestive Diseases Week, Washington D.C., USA. 2015 (Oral Presentation) 
5. Neutrophil count, but not other components of a white cell count, reflects the impact 
of the systemic inflammatory response and long term survival in patients following 
elective surgery for colorectal cancer.                                              
Digestive Diseases Week, Washington D.C., USA. 2015 (Poster Presentation)  
6. The post-operative systemic inflammatory response predicts development of infective 
complications following colorectal cancer surgery.                          
West of Scotland Surgical Association AGM, Glasgow, UK. 2015 (Poster 
Presentation) 
19 
 
7. Post-operative C-reactive protein concentration: a potential therapeutic target 
following surgery for colorectal cancer?                       
American Society of Clinical Oncology GI Symposium, San Francisco, USA. 2016 
(Poster Presentation)     
8. Does pre-operative aspirin and statin prescription modulate the post-operative 
systemic inflammatory response following surgery for colorectal cancer?                          
American Society of Clinical Oncology GI Symposium, San Francisco, USA. 2016 
(Poster Presentation)         
 
  
20 
 
Dedication 
To my wife, Katie and my two daughters Lily and Kaitlyn who have supported my 
throughout this process. Their continual encouragement ensured my onward progress and 
motivated me to finish this thesis.  
  
21 
 
Definitions/Abbreviations 
APC:   Adenomatous Polyposis Coli 
APR:   Abdomino-perineal Resection 
ASA:   American Society of Anaesthesiologists 
BMI:   Body Mass Index 
CRM:   Circumferential Resection Margin 
CRP:   C-reactive Protein 
CT:   Computed Tomography 
DNA:   Deoxyribonucleic Acid 
EGFR:  Epidermal Growth Factor Receptor 
ERAS:  Enhanced Recovery After Surgery 
FAP:   Familial Adenomatous Polyposis 
FIT:   Faecal Immunochemical Test 
gFOBt:  Guaiac Based Faecal Occult Blood Test 
HNPCC:  Hereditary Nonpolyposis Colorectal Cancer Syndrome 
IL-6:   Interleukin-6 
LNR:   Lymph Node Ratio 
MMP-9:  Matrix Metallopeptidase 9 
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MDSC:  Myeloid Derived Suppressor Cells 
MDT:   Multi-disciplinary Team 
mGPS:  Modified Glasgow Prognostic Score 
MMR:  Mismatch Repair Gene 
MRI:   Magnetic Resonance Imaging 
MSI:   Microsatellite Instability 
NLR:   Neutrophil Lymphocyte Ratio 
NPS:   Neutrophil-Platelet Score 
NSAID:  Non-Steroidal Anti-Inflammatory Drugs 
PET:   Positron Emission Tomography 
PLR:   Platelet Lymphocyte Ratio 
PNI:    Perineural Invasion 
poGPS:  Post-operative Glasgow Prognostic Score 
ROC:   Receiver Operating Curves 
SIR:   Systemic Inflammatory Response 
SSI:   Surgical Site Infection 
TME:   Total Mesorectal Excision 
TNF:   Tumour Necrosis Factor 
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TNM:   Tumour, Node, Metastases 
VEGF:  Vascular Endothelial Growth Factor 
WCC:   White Cell Count 
 
 
 
 
 
1 Introduction 
1.1 Epidemiology of Colorectal Cancer 
Colorectal cancer is the third most common cancer diagnosed worldwide in men and the 
second most common in women with 1,360,000 cases diagnosed in total in 2012. The 
majority of cases are found in developing countries with the highest rates found in 
Australia and New Zealand and lowest rates in Western Africa (WHO-Globocan, 2012). 
More deaths are recorded in the less developed parts of the world, resulting in poorer 
survival statistics for these regions (WHO-Globocan, 2012). 
In the United Kingdom, colorectal cancer is now the fourth most common cancer (Figure 
1.1). Its incidence has been increasing over the last 4 decades, with the largest increases 
seen in the elderly population (CRUK, 2014b). In total greater than 41,000 people were 
diagnosed with colorectal cancer in 2011, with 95% of these occurring in people aged 
greater than 50 years old and 43% in those aged over 75 years old. Colorectal cancer is the 
second most common cause of cancer death in the United Kingdom, after lung cancer, with 
approximately 16,200 deaths in 2012 (CRUK, 2014b).  
 
Figure 1.1 The 20 Most Common Cancers in the UK 2014  
(Reproduced Cancer Research UK)  
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In Scotland, colorectal cancer is the fourth most common cancer diagnosed and the third 
most common cause of cancer death. The lifetime risk of developing colorectal cancer is 1 
in 15 for men and 1 in 19 for women. In 2013, approximately 2,100 males and 1,712 
females were diagnosed with colorectal cancer (SPHO, 2014).  
Despite increases in incidence, there has been a trend for a reduction in the mortality from 
colorectal cancer over the last 30 years with approximately 60% of patients surviving at 5 
years (Oliphant et al., 2013, SPHO, 2014). This may be due to improved treatment 
modalities, earlier presentation, the advent of national bowel screening programmes and 
increased surgical specialisation (Oliphant et al., 2013, Oliphant et al., 2014b). Despite 
this, mortality has been noted to be higher in areas of socioeconomic deprivation, a 
problem affecting large parts of Scotland in particular, with around 1,578 deaths occurring 
in Scotland in 2013 (SPHO, 2014). 
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1.2 Colorectal Cancer Carcinogenesis Pathways 
Colorectal cancer arises from one or a combination of three mechanisms: chromosomal 
instability (adenoma-carcinoma sequence), microsatellite instability and hypermethylation. 
1.2.1 Adenoma-Carcinoma Sequence 
Greater than 90% of colorectal cancers are said to arise in colorectal adenomas. This forms 
the classical adenoma-carcinoma sequence (Arends, 2013) and involves a stepwise 
transformation from normal mucosal epithelium to adenomas and through eventually to 
carcinomas (Walther et al., 2009). This stepwise transformation would appear to be 
associated with accumulating genetic mutations within the tumour cell itself (Figure 1.2). 
The most frequently documented of these are the APC, KRAS, MMR, MLH1 and MSH2 
(Arends, 2013). As these mutations and alterations occur over a period of time, there is 
potential to intervene during this process, ideally at the adenoma stage. By removing these 
adenomas then this process can be effectively halted and the long term effect of this would 
be overall reduction in the number of colorectal cancers. This ideology forms the basis of 
the aims of the National Bowel Screening Programme.  
 
Figure 1.2 Adenoma–carcinoma sequence model for chromosomal instability in 
colorectal cancer  
(Reproduced from Walther et al. 2009) 
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1.2.2 Microsatellite Instability 
Microsatellite instability (MSI) is present in around 15% of colorectal cancer cases. MSI 
occurs when there are mutations in the DNA mismatch repair genes (MMR). These are the 
genes that correct DNA replication errors. Mutations in these genes cause these mismatch 
repair genes to become inactive, resulting in base pair mismatches during DNA replication 
(Armaghany et al., 2012). 
Lynch Syndrome or Hereditary Nonpolyposis Colorectal Cancer Syndrome (HNPCC) is 
due to autosomal dominant inheritance of a mutant and wild-type DNA mismatch repair 
gene. Only about 3% of patients with MSI will develop Lynch syndrome. Patients with 
Lynch syndrome develop a few colorectal polyps which are thought to progress (due to the 
MMR mutations) at a faster rate to carcinomas. This has implications in terms of more 
frequent endoscopic surveillance (Arends, 2013). 
1.2.3 Hypermethylation 
Hypermethylation in the gene promoter region results in transcriptional inactivation of 
genes that are involved in tumour suppression or the cell cycle (Armaghany et al., 2012). 
Colorectal cancers which are formed via this pathway account for 10-20% of all colorectal 
cancers and are often associated with BRAF mutations (Arends, 2013). The presence of 
BRAF mutations has implications on the types of adjuvant chemotherapy given to patients, 
based on their efficacy in randomized clinical trials. For example, anti-epidermal growth 
factor receptor (EGFR) therapies have been shown to be less effective in patients with 
BRAF mutation.  
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1.3 Aetiology of Colorectal Cancer 
The aetiology of colorectal cancer is not fully understood and thought to be multi-factorial. 
The majority are said to be sporadic and result from random genetic mutations or 
interactions between the host and various environmental factors. The remainder are 
hereditary, typically caused by certain medical conditions or inherited through well 
documented genetic alterations that predispose the patient to developing colorectal cancer.   
1.3.1 Sporadic Colorectal Cancer 
A vast number of factors have been implicated in the development of sporadic colorectal 
cancer. The evidence for most of these in terms of definite causative agents is lacking. 
These factors include certain lifestyle elements such as diet, obesity and smoking status as 
well as certain medications that are believed to increase the risk of developing colorectal 
cancer.  
1.3.1.1 Age 
Age remains the single biggest risk factor for colorectal cancer. 95% of colorectal cancers 
diagnosed are in people aged over 50 years old (CRUK, 2014b). Therefore as people get 
older, their risk of developing colorectal cancer increases. This is perhaps due to increased 
exposure to other environmental risk factors and also age related degradation of the genetic 
code which can lead to genetic mutations. Improved health and social care has meant that 
people are living longer, resulting in a natural increase in the incidence of cancer in an 
increasingly elderly population.    
1.3.1.2 Diet & Lifestyle 
The highest rates of colorectal cancer are found in the Western world. Migrants who move 
to another country have been found to adopt the incidence rates of their host country within 
a generation (Muir and Parkin, 1985). Therefore many people believe that a Western 
lifestyle is responsible for the development of many cases of colorectal cancer.  
There has been much research into dietary components that may increase the risk of 
developing colorectal cancer.  A diet that is high in fibre is said to be protective against the 
development of colorectal cancer (CRUK, 2014b, Aune et al., 2011a). High fibre diets 
enable smoother passage of faeces through the colon. Why a diet high in fibre reduces the 
risk of developing colorectal cancer is not entirely clear. People who eat lot of fibre may 
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eat less of the food groups that increase the risk of colorectal cancer such as red meat or 
processed meat or it may be that the colonic mucosa is exposed to toxins for a shorter 
period of time, reducing the risk of developing colorectal cancer.  
Eating moderate amounts of fruit and vegetables may reduce the risk of colorectal cancer. 
One meta-analysis suggested the reduction could be by as much as 10% in people who ate 
a moderate amount of fruit or vegetables a day (Aune et al., 2011b). It can be postulated 
that antioxidants and vitamins that are present in many fruits and vegetables may prevent 
the cell damage that may lead to the development of colorectal cancer (CRUK, 2014b).  
Red meat and processed meats are thought to increase the risk of developing colorectal 
cancer, as are diets high in fats and sugar. Conversely, fish, high levels of calcium and 
Vitamin D and dairy produce are thought to be protective against developing colorectal 
cancer (CRUK, 2014b).   
1.3.1.3 Obesity 
It has been long established that obesity is a risk factor for developing colorectal cancer. In 
those who are obese (Body Mass Index (BMI) >30 kg/m
2
), the risk of developing 
colorectal cancer is 33% higher than those of a normal BMI. This association is stronger in 
men than in women (Ma et al., 2013). Furthermore, men with predominantly central 
(abdominal) obesity were at greater risk of developing colorectal cancer with a 2cm 
increase in waist circumference associated with a 4% increase in risk of developing 
colorectal cancer (Moghaddam et al., 2007).   
1.3.1.4 Smoking and Alcohol 
Smoking is a risk factor for developing colorectal cancer (Walter et al., 2014). People who 
smoke cigarettes have a significantly increased incidence of colorectal cancer. 
Furthermore, the duration of smoking, in numbers of pack years, was also significantly 
associated with the increased incidence of colorectal cancer (Liang et al., 2009). 
There have been numerous reports that alcohol consumption is related to the risk of 
developing colorectal adenomas and colorectal cancers (Fedirko et al., 2011, Zhu et al., 
2014). It remains unclear how excess alcohol consumption causes this increased risk of 
cancer development. Rather than being a carcinogen itself, it may act as a promoter of 
tumour growth and dissemination. Ethanol is metabolised into acetaldehyde and free 
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radicals, which are known to carcinogenic and therefore may promote cancer growth 
(Poschl and Seitz, 2004).    
1.3.1.5 Medications 
Several medications have been shown to have a protective effect with respect to the 
development of colorectal cancer. 
1.3.1.5.1 Aspirin 
Patients’ prescribed non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin have 
been reported to have less aggressive tumours and be less likely to present with metastatic 
disease (Benedetti et al., 2003) or indeed develop metastatic disease (Rothwell et al., 
2012). Exactly how these drugs cause this effect remains unclear, however NSAIDs have 
been reported to have effects directly on the tumour as well as beneficial effects on both 
the local and systemic inflammatory response, both of which have been associated with 
tumour progression (Park et al., 2014).   
1.3.1.5.2 Statin 
Statins, a group of drugs commonly prescribed for the treatment of hypercholesterolaemia, 
have been reported to reduce the risk of developing colorectal cancer (Lytras et al., 2014) 
as well as a reduction in mortality associated with colorectal cancer (Liu et al., 2014). 
Statins work primarily by inhibiting 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) 
reductase, potentially preventing production of non-steroidal isoprenoids and also exhibit 
pro-apoptotic, anti-angiogenic and immunomodulatory effects which likely prevent the 
growth of tumours (Vallianou et al., 2014).    
1.3.1.5.3 Metformin 
Metformin is a drug commonly prescribed in type 2 diabetes mellitus. Its method of action 
is to lower circulating levels of both glucose and insulin in patients with insulin resistance 
by reducing hepatic glucose output. In addition to this, the use of metformin appears to be 
associated with a reduced risk of colorectal cancer (Singh et al., 2013, Franciosi et al., 
2013) as well as lowering risks of mortality associated with cancer (Noto et al., 2012, 
Franciosi et al., 2013). Its exact mechanism of action is unclear but it is thought that 
metformin induces cell cycle arrest, apoptosis, activation of the immune system and 
possibly removes cancer stem cells (Franciosi et al., 2013). 
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1.3.1.6 Systemic Inflammatory Response 
Inflammation is now established as a main factor that is involved in the development of 
cancer throughout the body (Roxburgh and McMillan, 2010, Diakos et al., 2014). Indeed, 
one study of 22,887 patients, reported elevated concentrations of CRP in those who 
eventually developed colorectal cancer (Erlinger et al., 2004). Inflammation is now 
recognised as a ‘hallmark of cancer’ and a key proponent of tumour proliferation and 
dissemination (Hanahan and Weinberg, 2011). Inflammation also has links with several 
other risk factors for cancer development and through a complex network of processes 
appears to be detrimental to the outcomes of patients with a range of tumours. It remains to 
be seen whether modulating this inflammatory response either empirically i.e. prior to any 
cancer diagnosis or following a cancer diagnosis, has any impact on improvement of 
outcomes in patients with cancer (Diakos et al., 2014).   
 
 
Figure 1.3 Therapeutic Targeting of the Hallmarks of Cancer  
(Reproduced from Hanahan and Weinberg 2011)  
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1.3.2 Hereditary Colorectal Cancer 
In certain colorectal cancer cases the specific cause is more obvious. This includes either 
specific diseases or medical conditions that predispose patients to the development of 
colorectal cancer or inherited forms of the disease.  
1.3.2.1 Inflammatory Bowel Disease 
Inflammatory bowel disease such as ulcerative colitis or Crohn’s disease is associated with 
an increased risk of developing colorectal cancer. Ulcerative colitis and colorectal cancer 
increases with time, with the risk being approx. 2% at 10 years, 12% at 20 years and 18% 
at 30 years (Eaden et al., 2001). The link between colorectal cancer and Crohn’s disease is 
not as well documented; however it is thought to be around 3% at 10 years duration 
(Canavan et al., 2006). This increase in risk related to inflammatory bowel disease is likely 
due to a chronic inflammatory state where continual production of inflammatory mediators 
such as tumour necrosis factor (TNF) and IL-6 promote signalling and prevent apoptosis of 
tumour cells (Canavan et al., 2006).  
1.3.2.2 Familial Adenomatous Polyposis 
Familial Adenomatous Polyposis (FAP) is an inherited condition that is characterised by 
hundreds or thousands of tiny polyps (adenomas) in the colon. If untreated, the risk of 
developing colorectal cancer is almost 100%. FAP is an autosomal dominant condition 
caused by a germline mutation in the adenomatous polyposis coli (APC) gene on 
chromosome 5. Patients usually develop cancer around the age of 40. Patients should 
initially undergo regular endoscopic surveillance but most will eventually have a 
prophylactic procto-colectomy (Galiatsatos and Foulkes, 2006).  
Patients with FAP can also develop benign tumours called desmoids, which often recur 
after they have been removed. Furthermore, patients with FAP can develop polyps (benign 
or malignant) in other areas of the body, most commonly the duodenum and stomach 
(Belchetz et al., 1996). 
1.3.2.3 Hereditary Non-polyposis Colorectal Cancer 
Hereditary Non-polyposis Colorectal Cancer (HNPCC) or Lynch Syndrome is a common 
hereditary cause of colorectal cancer caused by an autosomal dominant genetic mutation of 
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the DNA mismatch repair genes. It accounts for approximately 3% of all colorectal cancers 
(Schlussel et al., 2014). 
Patients with HNPCC tend to be young, have a predominance to develop right sided 
colonic tumours (70% proximal to splenic flexure) and often present with synchronous or 
metachronous tumours (Lynch et al., 1997). Patients with Lynch syndrome can also 
develop tumours in other organs such as the endometrium, ovary, small bowel and 
hepatobiliary tract. Colorectal tumours in Lynch Syndrome are more commonly poorly 
differentiated or mucinous and often have a strong local inflammatory infiltrate (Jass, 
1998). This coupled with the young age of these patients confers a fairly good prognosis 
for these colorectal cancers.  
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1.4 Clinical Presentation 
The presentation of colorectal cancer depends on the location of the tumour and the extent 
of the disease present. Some patients will present with symptoms related to the primary 
tumour. These symptoms vary dependent on the location of the tumour itself. Other 
patients will have no symptoms at all and will have their colorectal cancer diagnosed via 
the Bowel Screening Programme and some patients will present with symptoms from 
distant metastases rather than symptoms from primary disease. 
1.4.1 Symptomatic Primary Disease 
Common symptoms associated with colorectal cancer include abdominal pain, alteration in 
bowel habit, rectal bleeding, and weight loss (Thompson et al., 2007, Astin et al., 2011). 
These symptoms may be present together or in part and are dependent on the location of 
the tumour itself. Right sided lesions tend not to present with rectal bleeding as any blood 
present in the lumen of the bowel tends to be degraded during passage of stool around the 
colon. Right sided cancers therefore tend to cause occult bleeding and often patients 
present with iron deficiency anaemia, and abdominal mass or abdominal pain (Khanbhai et 
al., 2014). Conversely, distal or left sided lesions often present with change on bowel habit, 
rectal bleeding or lower abdominal pain (Cappell, 2005). Distal rectal lesions often cause a 
change in bowel habit, rectal bleeding, tenesmus and urgency (Cappell, 2005). Around 10-
20% of patients will present as an emergency with obstruction or perforation having had 
little symptoms prior to this episode (Thompson et al., 2007).   
1.4.2 Bowel Screening Programme 
The Scottish National Bowel Screening Programme was introduced in pilot form in 2007 
and by 2009 had been rolled out across all Scottish Health Boards (Mackay et al., 2014). 
Patients aged 50-74 are invited to participate in the screening programme on a biennial 
basis. Currently, the guaiac based faecal occult blood test (gFOBt) is used as the primary 
screening tool (Figure 1.4). This measures the peroxidase activity of haematin in faeces 
(Mansouri et al., 2013). Patients are invited to participate and to send 2 samples from 3 
different bowel motions to the national centre for processing. If the gFOBt is positive then 
they are subsequently invited for colonoscopy following a pre-assessment check. If the 
gFOBt is weakly positive (1-4 windows out of 6 positive) then they are re-tested with a 
Faecal Immunochemical Test (FIT) – targets human haemoglobin and is a quantitative test- 
which has a higher sensitivity and similar specificity to gFOBt. If the gFOBt is negative 
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then nothing further will happen and the patient will be invited to undertake another 
screening test in 2 years (Mansouri et al., 2013).  
 
 
Figure 1.4 Overview of the Scottish National Bowel Screening Programme 
 
Over the first 3 rounds of the pilot programme uptake was around 55% with the positivity 
rate of approximately 2% and cancer detection rate of approximately 1.5 per 1000 screened 
(Steele et al., 2009). It is believed that in the long term, an effective bowel screening 
programme will reduce the incidence of colorectal cancer (by removing pre-cancerous 
polyps at colonoscopy) and increase the detection of early stage cancers.        
1.4.3 Metastatic Disease 
Some patients will present not with symptoms of the primary tumour but with symptoms 
from metastatic disease. Colorectal cancer can metastasise via the lymphatics, blood 
vessels or transperitoneally. Drainage of the abdominal cavity is via the portal vein and so 
haematogenous spread tends to affect the liver first, followed by the lungs and bone. 
36 
 
However, in low rectal lesions, drainage is via inferior rectal vein which drains into the 
inferior vena cava rather than the portal system and so may metastasise to the lungs 
initially. Therefore symptoms can be related to multiple sites in the body and can include 
upper abdominal pain or jaundice from liver metastases; shortness of breath from lung 
metastases; confusion or focal neurology from cerebral metastases or bony pain or 
discomfort from bony metastases. 
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1.5 Investigations and Diagnosis 
In those patients who are symptomatic, the diagnosis of colorectal cancer is made using a 
combination of history taking, clinical examination and diagnostic tests. Histopathological 
confirmation of the presence of malignancy is required prior to elective surgical 
intervention. In some situations, more than one diagnostic test may be required to obtain a 
definitive diagnosis. Furthermore, accurate staging of the disease is required to ensure 
appropriate management of the disease present, be that treatment with curative intent or 
palliative treatment.   
1.5.1 Blood Tests 
There is no specific blood test that is capable of detecting the presence of colorectal cancer. 
Routine blood tests such as a full blood count may show a microcytic anaemia that may 
give an indication that there is occult blood loss from the gastrointestinal tract and raise 
suspicions of a malignant process. Other blood tests such as measures of renal function, 
inflammatory status and liver function may be beneficial in assessing the general health of 
the patient, assessing any suspicions for the presence of metastatic disease and offering 
some prognostic information regarding outcome of any future treatment.  
1.5.2 Endoscopic Evaluation 
Endoscopic assessment of the large bowel is the gold standard investigation where 
colorectal cancer is suspected. Colonoscopy therefore should be offered to patients who 
have no significant co-morbidities and if a suspicious lesion is seen it should be biopsied in 
order to obtain a histological diagnosis (NICE, 2011). Colonoscopy is a relatively safe 
procedure with a high sensitivity for detecting colorectal cancer. It allows biopsies of 
suspicious lesions and the opportunity to perform polypectomy (removal of pre-cancerous 
polyps endoscopically). It does not involve any ionising radiation but may require some 
intravenous sedation to tolerate the examination. The risks associated with colonoscopy 
include bleeding, perforation (0.01%), failure to examine the entirety of the large bowel 
and the possibility of missed lesions (Bowles et al., 2004, Arora et al., 2009). Patients who 
have a failed colonoscopy should either be offered a repeat colonoscopy or a CT 
Colonography (see below).  
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1.5.3 Computed Tomography 
Computed tomography (CT) colonography can be used as an alternative to colonoscopy in 
diagnosing colorectal cancer. It is generally reserved for patients who are not suitable for 
colonoscopy or who have had a failed colonoscopy and is generally well tolerated (Koo et 
al., 2006, Rosman and Korsten, 2007, Ng et al., 2008). However, unlike with colonoscopy, 
histological diagnosis is not possible and if deemed necessary then the patient will require 
a colonoscopy.  
CT also plays a role in the staging of patients with colorectal cancer. Contrast-enhanced 
CT of the chest, abdomen and pelvis is routinely performed in all patients who are 
diagnosed with colorectal cancer. It allows local staging of colonic tumours and also 
detection and assessment of distant metastases.  
1.5.4 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is not routinely used to detect colonic lesions but can 
be useful in some circumstances (Zijta et al., 2010). It can also be used to further assess 
suspicious lesions identified from staging CT scans situated in the liver. MRI allows 
accurate assessment of liver metastases and suitability of them being amenable to resection 
or ablation (Blyth et al., 2008). 
MRI is also utilised in local staging of rectal cancers as it has been shown to be superior to 
CT in this regard. It enables clinicians to accurately assess factors such as the 
circumferential resection margin, venous invasion, tumour and nodal staging. In doing so it 
permits selection of patients who would be suitable to go straight for surgery and those 
who would benefit from neoadjuvant therapy prior to surgical resection (Mercury Study 
Group, 2006, Purkayastha et al., 2007).   
1.5.5 Staging of Colorectal Cancer 
The staging of colorectal cancer allows quantification of the extent of disease and provides 
a framework for deciding on the appropriate treatment for the patient. The most commonly 
used staging system worldwide is the Tumour, Node, Metastases (TNM) system that was 
produced by the American Joint Committee on Cancer (AJCC) (AJCC, 1992). This system 
stages the cancer using three components, the tumour itself (T), regional lymph node 
involvement (N) and the presence of distant metastases (M). These are combined to form 
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stage groupings (Table 1.1). In the UK an alternative staging system called the Duke’s 
Classification is also still used. This stages the cancer from stage A to D and is similar to 
the TNM system, using tumour grade, nodal involvement and the presence of distant 
metastases. 
 
  
Table 1.1 TNM staging system for colorectal cancer 
Primary Tumour (T) 
Tx Tumour cannot be assessed 
Tis Carcinoma in situ 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades subserosa 
T4 Tumour directly invades into adjacent 
organs or structures or through the visceral 
peritoneum 
Regional Lymph Nodes (N) 
Nx Lymph nodes cannot be assessed 
N0 No lymph node metastases 
N1 Metastases in 1-3 lymph nodes 
N2 Metastases in ≥4 lymph nodes 
Distant Metastases (M) 
Mx Metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases present 
  
 
Final staging of colorectal cancer relies on pathological assessment of the resected 
specimen. This can only be performed following surgery. Prior to treatment, staging is 
reliant on clinical examination, direct visualisation of the tumour and radiological imaging 
of the rest of the body. A CT of chest, abdomen and pelvis is performed to assess the 
invasiveness of the tumour itself as well as to assess involvement of the regional lymph 
nodes and detect potential distant metastases. Patients with suspicious lesions that may 
represent distant metastases may require further imaging such as Positron Emission 
Tomography (PET) CT or MRI to further clarify whether metastatic disease is present 
prior to surgical intervention. In patients with rectal cancer, an MRI of the pelvis is also 
performed to assess the circumferential resection margin and extension of disease out with 
the mesorectum. Patients where the circumferential resection margin may be involved may 
benefit from neo-adjuvant chemoradiotherapy prior to surgical resection (Brown and 
Daniels, 2005). 
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Whilst complete radiological staging is preferable prior to surgery it may not always be 
possible as some patients will require an emergency operation for a complication related to 
a newly diagnosed cancer. In these patients radiological staging can be completed 
following surgery.  
1.5.6 Multi-disciplinary Team Meetings 
The multi-disciplinary team (MDT) has become an essential component of the 
investigation and treatment of patients with suspected colorectal cancer (Wood et al., 
2008). It involves regular meetings of a group of health professionals from multiple 
disciplines including surgeons, radiologists, pathologists, oncologists and nurse specialists, 
each with specialised knowledge in their field that relates to the management of colorectal 
cancer (Fleissig et al., 2006). These regular meetings allow well-co-ordinated and high 
quality patient centred care, facilitating prompt and appropriate diagnostic techniques, 
evidence-based decision making and top quality treatment from a range of professions 
(Fleissig et al., 2006, Taylor et al., 2010). Their routine use has ensured that each patient 
receives the most appropriate treatment for their cancer. The use of MDT meetings has 
seen improvement in 5 year survival in colorectal (Morris et al., 2006a) and oesophageal 
cancer (Stephens et al., 2006), improved 2 year survival in head and neck cancer (Birchall 
et al., 2004) and improved survival in lung cancer (Coory et al., 2008). Furthermore, in 
rectal cancer they have been reported to reduce the rate of positive circumferential 
resection margins (Burton et al., 2006).  
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1.6 Management of Colorectal Cancer 
The management of patients with colorectal cancer has significantly evolved over the last 2 
decades. Treatment is multi-faceted involving surgical resection, adjuvant and/or neo-
adjuvant therapy and palliative therapy (surgical or oncological). For the majority of 
patients, surgery will be the main treatment option and represents the best chance at cure.  
1.6.1 Surgery 
Surgery for patients with colorectal cancer should only be performed by appropriately 
trained surgeons who are part of a multi-disciplinary team (ACPGBI, 2007). 
Approximately 90% of surgery performed will be planned or elective surgery. The 
remainder of those who undergo surgery will have an emergency operation. Not everyone 
diagnosed with a colorectal cancer will undergo operative intervention. For some, their 
disease is not curable at diagnosis and for others the risks of surgery (usually due to 
medical co-morbidities) will outweigh potential benefits of surgical resection. In these 
patients, non-operative strategies to palliate symptoms and the disease should be adopted 
(see below). 
1.6.1.1 Elective Surgery 
The majority of patients will undergo elective surgery for their colorectal cancer. These 
patients will have been diagnosed by attending the outpatient department with symptoms 
requiring investigation or through the National Bowel Screening Programme.  
The goals of surgical resection are to remove the tumour along with a section of bowel and 
its feeding blood vessels and lymph nodes. This ‘oncological resection’ is determined by 
the location of the tumour itself and its blood supply. Once the surgical specimen is 
removed, intestinal continuity is usually restored by anastomosing the remaining two ends 
of bowel together either with sutures or stapling devices. Where this is not possible or 
desirable the distal end of bowel is exteriorised onto the abdominal wall with a stoma. 
In those patients with rectal cancers, the surgeon must decide whether the anal sphincter 
complex can be preserved whilst ensuring the bowel can be divided distal to the tumour 
without compromising oncological clearance. If this is not possible then an abdomino-
perineal resection (involving removing the anus and sphincter complex) with a permanent 
end colostomy should be undertaken. More recently, a more radical resection involving 
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removing the levator muscles has been described, the so-called cylindrical or extra-levator 
APR with greater oncological clearance and reduced risk of local recurrence (Dalton et al., 
2012). 
In patients with tumours situated below the peritoneal reflection, the tumour should be 
excised following the principles of TME (Total Mesorectal Excision). First described by 
Heald and colleagues it entails removing the specimen with the mesorectum intact. The 
mesorectum envelopes the bowel and by removing it intact has been shown to reduce the 
rates of local recurrence (Heald et al., 1982).     
1.6.1.2 Emergency Surgery 
In some patients, the presence of tumour perforation, bowel obstruction or bleeding will 
necessitate emergency surgery. Whilst the principles of surgical resection remain the same 
as those undergoing elective surgery, restoring intestinal continuity is sometimes not 
attempted due to the patients general condition and comorbidities and the higher risk of 
anastomotic dehiscence. Patients undergoing emergency surgery have been reported to 
have higher complication rates, poorer cancer-specific survival and increased mortality 
rates compared to elective surgery (McArdle and Hole, 2004, Crozier et al., 2009). 
Increased access to diagnostic investigations and the introduction of bowel screening have 
meant that the number of emergency procedures has decreased over the last few decades 
but a substantial number of patients still present as an emergency.     
1.6.1.3 Surgery Performed by Specialists 
Prior to subspecialisation of surgeons, surgery for colorectal cancer was performed by a 
variety of surgeons with varying outcomes. McArdle and Hole reported a wide range in the 
rates of mortality, anastomotic leak, curative resection and survival in patients having 
surgery for colorectal cancer between 1974 and 1979 (McArdle and Hole, 1991). 
Reorganisation of cancer services has meant that in the main, elective colorectal cancer 
surgery is performed by specialist colorectal surgeons. In practice, this means fewer 
surgeons perform colorectal cancer surgery but each surgeon performs more specialist 
procedures on an annual basis. This has resulted in improved long term survival for 
patients having elective colorectal cancer surgery (Oliphant et al., 2013).   
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1.6.2 Enhanced Recovery after Surgery (ERAS) 
Enhanced Recovery after Surgery (ERAS) protocols have become a routine part of post-
operative care. ERAS is a method of peri-operative care involving multimodal, protocol 
driven strategies designed to improve morbidity and shorten hospital stay following 
surgery (Wilmore and Kehlet, 2001).  
The number of components used in each ERAS protocol varies from centre to centre. 
Furthermore, there is evidence to suggest that only certain components such as 
laparoscopic surgery, early enteral nutrition and early mobilisation play a role in improving 
outcomes following surgery (Vlug et al., 2012). Regardless of how they are constructed, 
ERAS protocols have been shown to reduce morbidity and shorten length of stay following 
elective colorectal surgery (Rawlinson et al., 2011).   
1.6.3 Neoadjuvant Therapy 
In patients with rectal cancer there is a role for pre-operative radiotherapy to downstage the 
tumour. It has become standard practice to utilise pre-operative chemo-radiotherapy for 
patients with T3/4 tumours, nodal disease or where the circumferential resection margin is 
threatened on pre-operative staging MRI scans (Engstrom et al., 2009).  
Pre-operative radiotherapy can be delivered in conventional fractionation (45-50 Gy in 25 
fractions over a 5 weeks period) or short course therapy (25 Gy in 5 fractions daily for 1 
week). Conventional fractionation is usually combined with synchronous 5-fluorouracil (5-
FU) chemotherapy, known as chemo-radiotherapy, in order to improve its efficacy. 
Surgery is usually performed 5-8 weeks following this in order to allow for maximal 
tumour shrinkage. With short course radiotherapy, surgery happens within 10 days of it 
being complete, as such it is not useful for downsizing tumour bulk but has been shown to 
reduce local recurrence rates (Colorectal Cancer Collaborative, 2001). Which of these 
methods of delivering pre-operative radiotherapy are optimal remains a controversial topic. 
1.6.4 Adjuvant Therapy 
Adjuvant therapy is treatment given after surgery in order to reduce the risk of cancer 
recurrence. The mainstay of this treatment is chemotherapy. Adjuvant chemotherapy is 
offered to patients deemed to have a high risk of recurrence. These high risk features 
include: node positive disease, serosal involvement (T4), perforated or obstructed tumours, 
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poorly differentiated tumours and tumours with extra-mural venous invasion (ACPGBI, 
2007). Chemotherapies are toxic chemicals that damage normal cells as well as tumour 
cells. As such, patients often experience side effects including fatigue, nausea and 
vomiting, diarrhoea, neutropenia, myelosuppression and peripheral neuropathy.  
Which specific chemotherapeutic agents to use is a vast topic that is dependent on a variety 
of tumour biological markers. Potential agents include 5-FU, FOLFOX (folinic acid, 5-FU 
and oxaliplatin), capecitabine or Xelox (capecitabine and oxalipatin). The duration of 
therapy varies but typically lasts from 6-8 months. In node positive disease, adjuvant 
chemotherapy can improve overall survival by 13% (NICE, 2006). 
In rectal cancers, where there is a positive resection margin, adjuvant radiotherapy can be 
used as a salvage technique, as long as they did not receive pre-operative radiotherapy. 
However, the benefit on prevention of local recurrence is smaller compared with pre-
operative radiotherapy (Colorectal Cancer Collaborative, 2001).    
1.6.5 Palliative Therapy 
In patients with inoperable disease, metastatic disease or who are not medically fit for 
resection then palliative chemotherapy can be used to limit disease progression and treat 
symptoms. Patient selection is important as the side effects from chemotherapy can be 
detrimental to the patient’s quality of life and performance status has been reported to be 
an important factor in outcomes with palliative therapies (Thirion et al., 1999, Simmonds, 
2000). Some studies have shown that compared to best supportive care, palliative 
chemotherapy can improve life expectancy by approximately 3-6 months (Simmonds, 
2000).  
Ultimately patients may be left with no therapeutic options and in these situations quality 
of life and symptom control are of the upmost importance. Good communication between 
the surgical team, oncology team and palliative care team are important in ensuring the 
patient has adequate control of their symptoms.  
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1.7 Prognostic Factors 
There are a number of tumour related factors that have been reported to have prognostic 
value in patients with colorectal cancer. These range from the stage and grade of tumour to 
various tumour characteristics that have been described as conveying high risk of 
recurrence and poor long term outcomes. These prognostic factors are often used in 
determining whether patients’ should receive adjuvant therapy (see above) following 
surgical resection. 
1.7.1 Duke’s Classification 
Originally described by Cuthbert Dukes in 1937 (Dukes, 1937), his classification of rectal 
cancers has undergone multiple modifications since its original description to attempt to 
improve stratification, include colon cancers and those with metastatic disease. Dukes 
system stratifies cancers dependent on their depth of invasion into the bowel wall, the 
presence (or absence) of lymph node metastasis and presence of distal metastases. Dukes A 
describes a tumour involving the mucosa or submucosa only; Dukes B1 tumours extend to 
the muscularis propria with Dukes B2 tumours penetrating through the muscularis propria. 
Dukes B tumours by definition have no lymph node involvement. In contrast, Dukes C 
tumours have lymph node involvement. Dukes C1 tumours extend into the muscularis 
propria but not through it and Dukes C2 tumours extend through the muscularis propria. 
Dukes D tumours involve distant metastases. Whilst its use has been superseded by the 
TNM staging system (see below) most pathological specimens in the UK are still described 
in terms of Dukes staging as well as TNM staging. 
Table 1.2 Dukes stage and 5-year survival in patients with colorectal cancer 
  (Adapted from National Cancer Intelligence Network 2009) 
Stage 5-year Survival 
Dukes A 93% 
Dukes B 77% 
Dukes C 48% 
Dukes D 7% 
 
1.7.2 TNM Classification 
The tumour, node, metastases (TNM) classification was developed by the American Joint 
Committee on Cancer (AJCC) and International Union against Cancer (UICC). It is 
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derived based on the invasiveness of the tumour itself (T-stage), the degree of regional 
lymph node involvement (n-stage) and the presence of distant metastases. It is updated on 
a regular basis, currently there are 7 editions but, in the UK, the current recommendation 
from the Royal College of Pathologists is to use version 5 (RCPath, 2014). Both TNM and 
Dukes staging are reliant on a good quality surgical specimen and also a satisfactory lymph 
node harvest in order to adequately stage the tumour (Johnson et al., 2006). A specimen 
should contain at least 12 lymph nodes (RCPath, 2014) and a specimen containing fewer 
lymph nodes than this can result in a tumour being under-staged.  A comparison of TNM 
staging and Dukes staging is shown in Table 1.3.  
Table 1.3 Comparison of TNM Staging and Dukes Classification 
(Adapted from John Hopkins Colon Cancer Website – Staging of Colorectal 
Cancer) 
TNM Classification Dukes’ 
Classification 
Stages T N M Stages 
Stage 0 Tis N0 M0  
Stage I T1 N0 M0 A 
T2 N0 M0 B1 
Stage II T3 N0 M0 B2 
T4 N0 M0 B2 
Stage III T1, T2 N1 or N2 M0 C1 
T3, T4 N1 or N2 M0 C2 
Stage IV Any T Any N M1 D 
 
  
1.7.3 Grade of Tumour 
Tumour differentiation grade is a subjective measure of how well the tumour is 
differentiated. Colorectal tumours can be characterised as low grade (well or moderately 
differentiated) and high grade (poorly differentiated). A high tumour differentiation grade 
has been described as an adverse prognostic indicator (Compton, 2003). Furthermore, 
tumour grade differentiation has been shown to be associated with TNM stage, T stage and 
lymph node metastasis (Derwinger et al., 2010). A higher grade tumour is significantly 
more likely to be associated with a higher positive lymph node rate in stage III (Dukes’ C) 
disease.     
1.7.4 Venous Invasion 
Venous invasion is diagnosed pathologically when there are tumour cells seen within an 
endothelium lined space surrounded by smooth muscle and/or containing red blood cells 
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(Sternberg et al., 2002). The presence of venous invasion is now well recognised as an 
adverse prognostic indicator (Roxburgh et al., 2010a, Roxburgh et al., 2010b). The use of 
elastic staining improves the detection rates of venous invasion and has been reported to 
improve its use a prognostic marker in colorectal cancer and forms part of the routine 
pathological dataset (RCPath, 2014).   
1.7.5 Perineural Invasion 
Perineural invasion (PNI) occurs when tumour cells invade the nerves and spread along the 
nerve sheaths (Liebig et al., 2009). In colorectal cancer, the presence in the resected 
specimen of perineural invasion is said to be a high risk factor for recurrence and poorer 
survival with some studies reporting a 4-fold increase in survival for patients with PNI-
negative tumours (Liebig et al., 2009). Its presence is under-reported in colorectal 
specimens and it may explain the difference in outcomes seen in those with node-negative 
disease.      
1.7.6 Peritoneal Involvement 
Peritoneal involvement is present if there are tumour cells visible on the peritoneum or free 
in the peritoneal cavity. Again its presence is a poor prognostic indicator and has been 
reported to be associated with disease recurrence and metastases (Morris et al., 2006b, 
Stewart et al., 2007). 
1.7.7 Tumour Perforation 
Tumour perforation occurs when a visible defect is identified during pathological analysis 
in the bowel wall through to the lumen of the bowel. This is a poor prognostic indicator 
and has been associated with tumour recurrence and metastases, independent of tumour 
stage. (Petersen et al., 2002)   
1.7.8 Margin Involvement 
A positive longitudinal or circumferential resection margin is one that has tumour cells at 
the margin or within 1mm of the margin. It indicates that the tumour has not been fully 
excised and as such is a well-documented poor prognostic marker for local recurrence and 
metastatic disease. Particularly in rectal cancer, a positive circumferential resection margin 
(CRM) is associated with the development of metastatic disease and poor survival 
(Nagtegaal and Quirke, 2008).  
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1.7.9 Petersen Index 
Petersen and colleagues attempted to clarify why there were such differences in outcomes 
in patients with stage II (Dukes’ B) disease. The aim was to identify patients who would 
benefit from adjuvant therapy. They assessed 268 colonic cancers, staged as Dukes’ B 
tumours and evaluated all pathological factors that could be of prognostic benefit. On 
multivariate analysis, 4 factors were independently prognostic – peritoneal involvement, 
venous invasion, margin involvement and tumour perforation (Petersen et al., 2002). The 
presence of each was awarded 1 point with the exception of tumour perforation which was 
awarded 2 points. Patients were then grouped in to those at low risk (score 0-2) and those 
at high risk (score 3-5). The Petersen index was subsequently validated another cohort of 
patients with Dukes’ B disease by identifying those at higher risk of disease recurrence and 
poorer survival (Morris et al., 2007).    
1.7.10 Lymph Node Ratio  
The lymph node ratio (LNR) is calculated by dividing the number of positive lymph nodes 
(lymph nodes with tumour deposits present) by the total number of lymph nodes harvested. 
In a study of 26,181 patients a ratio of 0.4 was used as a cut off to divide the patients into 2 
groups and reported that the LNR was a strong independent indicator for cancer-specific 
survival (De Ridder et al., 2006). The use of a ratio has some advantages over the total 
lymph node yield as there is less chance of under-staging and under-treating patients as 
may happen if the lymph node yield was poor. This is perhaps why it is seen as a useful 
prognostic marker. Despite this, the LNR is not commonly used possibly because there is 
no consensus on the optimal cut off for dividing patient groups, hence limiting its 
usefulness as a prognostic marker. 
1.7.11 Tumour Necrosis 
Tumour necrosis is a feature of solid tumours. It is believed that it occurs because the 
tumour becomes ischaemic due to rapid growth and expansion. Therefore it has been 
associated with aggressive, more advanced tumours and is associated with poor prognosis. 
In a study of 343 patients undergoing surgery for colorectal cancer, tumour necrosis was 
associated with a systemic inflammatory response, TNM stage, and Petersen index. 
Furthermore, it was also associated with reduced cancer-specific survival (Richards et al., 
2012b).
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1.8 Inflammation and Cancer 
It is now recognised that disease recurrence and long term survival in all tumour types is 
not solely influenced by the characteristics and prognostic factors related solely to the 
tumour (see above). Whilst these factors undoubtedly play an important role in providing 
vital prognostic information they do not fully explain the differences in outcomes seen in 
patients with cancers of the same pathological stage e.g. Dukes’ B colorectal cancer.  
Patient or host characteristics which can be modifiable such as exercise tolerance, BMI and 
smoking status as well as non-modifiable characteristics such as age and sex are also 
related to outcomes in patients with cancer. 
Furthermore, the presence or absence of an inflammatory response either locally at the 
tumour site or in the patient generally (systemically) affects the ability of the body to 
generate an adequate anti-tumour response.  
A link between inflammation and cancer has long been established. In 1863 Rudolph 
Virchow noted the presence of leucocytes in tumours and made the connection between 
inflammation and cancer (Balkwill and Mantovani, 2001). Indeed, chronic inflammatory 
conditions such as Inflammatory Bowel are known to increase the risk of developing 
colorectal cancer. So much so that inflammation is now considered one of the ‘Hallmarks 
of Cancer’, its presence enabling tumour cells to survive, proliferate and disseminate 
(Hanahan and Weinberg, 2011).    
1.8.1 Host Response 
The body’s immune system is responsible for protecting the body against foreign 
pathogens. It is composed of a non-specific component (innate) and a specific component 
(adaptive). Indeed some of the body’s own defence mechanisms can promote tumour 
progression as well as others its destruction. Rather than one specific component of the 
body’s immune system being key, a homeostatic balance between these pro and anti-
tumour effects appears the most important determinant affecting cancer outcomes 
(Roxburgh et al., 2013).   
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1.8.1.1 The Innate Immune System 
The innate immune system does not confer long lasting immunity but serves as an 
immediate defence mechanism to pathogens and includes physical, chemical and 
microbiological barriers as well as elements of the immune system (Parkin and Cohen, 
2001).  It involves recruitment of myeloid cells such as neutrophils, 
macrophages/monocytes, eosinophils, basophils, mast cells, dendritic cells and natural 
killer cells.  Furthermore, antigen presenting cells from the innate immune system such as 
dendritic cells provide a basis for activation of the adaptive immune system (Turvey and 
Broide, 2010).  To enhance these cellular defence mechanisms, a humoral component of 
the innate immune system includes complement proteins and acute phase proteins such as 
CRP.  These proteins are involved in both sensing pathogens and facilitating clearance of 
pathogens (Turvey and Broide, 2010). Moreover, innate immune cells need to be recruited 
to the site of inflammation and activated appropriately. This involves interaction of cellular 
receptors such as adhesion molecules and external molecules such as cytokines.  Cytokines 
are produced by cells all over the body and have a variety of different functions including 
cell activation, division, apoptosis or cell movement (Parkin and Cohen, 2001).  Cytokines 
that are produced by leucocytes and mainly affect white cells are referred to as interleukins 
and those which have chemoattractant activity as known as chemokines. 
CRP is a pentameric protein found in blood and produced by the liver. It is a key 
component of the innate immune system. It primarily acts as an opsonin and acts to 
enhance clearance of pathogens (Gabay and Kushner, 1999). It has both pro and anti-
inflammatory properties and has been reported to begin rising several hours after injury, 
peaking at 48 hours post injiury. CRP concentrations following surgery vary depending on 
the type of procedure. Whether CRP could be used as a marker of the degree of trauma in 
the body remains to be seen.    
Interleukin-6 (IL-6) is a pro-inflammatory cytokine that is produced throughout the body. 
It is produced in response to injury and stimulates both CRP and neutrophils to migrate to 
the site of injury. It also peaks and falls following injury but at an earlier stage compared to 
CRP.  
Neutrophils are the most abundant cell that constitutes the white cell count. They are a key 
part of the innate immune system and act as first responders, migrating to the site of injury 
and beginning to destroy invading microbes either by phagocytosis, secretion of anti-
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microbial substances or formation of neutrophil extracellular traps (NETs). Neutrophils 
can exhibit both pro and anti-tumour properties but elevated circulating concentrations 
have been shown to be associated with poorer outcomes in a variety of cancers (Atzpodien 
and Reitz, 2008).    
1.8.1.2 The Adaptive Immune System 
Unlike the innate immune system, the adaptive immune system provides a specific 
response against a pathogen. It is mainly composed of lymphocytes and responds to 
recognition of ‘non-self’ antigens. It provides a stronger response to these antigens and 
also enables the body to create an immunological memory of these antigens, should they 
be encountered again. Adaptive immunity involves both humoral (B cells) and cell-
mediated immunity (T-cells) although they often work together. Adaptive immunity begins 
when antigen-presenting cells recognise the presence of foreign antigens. B cells produce 
antibodies (immunoglobulins) in response to specific antigens. These antibodies bind to 
these antigens, triggering the complement cascade and alerting phagocytes of their 
presence in order for them to be destroyed (Janeway, 2001).  
There are several different types of T-cells that make up the cell mediated response: helper 
T cells (CD4+), cytotoxic T cells (CD8+), memory T cells (C45R0+) and regulatory T 
cells (FOXP3+). Each has its own role to play in detection, and removal of foreign 
antigens from the body (Janeway, 2001). Cytotoxic T cells are responsible for cell death, 
releasing cytotoxins that destroy the specific antigen.    
1.8.2 The Tumour Microenvironment 
Solid tumours consist of the tumour cells themselves, which are contained within a 
complex system of mesenchymal and inflammatory cells. This is known as the tumour 
microenvironment and as well as tumour cells, contains the invasive margin, stroma, blood 
vessels and lymphatics (Balkwill et al., 2012, McAllister and Weinberg, 2014). It has 
recently become apparent that interactions between the tumour cells and the tumour 
microenvironment are responsible for regulating tumour growth and progression 
(McAllister and Weinberg, 2014). These interactions are controlled by a complex system 
of cytokines, chemokines, growth factors and inflammatory enzymes. Indeed, the structure 
and functions of the tumour microenvironment are said to be similar to the processes of 
wound healing or inflammation (Balkwill et al., 2012). Whilst there has been particular 
interest towards the immune cells within the tumour microenvironment, which have been 
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reported to influence tumour progression and outcomes, targeting other non-tumour cells 
or mediators of communication between tumour microenvironment components may yet 
be of therapeutic benefit (Balkwill et al., 2012).  
1.8.3 The Local Inflammatory Response 
It has been well documented that the infiltration of inflammatory cells locally around the 
tumour is associated with improved cancer specific outcomes in patients with colorectal 
cancer, regardless of tumour stage (Roxburgh and McMillan, 2012, Richards et al., 2014). 
It has been assumed that this is a direct response from the patient and represents an 
effective immune response (Richards et al., 2014).  There have been numerous studies that 
have attempted to clarify the exact components of this inflammatory infiltrate. What 
appears to be clear however is that an increasing density or number of these inflammatory 
cells, such as infiltrating T lymphocytes and macrophages, are associated with improved 
clinical outcomes. A number of scoring systems have been devised in an attempt to predict 
outcomes based on this local inflammatory response; however none have become part of 
routine clinical practice. 
In the late 1980’s Jass and colleagues devised a scoring system based on 4 pathological 
characteristics: the presence of peritumoural lymphocytic infiltrate, the invasive margin 
(expanding/infiltrating), limitation of growth to bowel wall and lymph node involvement 
(Jass et al., 1987). The presence of a peritumoural infiltrate was associated with improved 
outcomes. Despite being validated on multiple occasions as a stage independent 
determinant of cancer-specific survival (Roxburgh and McMillan, 2012), the subjective 
nature of its measurements have limited its widespread clinical use.  
Klintrup and colleagues used semi-quantitative analysis of the peritumoural inflammatory 
infiltrate using standard Haematoxylin and eosin (H&E) stained sections. They reported 
that high grade inflammatory cell infiltrate at the invasive margin was associated with 
improved survival in patients with node negative colorectal cancer. Conversely, those with 
low grade inflammatory cell infiltrate had poor prognosis with a 5 year survival of 47%, 
despite these patients having node negative disease (Klintrup et al., 2005). This work was 
subsequently externally validated in a cohort of node negative colorectal cancer patients 
(Roxburgh et al., 2009).  
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The Galon Immune Score is based on quantitative immunohistochemistry on specific T-
cell subtypes at the invasive margin and centre of the tumour (Galon et al., 2012). It has 
been shown to be associated with tumour recurrence (Mlecnik et al., 2011). However, the 
complexity of immunohistochemistry and the difficulty in reliably repeating this process 
has limited its widespread use.  
Overall, while there is clear evidence that an increased inflammatory cell infiltrate, is a 
good prognostic marker. The presence of several different scoring systems utilising 
different methods of scoring and different cell types means their reproducibility and 
reliability, in terms of widespread clinical use, is limited. 
1.8.4 The Systemic Inflammatory Response 
As previously mentioned, the importance of inflammation in the growth and progression of 
cancer has become more apparent in the last decade. Inflammation itself is a normal 
physiological process that occurs in response to injury and indeed to surgical trauma. 
Whilst in these circumstances its response is measured and enables healing of the injured 
site; in cancer, the normally tight physiological controls are lost or weakened to such an 
extent that an exaggerated inflammatory response is often present. Rather than being 
beneficial, this exaggerated inflammatory response then results in massive release of pro-
inflammatory cytokines, many of which are used by the tumour to aid tumour growth and 
progression. 
In patients with cancer, whilst the presence of increased inflammatory infiltrate at a local 
level around the tumour itself has been shown to be beneficial, the presence of a systemic 
inflammatory response has been reported to be associated with disease progression, 
recurrence and poor long term survival, independent of tumour stage and tumour type 
(Roxburgh and McMillan, 2010, Proctor et al., 2011b, Guthrie et al., 2013a, McMillan, 
2013b). Moreover, a systemic inflammatory response has been reported to be associated 
with functional decline, weight loss, cachexia and low levels of skeletal muscle (Scott et 
al., 2002, McMillan, 2009, Richards et al., 2012c, Douglas and McMillan, 2014) as well as 
increased development of post-operative complications following surgery for colorectal 
cancer (Moyes et al., 2009). 
There are various ways of measuring the systemic inflammatory response. The 
stereotypical marker of the systemic inflammatory response is CRP, but other readily 
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available and easy to obtain biochemical markers such as albumin, white cell count and 
interleukin-6 (IL-6) are also good measures of the systemic inflammatory response. Given 
that patients with cancer often require multiple routine blood sampling, this has become an 
accepted method of monitoring these biochemical markers. 
CRP is an acute phase protein synthesised in the liver and responds to a variety of 
inflammatory cytokines, the main one being IL-6 (Gabay and Kushner, 1999). It is used in 
a variety of settings clinically to monitor the response to illness and response to medical 
therapy. CRP acts by activating complement and binding with Fc receptors as well as 
acting as an opsonin for foreign pathogens. Several systematic reviews, including 105 
studies involving 21,733 patients, have reported the prognostic value of CRP in patients 
with breast, gastric, hepatocellular, urological, colorectal, pancreatic and oesophageal 
cancer (Han et al., 2011, Yu et al., 2013, Zheng et al., 2013, Dai et al., 2014, Pathak et al., 
2014, Stevens et al., 2014). Raised CRP concentrations were reported to be associated with 
poorer survival. Therefore, a raised CRP appears to be associated with poorer survival in 
patients with cancer, regardless of tumour type. 
Albumin is a negative acute phase protein, synthesised by the liver. Its serum 
concentrations can be used to estimate synthetic liver function and are known to decrease 
in the presence of inflammation. This is the result of an increased demand of amino acids 
for acute phase protein synthesis which results in progressive loss of available protein such 
as albumin. It has also been reported as a prognostic marker in patients with cancer. A 
recent systematic review, including 59 studies involving a total of 16, 666 patients, 
reported the prognostic value of albumin in patients with cancer (Gupta and Lis, 2010). In 
these studies, lower serum albumin concentrations were associated with poorer survival in 
patients with cancer, regardless of tumour type.  
IL-6 is a pro-inflammatory cytokine that is produced by many cells throughout the body in 
response to injury. IL-6 levels have been reported to rise from approximately 2 hours 
following stimulus and peak at approximately 12-24 hours.  IL-6 production is primarily 
regulated by a negative feedback mechanism through suppressors of cytokine signaling 
(Socs) molecules, coded by genes of the JAK-STAT pathway (Kishimoto, 2010).  IL-6 is 
thought to be the main inducer of acute phase proteins such as CRP from hepatocytes as 
well as causing differentiation, proliferation and maturation of haemopoietic progenitors.  
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The white cell count (WCC) is a group of inflammatory cells that can also be used as a 
marker of the systemic inflammatory response. The total white cell count consists of: 
neutrophils, lymphocytes, monocytes, basophils and eosinophils. Neutrophils are the major 
component of the WCC. They are ‘first responders’ present at the site of injury within 1 
hour and peak at 24 hours.  Levels begin to wane after 48 hours with neutrophils cleared 
from circulation via the liver, spleen and bone marrow (Kolaczkowska and Kubes, 2013). 
There is little evidence that a raised WCC has prognostic value in patients with cancer.    
1.8.5 Systemic Inflammation Based Prognostic Scores 
A number of prognostic scores based on various different combinations of these 
inflammatory markers have been derived. This has been driven by the need to standardise 
the measurement of the systemic inflammatory response and also provide a measure 
capable of predicting outcomes. 
The most extensively validated of these scores is the modified Glasgow Prognostic Score 
(mGPS). This cumulative, prognostic score is based on thresholds of both CRP and 
albumin, It is scored as follows: CRP<10 mg/L scores 0, CRP >10 mg/L and albumin ≥35 
g/L scores 1 and CRP >10 mg/L and albumin <35 g/L scores 2 (Roxburgh and McMillan, 
2010). The mGPS has been shown to predict outcomes in patients with a range of solid 
tumours (Proctor et al., 2011b). A recent review of >50 studies involving >30,000 patients 
reported that a raised mGPS was independently associated with poor survival in patients 
with cancer, regardless of tumour type (McMillan, 2013b).  
The neutrophil-lymphocyte ratio (NLR) is another prognostic score that has been 
extensively reported to predict outcomes in patients with cancer. The NLR takes the 
absolute neutrophil count and divides it by the absolute lymphocyte count, with a threshold 
of 5 originally used to distinguish between those with a high and those with a low NLR 
score (Walsh et al., 2005). Despite different centres utilising different thresholds to 
differentiate low and high scores the NLR has been extensively validated. In greater than 
60 studies evaluating >37,000 patients, and an elevated NLR was reported to predict poor 
outcomes in patient with a variety of cancers (Guthrie et al., 2013a). 
The platelet-lymphocyte ratio (PLR) is constructed from the absolute platelet count and 
lymphocyte count in a similar way to the NLR. An elevated PLR has been reported to be 
associated with reduced cancer-specific survival (Proctor et al., 2011a). 
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Despite these scores being extensively validated, their clinical use remains limited and 
mainly in clinical research.     
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1.9 The Physiological Response to Surgery  
Following surgical intervention, normal physiological processes occur in the body to aid 
with tissue healing and recovery, known as the surgical stress response.  Serum markers 
that can measure the degree of surgical trauma may be of clinical benefit to monitor patient 
recovery following surgery as well as objectively assessing whether operative techniques 
or multi-modality peri-operative care protocols such as Enhanced Recovery after Surgery 
(ERAS) modify this stress response or whether the patient is likely to develop post-
operative complications that may impact on quality of life and long term survival. 
1.9.1 The Surgical Stress Response 
Injury to the body causes a stereotypical cascade of neuroendocrine, cytokine, acute phase 
and metabolic responses (Cuthbertson, 1979).  Within minutes there is activation of the 
sympathetic nervous system resulting in a neuroendocrine response of increased secretion 
of catecholamines (adrenaline and noradrenaline) into the circulation leading to 
tachycardia, hypertension, fever and tachypnoea (Desborough, 2000).  Simultaneously, 
there is increased secretion of the pituitary hormones such as corticotrophin, growth 
hormone and arginine vasopressin.  Production and release of pro-inflammatory cytokines 
such as tumour necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), IL-8, IL-12, IL-
18 and in particular interleukin 6 (IL-6) then follows (Marik and Flemmer, 2012, Dinarello 
et al., 2013).  There are also changes in circulating myeloid cells, in particular towards 
increased numbers of white cells (WCC) dominated by neutrophils as well as increased 
numbers of myeloid derived suppressor cells and platelets as well as changes in plasma 
concentrations of a number of acute phase proteins, in particular CRP (Pepys and 
Hirschfield, 2003, Kao et al., 2006, Cole et al., 2008). 
It has been hypothesised that the degree of elevation of these markers may reflect the 
degree of surgical trauma following surgery. However, to date no studies have compared 
these different markers of the systemic inflammatory response to try and ascertain which 
markers are the most reliable and clinically useful. If these could indeed be identified then 
these markers could be utilised to ascertain whether the benefit of laparoscopic surgery and 
multi-modal post-operative recovery programmes such as ERAS are due to a reduced post-
operative systemic inflammatory response and reduced surgical trauma.       
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1.9.2 The Role of Enhanced Recovery after Surgery (ERAS) 
Enhanced Recovery after Surgery (ERAS) involves multimodal, protocol driven 
perioperative care which proponents have asserted reduce the stress response to surgery 
(Wilmore and Kehlet, 2001). ERAS is now widely used in many different surgical 
specialties and procedures in surgical units across the UK and Europe. However, no 
standard protocol exists for such programmes and as such the number of components used 
varies between units, making comparison of different ERAS studies challenging (Neville et 
al., 2014). Despite this variability, ERAS has been widely reported to reduce hospital 
length of stay and complications following a range of surgical procedures (Greco et al., 
2014).  
The trauma of surgery leads to well understood metabolic, neuroendocrine and immune 
responses (see above), the aims of which are to promote physiological stability and wound 
healing (Cuthbertson, 1979).  Although it is recognised that laparoscopic surgery generates 
a reduced post-operative systemic inflammatory response, evidenced by reduced post-
operative concentrations of CRP, the impact of individual components of ERAS protocols 
on the systemic inflammatory response is unclear. Given that ERAS programmes have 
been developed to reduce patients’ hospital stay and improve recovery, presumably by 
reducing the stress/systemic inflammatory response, it would be important to know which 
of the components reduced the systemic inflammatory response in order to create a more 
streamlined, sustainable and manageable ERAS programme. This would require a reliable 
and readily available biomarker of the systemic inflammatory response to be identified to 
determine which components affect the systemic inflammatory response and then to 
continue monitoring ERAS programmes as they continue to develop.  
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1.9.3 Complications Following Surgery for Colorectal Cancer 
Despite advances in oncological treatment, the main method of treatment of colorectal 
cancer remains surgery. Surgery is not risk free and is often associated with a significant 
rate of post-operative complications. This complication rate ranges from 20% to 40 % in 
the published literature (Velasco et al., 1996). A post-operative complication can be 
considered as anything that causes the patient to deviate from what is considered a normal 
post-operative course (Dindo et al., 2004). These complications can be classified by type of 
complication (infective or non-infective) or by severity of complication. The Clavien-
Dindo classification attempted to classify complications by their severity based on the 
action required to treat them. In greater than 6000 patients, this scoring system was found 
to be reliable, reproducible and comprehensive in classifying post-operative complications 
by severity (Dindo et al., 2004). This had the advantage over other severity scoring 
systems of being more objective and easier to replicate across a variety of surgical 
procedures and centres. 
Regardless of how complications are classified, what has become clear is that they are 
detrimental to the patient in multiple ways. Complications not only result in short term 
problems such as increased length of stay, but have also been reported to adversely affect 
oncological outcome (Law et al., 2007a, Law et al., 2007b), quality of life (Brown et al., 
2014) and long term survival following surgery (Khuri et al., 2005, McArdle et al., 2005). 
Therefore, much attention has been directed to try and reduce the risk of developing 
complications such as the use of pre-operative antibiotics, specific skin preparation and 
specialist surgeons. Despite this, complication rates remain significant. The systemic 
inflammatory response both pre-operatively and post-operatively have been reported to be 
associated with increased risk of development of complications (Moyes et al., 2009, Platt 
et al., 2012, Ramanathan et al., 2013). The pre-operative scoring system, the modified 
Glasgow prognostic score (mGPS) has been reported to be associated with post-operative 
complications but no such scoring system has been described in the post-operative period. 
If such a score could be devised then it may be of clinical utility in identifying, early in the 
post-operative phase, patients at increased risk of developing complications, or conversely, 
identify those at low risk and facilitate early discharge from hospital. Furthermore, if the 
post-operative systemic inflammatory response is associated with the development of 
complications then it could be hypothesised that modification of the post-operative 
systemic inflammatory response, either by operative technique or anti-inflammatory 
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medication may reduce the risk of developing complications and hence improve outcomes 
following cancer surgery.   
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1.10 Aims of Thesis 
This thesis aims to: 
 Determine the attitudes towards systemic inflammation based scoring systems and 
their use in routine clinical practice 
 Examine other pre-operative markers of the innate immune system and determine 
whether they accurately reflect systemic inflammation and are capable of predicting 
outcomes 
 Determine whether common markers of systemic inflammation can reflect surgical 
trauma and in turn use these markers to analyse the post-operative systemic 
inflammatory response and its effects on outcomes  
 Using these markers analyse whether individual components of ERAS reduce the 
systemic inflammatory response 
 Ascertain whether the systemic inflammatory response can be modulated 
pharmacologically in order to improve outcomes following surgery for colorectal 
cancer.
 
 
 
 
 
2 A survey of attitudes towards the clinical 
application of systemic inflammation based 
prognostic scores in cancer  
2.1 Introduction 
Allocation of patients to the correct form of treatment, be that surgical, oncological or 
palliative, remains a difficult decision.  However, if patients were allocated to the most 
appropriate treatment then outcomes for all patients would improve, irrespective of new, 
more effective treatments.  Traditionally, in those with early stage operable disease the 
treatment decision has been made largely based on staging of the cancer itself e.g. the 
Tumour, Node, Metastasis (TNM) staging system whereas in advanced stage inoperable 
disease the treatment decision has been made largely based on the general health and 
fitness and whether the patient had lost weight (cachexia).   
In the last decade or so it has become apparent that a host inflammatory response, in 
particular the systemic inflammatory response, plays a key role in determining cachexia 
and the survival of patients with cancer (McMillan, 2009, Roxburgh and McMillan, 2010). 
With this new knowledge, a number of prognostic scoring systems that provide an 
objective measurement of the systemic inflammatory response have been developed and 
have been shown to have prognostic value in patients with cancer. These include the 
Glasgow Prognostic score/modified Glasgow Prognostic Score (GPS/mGPS), neutrophil-
lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), white cell-lymphocyte ratio 
(WLR) and others (Proctor et al., 2011a, East et al., 2014).  The mGPS (combination of the 
values of pre-operative serum albumin and C-reactive protein) and the NLR (ratio of 
neutrophil and lymphocyte counts) are the most widely reported prognostic scores 
worldwide and both have been shown to have prognostic value in a variety of common 
solid tumours (McMillan, 2013b, Guthrie et al., 2013a, Li et al., 2014a).  For example, by 
the end of 2012, the GPS/mGPS had been shown to have independent prognostic value in 
cancer patients in 51 studies involving 28,500 patients (McMillan, 2013b). Furthermore, 
the NLR has been shown to have independent prognostic value in 100 studies involving 
greater than 40 000 patients, with greater than 50% of these studies published since the 
start of 2012 (Templeton et al., 2014). 
Despite the plethora of reported studies for these prognostic scores, their value in routine 
clinical practice either as tools to stratify patients in terms of outcomes or for consideration 
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for therapies such as adjuvant chemotherapy or in clinical trials is not clear.  With this in 
mind, the aim of the present survey, in an international cohort, was to examine the range of 
opinions on the routine use of systemic inflammation based prognostic scoring systems and 
their potential incorporation into clinical guidelines.  
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2.2 Methods 
A worldwide survey designed to establish opinions on the use of systemic inflammation 
based prognostic scoring systems was created.  This was a web-based survey that included 
10 questions on ‘systemic inflammation based prognostic scores in cancer’ (Table 2.1).  
The survey was generated through the SurveyMonkey website (www.surveymonkey.com, 
SurveyMonkey, Paulo Alto, USA) and the access link emailed to the target group. The 
target group was selected primarily from two recent reviews (Mcmillan, 2013b, Guthrie et 
al., 2013a) and by performing a more recent literature search for articles using the 
keywords cancer, inflammation, recurrence, survival, mGPS and NLR. This literature 
search was performed at the end of January 2014.  Once a comprehensive list of articles 
was obtained, the email addresses of corresponding authors from each article formed the 
basis of a mailing list for distribution. The email sent out clearly stated that the aim of the 
survey was to establish whether there was a role for the application of systemic 
inflammation based prognostic scores in routine clinical practice and research and that 
participation was voluntary. Software on the website ensured duplication of responses from 
the same individual was not recorded. No incentives were used to promote or encourage 
participation. 
The survey was first sent out on 26
th
 February 2014 with a reminder sent out one week 
later. The survey remained open for 4 weeks and was closed on the 26
th
 March 2014.  Data 
was analysed and graphs of results compiled using Microsoft Excel 2007 (Redmond, WA, 
USA). 
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2.3 Results 
In February 2014, the survey was emailed to 238 individuals worldwide who had published 
articles related to systemic inflammation in patients with cancer.  43% were from Asia, 
42% from Europe, 12% from America and 3% from Australia. The response to survey 
question 1 is shown in Figure 2.1 (a & b). In total, 60 people completed the survey (25%). 
26 respondents (43%) were surgeons, 15 (25%) oncologists and 19 (32%) from other 
medical specialties. The proportion of respondents is shown in Figure 2.1 (b) with 55% of 
respondents being from Europe, 29% from Asia, 13% from Americas and 3% from 
Australia.   
In response to question 2, 39 (65%) of the respondents answered yes that they routinely 
measured the systemic inflammatory response in patients with cancer. The median number 
of patients each participant assessed per year was 100 and the median number of patients 
each participant assessed in total was 330. 
The response to question 3 is shown in Figure 2.2. Of the respondents, 11 (27%) reported 
its use for the purpose of prognostication and research, 11 (27%) reported its use for 
research purposes alone, 5 (12%) for the purpose of prognostication alone, 4 (10%) 
reported its use for audit purposes, and 3 (8%) for the purpose of treatment allocation.  
The response to question 4 is shown in Figure 2.3. Of those who responded, 16 (40%) 
answered the measure of the systemic inflammatory response they used was the GPS, 8 
(20%) answered the GPS/NLR and 6 (15%) answered the NLR alone. 
The response to question 5 is shown in Figure 2.4 (a). Of the respondents, 31 (56%) 
answered yes they would use a measure of the systemic inflammatory response to stratify 
patients entering clinical trials.  
The response to question 6 is shown in Figure 2.4 (b). Of the respondents, 20 (57%) 
answered that they would use the GPS, 4 (11%) answered the NLR and 4 (11%) answered 
the GPS/NLR for stratifying patients entering clinical trials. 
The response to question 7 is shown in Figure 2.5. Of the respondents, 12 (25%) reported 
that the clinical scenarios where a measure of the systemic inflammatory response offers 
most benefit were making decisions on palliative chemotherapy, 10 (21%) reported making 
decisions on allocation of adjuvant therapy, 6 (12%) reported on decisions about either 
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adjuvant therapy or palliative chemotherapy and 5 (10%) reported on all 4 categories. Only 
2 (4%) reported in making decisions on allocation of surgical treatment. 
The response to question 8 is shown in Figure 2.6 (a). Of the respondents, 46 (81%) 
answered yes to whether a measure of the systemic inflammatory response should be 
adopted into clinical guidelines.  
The response to question 9 is shown in Figure 2.6 (b). Of those who responded, 30 (60%) 
answered that the measure of the systemic inflammatory response they would prefer to use 
in clinical guidelines was the GPS, 7 (14%) answered GPS/NLR and 5 (10%) answered 
NLR.  
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2.4 Discussion 
The results of the present study showed that the majority of respondents routinely 
measured the systemic inflammatory response, used the GPS/mGPS, mainly for research 
and prognostication purposes, and that the majority of respondents reported that a measure 
of the systemic inflammatory response should be adopted into clinical guidelines. 
A small number of people responded to our survey (25%) although this rate falls within the 
average response rate of between 20 and 30% (SurveyMonkey, 2014). Factors that are 
known to improve the survey response rate include incentives, reduced survey length, 
reduced complexity of questions, and reminder emails (SurveyMonkey, 2014).  In the 
present study the questions were intentionally simple and limited to 10 in total and sent a 
reminder email to encourage respondents but did not employ any incentive for completing 
the survey.   
The survey was sent to potential participants worldwide with the majority to Asia and 
Europe.  The majority of respondents of this survey were surgeons (43%) with oncologists 
making up a quarter of respondents. The location of the respondents did not closely match 
the locations of the potential survey participants. Those invited to participate were mainly 
from Asia and Europe however, only 29% of respondents were from Asia while 55% were 
from Europe.  Perhaps this lack of response from Asia is due to cultural differences which 
were not present in those from Europe or due to greater language barriers. Whatever the 
reason, the poor response rate from Asia was disappointing given that the majority of work 
using these prognostic scores has been carried out in Europe and Asia. In the present study, 
respondents were asked to estimate how many patients with cancer they had assessed using 
these systemic inflammation based scores in each year. The response was approximately 
100 per year. With this volume of work it could be considered that those who responded 
were specialists and had an interest in systemic inflammation based scores. 
It has been widely reported that markers of the systemic inflammatory response are good 
prognostic markers in patients with cancer. The majority of survey respondents reported 
that they routinely assessed the systemic inflammatory response in patients with cancer and 
the majority used this assessment for research or prognostication purposes. This is not 
unexpected since the majority of studies examining these scoring systems were performed 
for research purposes or were performed retrospectively to aid prognostication of patients 
into high and low risk groups. Whilst CRP has been shown to have prognostic value in a 
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number of tumours, the mGPS, which utilises a combination of CRP and albumin at 
standard thresholds, has been shown to have superior prognostic value and obviates the 
problem of different CRP threshold values being used within and across different tumour 
types. In the present study, the majority of respondents reported that they would use 
GPS/mGPS as their method of assessing the systemic inflammatory response. This would 
appear to be consistent with the literature and whilst the participants of this survey have an 
interest in this field, it was not clear, prior to this survey, what views they had on the 
clinical application of systemic inflammation based prognostic scores, in particular which, 
if any, score that they would prefer to use clinically. 
Interestingly, only a small number of respondents reported that they used assessment of the 
systemic inflammatory response to determine treatment allocation and this is an area where 
proponents of these scoring systems would hope to expand their use in order to better 
stratify patients to appropriate treatment modalities (McMillan, 2013a). Of the survey 
respondents, 56% reported that they would use a measure of the systemic inflammatory 
response to stratify patients entering into clinical trials and 57% said they would choose 
mGPS/GPS for this.  Moreover, of the survey respondents, 25% reported that these scores 
were used in making decisions about palliative chemotherapy, 21% in making decisions 
about allocation of adjuvant therapy and 12% in making decisions either about adjuvant 
therapy or palliative chemotherapy.  Only 4% reported that a measure of the systemic 
inflammatory response would be of benefit in making decisions about allocation of 
surgical treatment.  This is of interest as the majority of respondents were surgeons, with 
the majority of research in these scoring systems having been undertaken by surgeons, yet 
the consensus was that it would not be of benefit to allocate surgical treatment based on 
these scoring systems. The basis of this approach is not clear.  However it may be that 
surgeons wish to operate on all patients with potentially curable disease. It remains to be 
seen whether this approach will be maintained in the long term, particularly in aggressive 
cancers such as pancreatic cancer where neoadjuvant therapy is increasingly used as first 
line therapy. 
Furthermore, recent work has suggested that markers of the systemic inflammatory 
response may be useful as a therapeutic target.  The recent addition of an anti-angiogenic 
monoclonal antibody to VEGF therapy, such as Bevacizumab to standard chemotherapy 
regimens has resulted in improved efficacy of these regimens.  However, recent studies 
have reported that patients with a raised neutrophil count, high NLR or mGPS 1 or 2 
received no significant survival benefit from these regimens (Botta et al., 2011, Botta et al., 
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2013, Maillet et al., 2014).  In addition, Botta and colleagues reported in their study that 
preoperative systemic inflammatory status was a marker of resistance to bevacizumab 
therapy (Botta et al., 2013). Also, recent work has suggested that the mGPS may be useful 
in stratifying oncological treatment. Hurwitz et al. recently reported that Ruxolitinib (a 
Janus Kinase 1 (JAK1)/Janus Kinase 2 (JAK2) inhibitor) along with capecitabine 
improved overall survival and progression free survival in patients with metastatic 
pancreatic cancer with inflammation characterised by mGPS 1 or 2 (Hurwitz, 2014).   
Of the survey respondents, 80% reported that they felt a measure of the systemic 
inflammatory response should be adopted into clinical guidelines and 60% reported that 
GPS/mGPS would be their preference. For example, cancer cachexia affects greater than 
50% of patients with advanced disease and its clinical definition and symptoms have been 
intensively discussed in recent years (Aapro et al., 2014, Douglas and McMillan, 2014).  
Recently, the European School of Oncology Task Force conducted a review the literature 
on cancer cachexia. They concluded that cachexia is a complex process but that along with 
anorexia, the presence of a systemic inflammatory response results in the features of the 
disease (Aapro et al., 2014).  Furthermore, Douglas and McMillan (2014) recently 
proposed that the mGPS be used as the basis for formation of an objective and clinically 
relevant definition of cachexia (Douglas and McMillan, 2014).  The findings of the present 
study would appear to confirm that the mGPS is the most commonly used systemic 
inflammation based score and therefore appropriate for forming the basis of an objective 
definition of cancer cachexia.   
The present study has a number of possible limitations. Firstly, respondents did not have to 
enter their location in order to complete the questionnaire, meaning the location for all the 
respondents was not obtained.  In all surveys there is a tension between making the sample 
size as large as possible in order to eliminate bias and asking questions appropriate to those 
surveyed. In the present survey, we targeted those with a known interest in systemic 
inflammation based prognostic scores (those who had already published in this field) in 
order to maximise the number of appropriate and meaningful responses. The mGPS and 
NLR are the most popular scores as they have the largest evidence base. Although other 
systemic inflammation based prognostic scores such as the derived NLR (dNLR), 
lymphocyte monocyte ratio (LMR) and platelet-lymphocyte ratio (PLR) have been 
reported they have not established a sufficient body of evidence in the literature. Moreover, 
where they have been directly compared, the mGPS had the greatest prognostic value in 
patients with cancer, independent of age, sex, deprivation and tumour stage (Guthrie et al., 
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2013b, Proctor et al., 2011a). Therefore, it is likely that the results of this survey reflect the 
reality of attitudes towards the application of these scores in those individuals with an 
interest in the field. It was of interest that 43% of the respondents were surgeons. This may 
reflect the activity of surgeons in this field. Indeed, it is recognised that surgeons are key 
members of the multi-disciplinary team that decides treatment allocation. Irrespectively, 
this would confirm that the survey was directed at clinicians in routine clinical practice. 
In summary, the present study has shown that in those who responded, the majority 
routinely measured the systemic inflammatory response in patients with cancer, with the 
majority using the GPS/mGPS, mainly for research and prognostication purposes.  The 
majority reported that these scoring systems were of most clinical benefit in making 
decisions on adjuvant therapy and palliative chemotherapy and that the systemic 
inflammatory response, as evidenced by the GPS/mGPS, should be adopted into clinical 
guidelines, such as a new, objective and clinically relevant definition of cancer cachexia.   
 
  
  
71 
 
 
 
Table 2.1 Survey of systemic inflammation based prognostic scores in cancer 
Survey Question 
1. What is your discipline (surgeon/oncologist/pathologist etc.) and in which country are 
you based? 
2. Do you or your colleagues routinely assess the systemic inflammatory response as 
part of the clinical assessment of patients with cancer? 
                 Since 2008, could you estimate how many patients have been assessed (a) in total      
                 and (b)per year?  
3. If you answered yes to question 2, for what purpose? 
                 Audit 
                 Prognostication 
                 Treatment allocation 
                 Research 
4. If you answered yes to question 2, what measure of the systemic inflammatory 
response do you use? 
                 GPS 
                 NLR 
                 Other 
5. Would you use a measure of the systemic inflammatory response to stratify patients 
entering into clinical trials? 
6. If you answered yes to question 5, which would you prefer to use? 
                 GPS 
                 NLR 
                 Other 
7. In which clinical scenario do you think a measure of the systemic inflammatory 
response offers most benefit to patients? 
                 In making decisions about allocation of surgical treatment for primary operable  
                 disease 
                 In making decisions on allocation of neoadjuvant treatment 
                 In making decisions on allocation of adjuvant treatment 
                 In making decisions on palliative chemotherapy 
8. Do you think that a measure of the systemic inflammatory response should be adopted 
into clinical guidelines? 
9. If yes, which would you prefer to use? 
                 GPS 
                 NLR 
                 Other 
10. If you do not think that a measure of the systemic inflammatory response is useful in 
the routine clinical assessment of cancer patients, please comment. 
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Figure 2.1 Responses to survey question 1. 
(a) What is your discipline? Respondents (n = 60) and (b) In which country 
are you based? Respondents (n = 31) 
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Figure 2.2 Responses to survey question 3. 
For what purpose do you measure the systemic inflammatory response? 
Respondents (n = 41). 
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Figure 2.3 Responses to survey question 4. 
What measure of the systemic inflammatory response do you use? 
Respondents (n = 40). 
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Figure 2.4 Responses to survey question 5. 
(a) Would you use a measure of the systemic inflammatory response to 
stratify patients entering into clinical trials? Respondent (n = 55) and (b) 
Which measure of the systemic inflammatory response would you use to 
stratify patients entering into clinical trials? Respondents (n = 35). 
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Figure 2.5 Responses to survey question 7. 
In which clinical scenario do you think a measure of the systemic 
inflammatory response offers most benefit to patients? Respondents (n=49). 
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Figure 2.6 Responses to survey questions 8 and 9. 
(a) Do you think that a measure of the systemic inflammatory response 
should be adopted into clinical guidelines? Respondents (n = 57) and (b) 
Which measure of the systemic inflammatory response should be included? 
Respondent (n = 50). 
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3 Neutrophil count is the most important 
prognostic component of the differential white 
cell count in patients undergoing elective 
surgery for colorectal cancer 
3.1 Introduction 
Although there have been improvements in the treatment and management of colorectal 
cancer, outcomes remain poor with approximately 40% of those who undergo curative 
surgery dying from their disease (Oliphant et al., 2013). Traditionally, likely outcomes 
following surgery and treatment options offered to patients have been determined by 
prognostic stratification systems based on pathological tumour characteristics such as the 
Tumour, Nodal, Metastasis (TNM) system (Ajcc, 2010). However, clinical outcomes vary 
considerably amongst patients within the same TNM stage (Horgan and McMillan, 2010). 
It is increasingly recognised that patient factors such as nutritional decline, functional 
decline and the presence of a systemic inflammatory response are associated with 
progression of cancer and poorer outcomes (McMillan, 2009, Roxburgh and McMillan, 
2010).  With reference to the systemic inflammatory response, prognostic scoring systems 
such as the modified Glasgow Prognostic Score (mGPS), a combination of C-reactive 
protein and albumin,(McMillan, 2013b) and various combinations of components of a 
differential white cell count (WCC) have been reported to be of value in many solid organ 
cancers including colorectal cancer (East et al., 2014, Guthrie et al., 2013a, Li et al., 2014a, 
Kwon et al., 2012).  Although apparently inferior to the mGPS and a number of different 
neutrophil-lymphocyte ratio (NLR) thresholds being reported, many recent publications 
have documented its prognostic value in patients with colorectal cancer (Clarke et al., 
2011, Guthrie et al., 2013b, Li et al., 2014a). However, it is not clear whether both 
components of the NLR contribute equally to the prognostic value since NLR reflects the 
activity of both the innate (neutrophil) and adaptive (lymphocyte) aspects of the immune 
system.  Indeed, it may be hypothesised that the neutrophil count has the dominant 
prognostic value. The aim of the present study was to examine, in detail, the relationships 
between the components of the differential white cell count and survival in patients 
undergoing elective surgery for colorectal cancer.  
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3.2 Methods 
3.2.1 Patients 
Patients were identified from a prospectively maintained database of elective and 
emergency colorectal resections performed in a single surgical unit at Glasgow Royal 
Infirmary.  Patients who, on the basis of pre-operative abdominal computed tomography 
and operative findings, were considered to have undergone potentially curative resection 
between 1997 and 2008 were included.  Exclusion criteria were neoadjuvant therapy, 
emergency presentation and presence of metastatic disease.  The study was approved by 
the West of Scotland Research Ethics Committee, Glasgow. 
Patient demographics and pre-operative laboratory measurements including the differential 
white cell count: total white cell count, neutrophil, lymphocyte, monocyte, eosinophil and 
basophil and platelet counts were analysed.  Data was also available for the mGPS.  
Tumours were staged according to the 5
th
 edition of the tumour, node, metastases (TNM) 
classification (AJCC, 2010) and any additional pathological data obtained from the 
pathology reports issued following resection.  Patients were routinely followed up for 5 
years following resection as per national guidelines. Date and cause of death were 
crosschecked with the cancer registration system and Registrar General (Scotland).  Cancer 
specific survival was measured from date of surgery until date of death. 
3.2.2 Statistical Analysis 
Kaplan Meier analysis of clinicopathological factors that are, a priori, known to be 
important predictors of outcome and of components of the differential white cell count 
(total white cell count, neutrophil count, lymphocyte count, monocyte count, eosinophil 
count, basophil count and platelet count) was performed and plots included to confirm the 
linearity of different variables (Figure 3.1). Statistically significant components of the 
differential white cell count were then included in a multivariate model along with the 
clinicopathological variables. Multivariate analysis was performed using backwards 
conditional Cox regression. A p-value of <0.05 was considered statistically significant. 
Analyses were carried out using SPSS version 21.0 (IBM, SPSS, IL, USA). 
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3.3 Results 
A total of 508 patients who underwent resection were included in the analysis.  The 
clinicopathological characteristics are summarised in Table 3.1.  The majority were over 
the age of 65 (67%) with similar numbers of males and females.  The majority had TNM 
stage II (50%) or III disease (39%) with the majority of tumours being colonic in origin 
(69%) and 21% had adjuvant chemotherapy following resection. Median follow up of 
survivors was 109 months (range 51-194). 
The relationship between the clinicopathological characteristics and both cancer-specific 
and overall survival in the whole cohort (n=508) is shown in Tables 3.1 & 3.2.  There were 
172 cancer deaths and 120 non-cancer deaths.  Using Kaplan Meier analysis, age, TNM 
stage, venous invasion, margin involvement, peritoneal involvement and tumour 
perforation (all p < 0.05) as well as white cell count and neutrophil count (both p < 0.05) 
were significantly associated with cancer-specific survival (Table 3.1). Similarly, age, 
TNM stage, venous invasion, margin involvement, peritoneal involvement and tumour 
perforation (all p < 0.05) as well as white cell count and neutrophil count (both p < 0.005) 
were associated with overall survival (Table 3.1). In the whole cohort, on multivariate 
survival analysis (Table 3.2), age (HR 1.29 CI 1.07-1.56, p = 0.007); site (HR 1.40, CI 
1.01-1.94, p = 0.041); TNM stage (HR 2.19, CI 1.64-2.91, p < 0.001); margin involvement 
(HR 2.97, CI 1.93-4.59, p < 0.001); peritoneal involvement (HR 1.48, CI 1.07-2.05, p = 
0.019) and mGPS (HR 1.54, CI 1.25-1.90, p < 0.001) were independently associated with 
cancer-specific survival. On multivariate analysis (Table 3.2), age (HR 1.60, CI 1.36-1.87, 
p < 0.001); sex (HR 1.40, CI 1.10-1.79, p = 0.007); TNM stage (HR 1.44 CI 1.15-1.80, p = 
0.001); venous invasion (HR 1.50, CI 1.17-1.94, p = 0.002); margin involvement (HR 
2.49, CI 1.69-3.68, p < 0.001); tumour perforation (HR 2.48, CI 1.23-4.99, p = 0.011); and 
the mGPS (HR 1.32, CI 1.12-1.56, p = 0.001) were independently associated with overall 
survival.  
The relationship between the clinicopathological characteristics and both cancer specific 
and overall survival in node negative colon cancer (n=226) is shown in Tables 3.2 & 3.3.  
There were 49 cancer deaths and 69 non-cancer deaths. Using Kaplan Meier analysis, 
TNM stage, venous invasion and margin involvement (all p < 0.05) as well as white cell 
count, neutrophil count, basophil count, platelet count and NLR (p < 0.05) were associated 
with cancer-specific survival (Table 3.3). Furthermore, age, venous invasion and tumour 
perforation (all p < 0.05) as well as white cell count and neutrophil count (all p < 0.05) 
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were associated with overall survival (Table 3.3). In the node negative colon cohort, on 
multivariate survival analysis (Table 3.2), age (HR 1.53, CI 1.05-2.23, p = 0.028); venous 
invasion (HR 2.23, CI 1.19-4.16, p = 0.012); mGPS (HR 1.52, CI 1.03-2.24, p = 0.035) 
and neutrophil count (HR 2.31, CI 1.13-4.71, p = 0.022) were independently associated 
with cancer-specific survival. On multivariate analysis (Table 3.2), age (HR 2.05, CI 1.59-
2.64, p < 0.001); sex (HR 1.57, CI 1.06-2.31, p = 0.023); venous invasion (HR 2.24, CI 
1.47-3.41, p <0.001); margin involvement (HR 3.19, CI 1.36-7.49, p = 0.008); mGPS (HR 
1.36, CI 1.06-1.75, p = 0.017) and neutrophil count (HR 1.74, CI 1.06-2.88, p = 0.030) 
were independently associated with overall survival.  
The neutrophil count was added to the mGPS in the same way as previously described 
(Proctor et al., 2013) to create the optimised Glasgow Prognostic Score (oGPS). In short, 
C-reactive protein (CRP) <10 mg/L scored 0; CRP >10 mg/L and albumin ≥ 35g/L scored 
1; CRP >10 mg/L and albumin < 35 g/L scored 2 and CRP >10 mg/L, albumin < 35 g/L 
and neutrophil count > 7.5 x10
9
/L scored 3. Kaplan Meier curve of the oGPS and cancer-
specific survival in the whole cohort is shown in Figure 3.4. As the oGPS score increase 
from 0 to 3 cancer-specific survival worsens (p < 0.001). Furthermore, on Cox regression 
analysis, the oGPS appears to be associated with both cancer-specific survival and overall 
survival in the whole cohort (CSS - HR 1.44, CI 1.21-1.70, p < 0.001; OS - HR 1.40, CI 
1.22-1.60, p < 0.001). 
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3.4 Discussion 
The results of the present study show that of the components of a white cell count, only the 
neutrophil count was independently associated with survival. In particular, a high 
neutrophil count was associated with poorer cancer-specific survival, especially in node 
negative colon cancer. Therefore, it would appear that the prognostic value of the NLR 
derives mainly from the neutrophil count in patients with colorectal cancer.  It remains to 
be determined whether this is the case in all solid tumours in which the NLR has been 
reported to have prognostic value.  
The results of the present study are consistent with the recent report of Jankova and 
colleagues (Jankova et al., 2013) who, in 322 patients with node positive colorectal cancer, 
concluded that NLR was independently and weakly associated with poorer overall survival 
but not cancer-specific survival. They also examined, using receiver operating 
characteristic (ROC) curves, optimal thresholds for the NLR but found that no single cut 
off could be recommended due to the weak association between NLR and survival 
(Jankova et al., 2013).  Furthermore, a recent longitudinal study reported that whilst 
preoperative NLR and mGPS were independently associated with cancer-specific survival 
only post-operative mGPS was independently associated with cancer-specific survival 
(Guthrie et al., 2013b). 
The present results may shed some light into the prognostic variability of the NLR, 
irrespective of the threshold used, since it is clear that the lymphocyte count, although it 
contributes approximately equally to the NLR (Figures 3.2 and 3.3), has relatively weak 
prognostic value compared with the neutrophil count alone.  A plausible explanation of 
why the neutrophil count has superior prognostic value is that it better reflects the basis of 
the systemic inflammatory response, which is primarily an upregulation of the innate 
immune system (Roxburgh et al., 2013).  
The results of the present study are consistent with the work of Proctor and colleagues 
(Proctor et al., 2013), who reported in a large unselected cohort of patients with cancer 
that, compared with other markers of the systemic inflammatory response, an elevated 
neutrophil count had independent prognostic value whereas the lymphocyte count did not.  
Moreover, they proposed that the neutrophil count was added to the mGPS and termed the 
score the Optimised GPS (oGPS).  It is therefore of interest that the neutrophil count along 
with mGPS, has been shown to be independently prognostic in patients with advanced 
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gastric cancer (Li et al., 2014b).  Therefore, the use of a neutrophil count, may add 
prognostic value to the mGPS in patients colorectal cancer. Indeed, in the present study, 
the use of the oGPS was useful in further stratifying cancer-specific survival in patients 
undergoing elective surgery for colorectal cancer. 
The recent addition of an anti-angiogenic monoclonal antibody to vascular endothelial 
growth factor (VEGF) therapy, such as Bevacizumab to standard chemotherapy regimens 
has resulted in improved efficacy of these regimens.  Recent studies have reported that a 
reduced neutrophil count and low NLR are associated with improved survival in advanced 
non-small cell lung cancer (Botta et al., 2013) and metastatic colorectal cancer (Botta et al., 
2011) treated with these therapies.  Indeed, it has previously been reported that neutrophils 
are found in increased number at tumour sites and that they are able to promote 
angiogenesis by secreting factors such as VEGF, interleukin-8 (IL-8) and matrix 
metallopeptidase 9 (MMP-9). In these studies, despite blockade of VEGF activity with 
Bevacizumab, patients with high circulating levels of neutrophils or high NLR received no 
significant survival benefit. This recent observation is consistent with the findings from the 
present study and suggests that it is neutrophils that drive tumour progression and 
dissemination. 
The results of the present study have implications not only for the prognostic value of 
scores other than the NLR that include components of the innate and adaptive immune 
systems, usually lymphocyte counts, for example, the platelet-lymphocyte ratio (PLR) 
(Kwon et al., 2012), white cell-lymphocyte ratio (WLR) (East et al., 2014), lymphocyte-
monocyte ratio (LMR) (Hu et al., 2014) and may explain why  the derived NLR (dNLR), 
based solely on neutrophil and white cell count had similar or better prognostic value 
compared with the NLR (Proctor et al., 2012).  
The present study is limited by its retrospective cross-sectional nature. Nonetheless, this is 
the first time that detailed analysis of the components of a white cell count has been 
examined in patients undergoing potentially curative surgery for colorectal cancer.     
In summary, the results of the present study clearly show the independent prognostic value 
of the neutrophil count and that it is the basis of the prognostic value of the NLR in 
patients with primary operable colorectal cancer.  These results have implications for 
prognostic scores based on the components of a differential white cell counts.  
84 
 
 
 
  
Table 3.1 Clinicopathological characteristics, components of the differential white cell 
count and survival in patient undergoing elective resection for colorectal 
cancer  
Characteristics n (%) or Median (range)  Cancer-
specific 
Survival 
Overall 
Survival 
   p-value
a
 p-value
a
 
Age (<65/65-74/>74) 165 (33)/ 163 (32)/ 180 (35) 0.010 <0.001 
Sex (Female/Male) 233 (46)/ 275 (54) 0.399 0.199 
Site (Colon/Rectum) 350 (69)/ 158 (31) 0.125 0.535 
TNM Stage (I/II/III) 55 (11)/ 254 (50)/ 199 (39) <0.001 <0.001 
Differentiation (Mod-well/Poor) 450 (89)/ 56 (11) 0.018 0.005 
Venous Invasion (No/Yes) 298 (59)/ 210 (41) <0.001 <0.001 
Margin involvement (No/Yes) 467 (92)/ 41 (8) <0.001 <0.001 
Peritoneal involvement (No/Yes) 384 (76)/ 124 (24) <0.001 0.020 
Tumour perforation (No/Yes) 498 (98)/ 10 (2) 0.002 <0.001 
Adjuvant therapy (No/Yes) 400 (79)/ 108 (21) 0.747 0.086 
Time dependent variable  
(1997-2002/2003-2008) 
214 (42)/ 294 (58) 0.367 0.109 
    
WCC (<8.5/8.5-11/>11) 320 (63)/ 118 (23)/ 60 (12) 0.029 <0.001 
Neutrophil (<7.5/>7.5) 434 (85)/ 64 (13) 0.007 0.001 
Lymphocytes (<1/1-3/>3) 49 (10)/ 427 (84)/ 22 (4) 0.717 0.940 
Monocytes (<0.9/>0.9) 413 (81)/ 70 (14) 0.053 0.019 
Eosinophils (<0.04/0.04-
0.4/>0.4) 
54 (11)/ 392 (77)/ 37 (7) 0.131 0.040 
Basophils (<0.01/0.01-0.1/>0.10) 276 (54)/ 201 (40)/ 6 (1) 0.102 0.001 
Platelets (<400/>400) 406 (80)/ 83 (16) 0.199 0.314 
NLR (<5/>=5) 405 (80)/ 93 (18) 0.533 0.125 
    
Alive/ cancer death/non-cancer  
death 
216 (43)/172(34)/120(23)   
NLR = neutrophil-lymphocyte ratio; TNM = Tumour, Nodal, Metastasis; WCC = white 
cell count 
a 
Log rank p-value  
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Table 3.2  Multivariate analysis of clinicopathological factors and components of 
differential white cell count following elective, potentially curative surgery for 
colorectal cancer 
 Cancer-specific Survival Overall Survival 
 HR (95% CI) p-value HR (95% CI) p-value 
Whole Cohort (n = 508)     
Clinicopathological Factors     
Age (<65/65-74/>74) 1.29 (1.07-1.56) 0.007 1.60 (1.36-1.87) <0.001 
Sex (Female/Male) - 0.109 1.40 (1.10-1.79) 0.007 
Site (Colon/Rectum) 1.40 (1.01-1.94) 0.041 - 0.182 
TNM Stage (I/II/III) 2.19 (1.64-2.91) <0.001 1.44 (1.15-1.80) 0.001 
Differentiation (Mod-well/Poor) - 0.275 1.41 (1.00-2.00) 0.053 
Venous Invasion (No/Yes) - 0.113 1.50 (1.17-1.94) 0.002 
Margin involvement (No/Yes) 2.97 (1.93-4.59) <0.001 2.49 (1.69-3.68) <0.001 
Peritoneal involvement (No/Yes) 1.48 (1.07-2.05) 0.019 - 0.600 
Tumour perforation (No/Yes) - 0.175 2.48 (1.23-4.99) 0.011 
Adjuvant therapy (No/Yes) - 0.230 0.75 (0.54-1.04) 0.080 
Time dependent variable  
(1997-2002/ 2003-2008) 
- 0.883 - 0.617 
     
Neutrophil (Threshold) (<7.5/>7.5) - 0.424 - 0.145 
mGPS (0/1/2) 1.54 (1.25-1.90) <0.001 1.32 (1.12-1.56) 0.001 
     
Node negative colon cohort  
(n = 226) 
    
Clinicopathological Factors     
Age (<65/65-74/>74) 1.53 (1.05-2.23) 0.028 2.05 (1.59-2.64) <0.001 
Sex (Female/Male) - 0.129 1.57 (1.06-2.31) 0.023 
TNM Stage (I/II) 4.14 (0.55-30.98) 0.167 - 0.774 
Differentiation (Mod-well/Poor) - 0.147 - 0.826 
Venous Invasion (No/Yes) 2.23 (1.19-4.16) 0.012 2.24 (1.47-3.41) <0.001 
Margin involvement (No/Yes) - 0.115 3.19 (1.36-7.49) 0.008 
Peritoneal involvement (No/Yes) - 0.665 - 0.152 
Tumour perforation (No/Yes) - 0.743 - 0.264 
Adjuvant therapy (No/Yes) - 0.416 - 0.389 
Time dependent variable  
(1997-2002/ 2003-2008) 
- 0.484 - 0.202 
     
Neutrophil (Threshold) (<7.5/>7.5) 2.31 (1.13-4.71) 0.022 1.74 (1.06-2.88) 0.030 
mGPS (0/1/2) 1.52 (1.03-2.24) 0.035 1.36 (1.06-1.75) 0.017 
CI = confidence interval; HR = hazard ratio; mGPS = modified Glasgow Prognostic Score; 
TNM = Tumour, Nodal, Metastasis; NLR = neutrophil-lymphocyte ratio; WCC = white 
cell count 
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Table 3.3  Clinicopathological characteristics, components of the differential white cell 
count and survival in patients undergoing elective resection for node 
negative colon cancer 
Characteristics n (%) or Median 
(range)  
Cancer-
specific 
Survival 
Overall 
Survival 
  p-value
a
 p-value
a
 
Age (<65/65-74/>74) 70 (31)/ 76 (34)/ 80 (35) 0.140 <0.001 
Sex (Female/Male) 106 (47)/ 120 (53) 0.840 0.323 
TNM Stage (I/II) 33 (15)/ 193 (85) 0.014 0.204 
Differentiation (Mod-well/Poor) 204 (91)/ 21 (9) 0.519 0.332 
Venous Invasion (No/Yes) 153 (68)/ 73 (32) 0.002 0.001 
Margin involvement (No/Yes) 218 (97)/ 8 (3) 0.032 0.064 
Peritoneal involvement (No/Yes) 181 (80)/ 45 (20) 0.274 0.651 
Tumour perforation (No/Yes) 221 (98)/ 5 (2) 0.631 0.011 
Adjuvant therapy (No/Yes) 202 (89)/ 24 (11) 0.519 0.140 
Time dependent variable  
(1997-2002/2003-2008) 
94 (42)/ 132 (58) 0.653 0.089 
    
WCC (<8.5/8.5-11/>11) 148 (67)/ 41 (19)/ 31 
(14) 
0.010 0.023 
Neutrophil (<7.5/>7.5) 190 (87)/ 29 (13) 0.004 0.034 
Lymphocytes (<1/1-3/>3) 23 (11)/ 187 (85)/ 9 (4) 0.859 0.575 
Monocytes (<0.9/>0.9) 178 (84)/ 35 (16) 0.094 0.535 
Eosinophils (<0.04/0.04-0.4/>0.4) 28 (13)/ 169 (79)/ 16 (8) 0.760 0.690 
Basophils (<0.01/0.01-0.1/>0.10) 114 (53)/ 97 (46)/ 2 (1) 0.009 0.144 
Platelets (<400/>400) 172 (80)/ 43 (20) 0.036 0.495 
NLR (<5/>=5) 170 (78)/ 49 (22) 0.007 0.056 
    
Alive/ cancer death/non-cancer  
death 
108 (48)/ 49 (22)/ 69 
(30) 
  
CI = confidence interval; HR = hazard ratio; mGPS = modified Glasgow Prognostic Score; 
TNM = Tumour, Nodal, Metastasis; NLR = neutrophil-lymphocyte ratio; WCC = white 
cell count 
a
 Log rank p-value 
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Figure 3.1 Kaplan Meier plots of TNM stage and components of the differential WCC 
and cancer-specific survival in total cohort 
(A) TNM stage, (B) white cell count, (C) neutrophil count, (D) lymphocyte 
count, (E) monocyte count, (F) eosinophil count, (G) basophil count, (H) 
platelet count 
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Figure 3.2 The relationship between the neutrophil count and the NLR (rs = 0.633, p < 
0.001) in patients undergoing elective surgery for colorectal cancer with 
node negative disease 
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Figure 3.3 The relationship between the lymphocyte count and the NLR (rs = 0.689, 
p<0.001) in patients undergoing elective surgery for colorectal cancer with 
node negative disease 
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Figure 3.4 Kaplan Meier plot of optimised Glasgow Prognostic Score (oGPS) and 
cancer specific survival in total cohort  
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4 The neutrophil-platelet score (NPS) predicts 
survival in primary operable colorectal cancer 
and a variety of common cancers 
4.1 Introduction 
It is now established that the presence of a pre-operative systemic inflammatory response 
is predictive of disease progression and poorer outcome, regardless of tumour stage, in 
patients with colorectal cancer (Roxburgh and McMillan, 2010). Indeed, systemic 
inflammation based scoring systems such as the modified Glasgow Prognostic Score 
(mGPS) and the Neutrophil-Lymphocyte ratio (NLR) have prognostic value in a range of 
common solid tumours (Guthrie et al., 2013a, McMillan, 2013b, Li et al., 2014a, 
Templeton et al., 2014, Park et al., 2015, Wang et al., 2015). However, with reference to 
the NLR, multiple thresholds have been used to define high and low NLR values and some 
have suggested that its prognostic value is mainly derived from the neutrophil count and 
that the lymphocyte count makes little contribution (Chapter 3). 
Therefore, it is of interest that recent in-vitro studies have suggested that a critical 
checkpoint early in the inflammatory process involves the interaction between neutrophils 
and platelets (Sreeramkumar et al., 2014). During this process, neutrophils that are 
recruited to injured tissues/vessels, scan for activated platelets and when detected 
neutrophils undergo intravascular migration, further elaborating the inflammatory process. 
This in-vitro research highlights the importance of the innate immune system, in particular 
neutrophils, in the elaboration of the systemic inflammatory response. If the interaction 
between neutrophils and platelets were of clinical relevance then it might be expected that 
an elevated neutrophil count in the presence of an elevated platelet count would result in an 
enhanced systemic inflammatory response. Indeed the combination of a platelet count and 
the NLR (COP-NLR) has recently been reported as a cumulative predictor of survival in 
patients with colorectal (Ishizuka et al., 2013), gastric (Ishizuka et al., 2014) and 
oesophageal cancer (Feng et al., 2014). Therefore, the aim of the present study was to 
examine whether a combination of the neutrophil count and the platelet count was 
predictive of survival in patients undergoing potentially curative surgery for colorectal 
cancer and in patients with a variety of common cancers.  
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4.2 Methods 
4.2.1 Patients 
For the colorectal cancer cohort, patients with histologically proven colorectal cancer who, 
on the basis of intra-operative findings and pre-operative computed tomography, were 
considered to have undergone potentially curative resection at a single centre between 
March 1999 and May 2013 (n = 813) were initially selected for analysis. Patients in whom 
a pre-operative neutrophil or platelet count were not available were excluded from analysis 
(n = 6) as were those patients with TNM stage 0 disease (n = 11). Patient characteristics 
were collected in a prospectively maintained database and all patient data was anonymised. 
All tumours were staged according to conventional tumour, node, metastasis classification 
and additional pathological data obtained from the pathology reports issued at the time of 
the resection.  
Pre-operatively, all patients received thromboembolism prophylaxis and antibiotic 
prophylaxis as per local protocols and blood samples were taken for routine laboratory 
analysis. Cut-off values for both neutrophil and platelet count were based on previously 
reported values (Leitch et al., 2007). The neutrophil-platelet score (NPS) was calculated as 
follows (Table 4.1): patients with a neutrophil count ≤7.5 x109/L and platelets ≤400 x109/L 
scored 0, patients with neutrophils >7.5 x10
9
/L or platelets >400 x10
9
/L scored 1 and 
patients with both neutrophils >7.5 x10
9
/L and platelets >400 x10
9
/L scored 2.  
Patients were routinely followed up for 5 years following resection as per national 
guidelines. Date and cause of death were crosschecked with the cancer registration system 
and Registrar General (Scotland).  Cancer specific survival was measured from date of 
surgery until date of death. The study was approved by the West of Scotland Research 
Ethics Committee, Glasgow. 
For the larger, common cancer cohort, data was taken from the Glasgow Inflammation 
Outcome Study (Proctor et al., 2015).  Patients with routine laboratory measurements of C-
reactive protein, albumin and a differential white cell count sampled between January 2000 
and December 2007, including neutrophil and platelet counts were obtained by 
systematically searching the North Glasgow biochemical and haematological database 
systems. Of the 160,481 patients identified, through linkage with the Scottish Cancer 
Registry using exact matches of the patient’s forename, surname and date of birth, 27 465 
were found to have an associated diagnosis of cancer. Of those that had common cancers 
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previously studied in the GIOS cohort, 9649 had been sampled within two years of their 
cancer diagnosis and were included in the analysis.  Cancers were coded according to the 
International Classification of Disease 10 (ICD-10) and broadly grouped according to the 
tumour site. Tumours were listed in order of the magnitude of their inflammatory status as 
previously demonstrated (Proctor et al., 2010).  Patient mortality was established through 
linkage with the Information Service Division for Scotland (ISD).  Patients were excluded 
if they did not have a blood sample within 2 years of their cancer diagnosis, had 
incomplete cancer registry follow up, under 16 years old, did not have a complete set of 
blood results available, had multiple tumours or metastatic disease or had a primary tumour 
of unknown origin.   
4.2.2 Statistical Analysis 
The comparison of clinicopathological variables across different NPS scores was 
performed using a Chi square test. The relationship between the NPS and 5-year survival 
was examined using log-rank survival analysis. Kaplan-Meier analysis was used to 
examine the relationship between patients characteristics, NPS, tumour site and cancer-
specific and overall survival. Cox proportional hazards multivariate regression models 
(stratified by tumour site) were used to correct for age and sex and examine the 
relationship between patient characteristics, NPS and survival. A two-sided p-value of < 
0.05 was considered statistically significant. Analyses were performed using SPSS 22.0 
(IBM, SPSS, IL, USA). 
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4.3 Results 
A total of 796 patients were included in the analysis of patients undergoing potentially 
curative surgery for colorectal cancer. The majority were over the age of 65 (66%), male 
(55%), underwent elective surgery (90%), had an open procedure (87%) and had node 
negative disease (61%). Median follow up of survivors was 49 (10-180) months with 173 
cancer deaths and 135 non-cancer deaths. Table 4.2 shows the distribution of the 
clinicopathological characteristics based on the NPS score. Mode of presentation, tumour 
site, T-stage, TNM stage, margin involvement, peritoneal involvement, tumour perforation 
and mGPS were significantly different between the 3 NPS groups. On multivariate 
analysis, adjusting for age and sex and stratified by TNM stage, incremental increase in the 
NPS was associated with poorer cancer-specific (NPS 1 – HR 1.37, p = 0.091; NPS 2 – HR 
1.61, p 0.082) and overall survival (NPS 1 – HR 1.48, p = 0.005; NPS 2 – HR 1.51, p 
0.056). 
Tables 4.3 & 4.4 show the relationship between pre-operative NPS, TNM stage and 5 year 
cancer-specific (CSS) and overall survival (OS). CSS in the whole cohort at 5 years varied 
from 97% in patients with stage I colorectal cancer to 62% in those with stage III 
colorectal cancer (p < 0.001) and from 79% in patients with NPS = 0 to 65% in patients 
with NPS = 2 (p = 0.001). When combined, 5 year CSS varied from 97% in patients with 
stage I disease and NPS = 0, to 60% in patients with stage III disease and NPS = 2 (p = 
0.026). OS at 5 years ranged from 86% in patients with stage I disease to 52% in patients 
with stage III disease (p < 0.001) and from 68% in patients with NPS = 0 to 48% in 
patients with NPS = 2 (p < 0.001). When combined, OS at 5 years ranged from 89% in 
patients with stage I disease and NPS = 0 to 49% in patients with stage III disease and NPS 
= 2 (p = 0.001). 
The combination of the platelet count and NLR (COP-NLR) was calculated (using an NLR 
threshold of 5) in order to determine its effect on survival in patients with operable 
colorectal cancer. CSS in the whole cohort at 5 years ranged from 78% in patients with 
COP-NLR = 0 to 67% in patients with COP-NLR = 2 (p = 0.010). Furthermore, on 
multivariate analysis, adjusting for age and sex and stratified by TNM stage, incremental 
increase in the COP-NLR was not independently associated with cancer-specific survival 
(COP-NLR 1 – HR 1.31, p = 0.112; COP-NLR 2 – HR 1.41, p 0.268). Therefore, in 
comparison to COP-NLR, the NPS was superior in predicting survival in patients with 
operable colorectal cancer. 
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As emergency surgery, presence of a colonic tumour and nodal status were associated with 
the NPS, to control for confounding of these, 5 year survival (both CSS and OS) was 
examined in patients undergoing elective surgery and then in patients with node negative 
disease and node negative colonic disease (Tables 4.3 & 4.4).  
In patients undergoing elective surgery, CSS at 5 years ranged from 97% in stage I disease 
to 63% in stage III disease (p < 0.001) and from 80% in patients with NPS = 0 to 62% in 
patients with NPS = 2 (p = 0.001). When combined, CSS at 5 years ranged from 97% in 
patients with stage I disease and NPS = 0 to 57% in patients with stage III disease and NPS 
= 2 (p = 0.019). A similar relationship was observed in OS at 5 years as survival ranged 
from 86% to 52% (p < 0.001) and from 69% to 41% (p < 0.001) with TNM stage and NPS 
alone, the combination of TMN stage and NPS stratified OS from 89% (TNM I, NPS = 0) 
to 42% (TNM III, NPS = 2) (p < 0.001).  
In patients undergoing elective surgery for node negative disease, CSS at 5 years ranged 
from 97% in stage I disease to 83% in stage II disease (p = 0.003) and from 89% in 
patients with NPS= 0 to 71% in patients with NPS = 2 (p = 0.002). When combined CSS 
ranged from 97% (TNM stage I, NPS = 0) to 68% (TNM stage II, NPS = 2) (p = 0.018). 
Similarly, OS at 5 years ranged from 86% to 71% (p = 0.012) and from 78% to 42% (p < 
0.001) with TNM stage and NPS alone and the combination of TNM stage and NPS 
stratified OS from 89% (TNM I, NPS = 0) to 37% (TNM II, NPS = 0) (p < 0.001).  
In patients undergoing elective surgery for node negative colonic disease CSS at 5 years 
ranged from 99% in stage I disease to 77% in stage II disease (p = 0.003) and from 91% in 
patients with NPS = 0 to 65% in patients with NPS = 2 (p < 0.001). When combined, CSS 
ranged from 98% (TNM stage I, NPS = 0) to 65% (TNM stage II, NPS = 2) (p = 0.004). 
Similarly, OS at 5 years ranged from 83% to 72% (p = 0.039) and from 78% to 46% (p < 
0.001) with TNM stage and NPS alone, the combination of TNM stage and NPS stratified 
OS from 56% (TNM stage I, NPS = 0) to 46% (TNM stage II, NPS = 2) (p = 0.002).     
The relationship between the clinicopathological characteristics and the NPS score in 
patients with a range of common cancers are in shown in Table 4.5. Age, sex, mode of 
presentation, tumour site, mGPS, survival status and survival length was significantly 
different between NPS groups. On multivariate analysis, adjusting for age and sex and 
stratified by tumour site, incremental increase in the NPS was significantly associated with 
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poorer cancer-specific (NPS 1 – HR 1.60, p < 0.001; NPS 2 – HR 2.14, p < 0.001) and 
overall survival (NPS 1 – HR 1.61, p < 0.001; NPS 2 – HR 2.19, p < 0.001).  
On Kaplan Meier survival analysis, a greater neutrophil-platelet score is associated with 
poorer cancer-specific survival in all patients (p < 0.001) (Figure 4.1). On Kaplan Meier 
survival analysis, based on individual tumour types is shown in Figure 5.2. Increasing NPS 
was significantly associated with poorer cancer-specific survival in patients with breast (p 
< 0.001), bladder (p < 0.001), colorectal (p < 0.001), gastroeosophageal (p < 0.001), 
gynaecological (p < 0.001), head and neck (p < 0.001), Hepaticopancreaticobiliary (HPB) 
(p = 0.009), prostatic (p < 0.001), pulmonary (p < 0.001) and renal cancers (p < 0.001). 
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4.4 Discussion 
The results of the present study show that the combination of neutrophils and platelets in a 
clinical scoring system, the neutrophil-platelet score (NPS), can be used to predict survival, 
independent of TNM stage, in patients undergoing potentially curative surgery for 
colorectal cancer. Furthermore, the results of the present study provide evidence that this 
simple, novel, objective score has prognostic value in a variety of common cancers. These 
results confirm the importance of activation of the innate immune response in predicting 
outcome in patients with cancer. 
The results of the present study are consistent with those of Ishizuka and colleagues who 
reported that the combination of platelets and the NLR was a predictor of post-operative 
survival in both colorectal and gastric cancer (Ishizuka et al., 2013, Ishizuka et al., 2014). 
However, recent evidence would appear to suggest that when using the differential white 
cell count to predict outcomes, the neutrophil count is the dominant component and as a 
result the lymphocyte count adds little to its prognostic effect (Chapter 3). Furthermore, 
recent work (Ishizuka et al., 2013, Ishizuka et al., 2014) has suggested that the combination 
of a platelet count to the NLR (COP-NLR) improves the prediction of outcome.  In the 
present study when the prognostic value of the COP-NLR was examined, the NPS had 
superior prognostic value.  Due to the differences in the formation of the COP-NLR and 
the NPS the basis of the difference in prognostic value is not clear.  Nevertheless, taken 
together these results would suggest that neutrophils and platelets were the main factors 
determining the prognostic value of the COP-NLR. 
There are other systemic inflammation based scores that have prognostic value in patients 
with primary operable colorectal cancer and a variety of common solid tumours. The most 
validated of these is the GPS/mGPS (McMillan., 2013b, Park et al., 2015, Proctor et al., 
2015). Indeed, it was of interest in the present study that as the NPS increased from 0 to 2 
the median concentration of CRP increased from 6 to 55 mg/L and median concentration 
of albumin decreased from 38 to 36 g/L (both p < 0.001). Therefore it would appear that 
both these scoring systems are related measures of the systemic inflammatory response. 
Nevertheless, the present results are of considerable interest since the GPS/mGPS requires 
the measurement of two acute phase proteins and in many centres they may not be 
routinely assessed. Together with previous results (Proctor et al., 2013) the present results 
show the complementary prognostic value of the NPS. 
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It is of interest that Kumar and colleagues recently reported that, in  1300 patients in phase 
I clinical cancer trials, the neutrophil-lymphocyte ratio (NLR) was an independent 
prognostic factor for overall survival (Kumar et al., 2015). Furthermore, they reported that 
the neutrophil count but not the lymphocyte count had prognostic value. This finding is 
consistent with our work in patients with primary operable colorectal cancer (Leitch et al., 
2007) (Chapter 3). The results of the present study demonstrate that the combination of 
increased neutrophils and platelets (both components of the innate immune response) was 
associated with an elaboration of the systemic inflammatory response and significantly 
poorer survival in patient with a range of common cancers. Taken together, these findings 
suggest that activation of the innate immune response is a key step in disease progression 
and poor survival in patients with cancer.  
The elaboration of this systemic inflammatory response and the presence of high numbers 
of neutrophils and platelets may result in an enhancement of cellular breakdown and 
proliferation (tissue remodelling). Specifically, neutrophils contain multiple enzymes such 
as, myeloperoxidase, interleukin-6 (IL-6), defensins lysozyme and collagenase which may 
directly promote cancer cell intravasation and extravasation (Ardi et al., 2007, Ten Kate et 
al., 2007). Moreover, activated platelets contain significant quantities of IL-6 and secrete 
factors such as vascular-endothelial growth factor (VEGF) and other factors that promote 
angiogenesis and may prevent recognition of cancer cells by the body’s own immune 
system (Ferrara and Davis-Smyth, 1997, Segal, 2005, Jain et al., 2010). Furthermore, both 
neutrophils and platelets are stimulated by IL-6. This may tip the tumour 
microenvironment towards disease dissemination and promotion of the growth of 
metastatic disease. 
The present study has a number of possible limitations. Detailed data on the use of pre-
operative chemo/radiotherapy in the colorectal cancer cohort and its relation to the timing 
of the pre-operative blood samples was not available. In both cohorts, data relating to other 
factors that may have affected neutrophil or platelet levels such as drugs and other co-
morbidities were not available. 
In conclusion, the neutrophil-platelet score can predict survival in patients undergoing 
potentially curative surgery for colorectal cancer and in a variety of common cancers. This 
confirms the importance of activation of the innate immune system in patients with cancer. 
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Table 4.1 The neutrophil-platelet score (NPS) 
Score Thresholds 
NPS 0 Neutrophils ≤ 7.5 x109/L and Platelets ≤400 x109/L 
NPS 1 Neutrophils >7.5 x10
9
/L or Platelets >400 x10
9
/L 
NPS 2 Neutrophils >7.5 x10
9
/L and Platelets >400 x10
9
/L 
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Table 4.2 The relationship between Neutrophil-Platelet Score (NPS) and 
clinicopathological characteristics in patients with colorectal cancer 
  All NPS = 0 NPS = 1 NPS = 2 p-value 
Clinicopathological  
Characteristic 
 n = 796 
(%) 
n = 621 
(%) 
n = 133 
(%) 
n = 42 
(%) 
 
Age      0.318 
 <65 266 (34) 210 (34) 42 (32) 14 (33)  
 65-74 272 (34) 221 (36) 39 (29) 12 (29)  
 >75 258 (32) 190 (30) 52 (39) 16 (38)  
Sex      0.553 
 Female 361 (45) 276 (44) 66 (50) 27 (64)  
 Male 435 (55) 345 (56) 67 (50) 23 (55)  
Presentation      <0.001 
 Elective 718 (90) 582 (94) 109 (82) 27 (64)  
 Emergency 78 (10) 39 (6) 24 (18) 15 (36)  
Adjuvant Therapy      0.241 
 No 585 (74) 464 (75) 94 (71) 27 (64)  
 Yes 211 (26) 157 (25) 39 (29) 15 (36)  
Tumour Site      <0.001 
 Colon 525 (66) 385 (62) 103 (77) 37 (88)  
 Rectum 271 (34) 236 (38) 30 (23) 5 (12)  
T-stage      <0.001 
 1 58 (7) 54 (9) 4 (3) 0 (0)  
 2 102 (13) 94 (15) 7 (5) 1 (2)  
 3 432 (54) 338 (54) 74 (56) 20 (48)  
 4 204 (26) 135 (22) 48 (36) 21 (50)  
N-stage      0.068 
 0 486 (61) 391 (63) 71 (53) 24 (57)  
 1 224 (28) 172 (28) 42 (32) 10 (24)  
 2 86 (11) 58 (9) 20 (15) 8 (19)  
TNM Stage      <0.001 
 1 132 (17) 124 (20) 7 (5) 1 (2)  
 2 354 (44) 267 (43) 64 (48) 23 (55)  
 3 310 (39) 230 (37) 62 (47) 18 (43)  
Differentiation      0.225 
 Mod/well 710 (90) 560 (91) 113 (86) 37 (88)  
 Poor 78 (10) 55 (9) 18 (14) 5 (12)  
Venous invasion      0.309 
 No 354 (45) 285 (46) 53 (40) 16 (38)  
 Yes 442 (55) 336 (54) 80 (60) 26 (62)  
Margin Involvement      <0.001 
 No 738 (93) 590 (95) 110 (83) 38 (91)  
 Yes 58 (7) 31 (5) 23 (17) 4 (9)  
Peritoneal Involvement      0.001 
 No 617 (78) 499 (80) 93 (70) 25 (60)  
 Yes 179 (22) 122 (20) 40 (30) 17 (40)  
Tumour perforation      <0.001 
 No 776 (98) 612 (99) 127 (96) 37 (88)  
 Yes 20 (2) 9 (1) 6 (4) 5 (12)  
Modified Glasgow 
Prognostic Score 
(mGPS) 
     <0.001 
 0 505 (63) 450 (73) 46 (35) 9 (21)  
 1 164 (21) 102 (16) 45 (34) 17 (41)  
 2 127 (16) 69 (11) 42 (31) 16 (38)  
Survival Status      <0.001 
 Alive 488 (61) 407 (66) 64 (48) 17 (40)  
 Cancer death 173 (22) 120 (19) 38 (29) 15 (36)  
 Non-cancer death 135 (17) 94 (15) 31 (23) 10 (24)  
Survival (Months)
$
  103 107 69 57 <0.001 
$
 median overall survival 
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Table 4.3 The relationship between the NPS and 5 year cancer-specific survival in patients undergoing curative resection of colorectal cancer 
 NPS = 0 
(Neut ≤ 7.5 x109/L and Plat 
≤400 x109/L) 
NPS = 1 
(Neut >7.5 x10
9
/L or Plat >400 
x10
9
/L) 
NPS = 2 
(Neut >7.5 x10
9
/L and Plat >400 
x10
9
/L) 
All 
(NPS 0-2) 
All Patients n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) 
Stage I 124 97 (2) 7 - 1 - 132 97 (2) 
Stage II 267 85 (3) 64 79 (6) 23 68 (11) 354  82 (2) 
Stage III 230 63 (4) 62 56 (7) 18 60 (12) 310 62 (3) 
All (Stage 0-III) 621 79 (2) 133 69 (5) 42 65 (8) 796 76 (2) 
Elective n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) 
Stage I 124 97 (2) 7 - 1 - 132 97 (2) 
Stage II 248 85 (3) 53 79 (6) 14 68 (13) 315 83 (2) 
Stage III 210 65 (4) 49 58 (8) 12 57 (15) 271 63 (3) 
All (Stage 0-III) 582 80 (2) 109 70 (5) 27 62 (10) 718 78 (2) 
Elective, Node Negative  n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) 
Stage I 124 97 (2) 7 - 1 - 132 97 (2) 
Stage II 248 85 (3) 53 79 (6) 14 68 (13) 315 83 (2) 
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All (Stage 0-II) 372 89 (2) 60 81 (6) 15 71 (12) 447 87 (2) 
Elective, Node Negative 
Colon  
n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) 
Stage I 71 98 (2) 6 - 0 - 77 99 (1) 
Stage II 161 89 (3) 40 82 (7) 12 65 (14) 213 77 (4) 
All (Stage 0-II) 232 91 (2) 46 84 (6) 12 65 (14) 290 89 (2) 
CSS - cancer-specific survival. Survival not calculated if n<10 
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Table 4.4 The relationship between NPS and 5 year overall survival in patients undergoing curative resection of colorectal cancer 
 NPS = 0 
(Neut ≤ 7.5 x109/L and Plat 
≤400 x109/L) 
NPS = 1 
(Neut >7.5 x10
9
/L or Plat >400 
x10
9
/L) 
NPS = 2 
(Neut >7.5 x10
9
/L and Plat >400 
x10
9
/L) 
All 
(NPS 0-2) 
All Patients n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) 
Stage I 124 89 (4) 7 - 1 - 132 86 (4) 
Stage II 267 73 (3) 64 68 (6) 23 45 (11) 354  70 (3) 
Stage III 230 54 (4) 62 45 (7) 18 49 (12) 310 52 (3) 
All (Stage 0-III) 621 68 (2) 133 56 (5) 42 48 (8) 796 65 (2) 
Elective n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) 
Stage I 124 89 (4) 7 - 1 - 132 86 (4) 
Stage II 248 74 (3) 53 68 (7) 14 37 (14) 315 71 (3) 
Stage III 210 55 (4) 49 45 (8) 12 42 (14) 271 52 (3) 
All (Stage 0-III) 582 69 (2) 109 56 (5) 27 41 (10) 718 66 (2) 
Elective, Node Negative  n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) 
Stage I 124 89 (4) 7 - 1 - 132 86 (4) 
Stage II 248 74 (3) 53 68 (7) 14 37 (14) 315 71 (3) 
All (Stage 0-II) 372 78 (3) 60 65 (7) 15 42 (14) 447 75 (2) 
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Elective, Node Negative 
Colon  
n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) 
Stage I 71 56 (12) 6 - 0 - 77 83 (5) 
Stage II 161 75 (4) 40 25 (10) 12 46 (15) 213 72 (4) 
All (Stage 0-II) 232 78 (3) 46 24 (9) 12 46 (15) 290 75 (3) 
OS - overall survival. Survival not calculated if n<10 
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Table 4.5 The relationship between NPS and patient demographics in an incidentally 
sampled cohort of patients with cancer 
  All NPS = 0 NPS = 1 NPS = 2 p-
value 
  n = 9649 n = 5933 
(%) 
n = 2779 
(%) 
n = 937 
(%) 
 
Age      <0.001 
 <65 4631  3032 (65) 1170 (25) 429 (10)  
 65-74 2885 1696 (59) 886 (31) 303 (10)  
 >75 2133 1205 (56) 723 (34) 205 (10)  
Sex      <0.001 
 Female 4584 2646 (58) 1468 (32) 470 (10)  
 Male 5065 3287 (65) 1311 (26) 467 (9)  
Presentation      <0001 
 Non-Emergency 6098 4236 (69) 1398 (23) 464 (8)  
 Emergency 3551 1697 (48) 1381 (39) 473 (13)  
Tumour Site      <0.001 
 Breast 1921 1611 (84) 268 (14) 42 (2)  
 Bladder 437 259 (59) 128 (29) 50 (11)  
 Gynaecological 507 298 (59) 142 (28) 67 (13)  
 Prostatic 509 322 (63) 159 (31) 28 (6)  
 Gastroesophageal  933 548 (59) 294 (32) 91 (9)  
 Haematological 914 678 (74) 188 (21) 48 (5)  
 Renal 459 288 (63) 134 (29) 37 (8)  
 Colorectal 1086 604 (56) 356 (33) 126 (11)  
 Head And Neck 633 365 (58) 204 (32) 64 (10)  
 Hepaticopancreaticobiliary 556 309 (56) 183 (33) 64 (11)  
 Pulmonary 1694 651 (38) 723 (43) 320 (19)  
mGPS      <0.001 
 0 4013 3305 (82) 629 (16) 79 (2)  
 1 2757 1504 (55) 931 (34) 322 (11)  
 2 2879 1124 (39) 1219 (42) 536 (19)  
Survival 
Status 
     <0.001 
Alive 3502 2757 (79) 633 (18) 112 (3)  
 Cancer death 5218 2620 (50) 1849 (35) 749 (15)  
 Non-cancer death 929  556 (60) 297 (32) 76 (8)  
Survival 
(Months)
$
 
      
 21 55 7 3 <0.001 
$
 median overall survival 
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Figure 4.1 The relationship between NPS and cancer-specific survival in all patients in 
the GIOS cohort. 
NPS 0 (top, small dash line); NPS 1 (middle, large dash line); NPS 2 (bottom, 
solid line); p<0.001 
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Figure 4.2 The relationship between the NPS and cancer-specific survival in each 
tumour site. 
NPS 0 (top, small dash line); NPS 1 (middle, large dash line); NPS 2 (bottom, 
solid line) 
Breast p<0.001; Bladder p<0.001; Gynaecological p<0.001; Prostatic p<0.001; 
Gastroesophageal p<0.001; Renal p<0.001; Colorectal p<0.001, Head and 
Neck p<0.001; HPB p=0.009 and pulmonary p<0.001. 
  
108 
 
 
 
5 Routine Clinical Markers of the Magnitude of the 
Systemic Inflammatory Response Following 
Elective Surgery: A Systematic Review 
 
5.1 Introduction 
It has long been recognised that injury to the body, either from trauma or from major and 
minor surgical procedures causes a stereotypical cascade of neuroendocrine, cytokine, 
acute phase and metabolic responses (Cuthbertson, 1979).  For example, following 
uncomplicated surgical injury, within minutes there is activation of the sympathetic 
nervous system resulting in a neuroendocrine response of increased secretion of 
catecholamines (adrenaline and noradrenaline) into the circulation leading to tachycardia, 
hypertension, fever and tachypnoea (Desborough, 2000).  At the same time there is also 
increased secretion of the pituitary hormones such as corticotrophin, growth hormone and 
arginine vasopressin.  Corticotrophin acts on the adrenal cortex to stimulate cortisol 
secretion peaking at approximately 4-6 hours following surgical injury whilst vasopressin 
affects the kidney and fluid balance.  There is then a subsequent increase in the production 
of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α), interleukin 1 
beta (IL-1β), IL-8, IL-12, IL-18 and in particular interleukin 6 (IL-6) (Marik and Flemmer, 
2012, Dinarello et al., 2013).  IL-6 peaks at approximately 18-24 hours following surgical 
injury.  These cytokines are produced in response to injury by many cells throughout the 
body and form a complex signalling system for subsequent production of acute phase 
proteins from the liver and increased stimulation of myeloid tissue (Bauer and Herrmann, 
1991, Baigrie et al., 1992, Gabay and Kushner, 1999).  There are changes in circulating 
myeloid cells, in particular towards increased numbers of white cells (WCC) dominated by 
neutrophils as well as increased numbers of myeloid derived suppressor cells and platelets.  
There are changes in plasma concentrations of a number of acute phase proteins, in 
particular C-reactive protein (CRP) (Pepys and Hirschfield, 2003, Kao et al., 2006, Cole et 
al., 2008) which peaks at approximately 48-72 hours (Colley et al., 1983).   
The net effect of the evolution of the systemic inflammatory response is increased 
catabolism of skeletal muscle in order to provide energy and substrates for the liver, to 
maintain fluid and cardiovascular homeostasis and for healing of the surgical wound 
(Desborough, 2000).  Therefore, while this response to injury has been referred to as the 
surgical stress or acute phase response it is more informatively known as the systemic 
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inflammatory response (SIR) since it affects all organs and tissues of the body (Gabay and 
Kushner, 1999).  It appears to be primarily the result of activation of the innate and 
humoral immune/inflammatory system.  A number of the components of the systemic 
inflammatory response have both pro and anti-inflammatory properties. Once healing of 
the injured site is established, anti-inflammatory components of the systemic inflammatory 
response become prominent, causing it to wane and return to the normal non-inflammatory 
state.   
Following uncomplicated surgery, the degree of elevation of these markers is considered to 
reflect the magnitude of the SIR (Desborough, 2000).  Most commonly cortisol, IL-6, 
WCC and CRP have been used in clinical practice.  Therefore, the aim of the present 
systematic review was to examine, across a range of surgical procedures, the magnitude of 
the SIR following elective surgery by using the markers cortisol, IL-6, WCC and CRP.  
Such information is a pre-requisite to objectively identifying those peri-operative 
interventions purported to have clinical value and those surgical procedures that may 
compromise immune function. 
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5.2 Methods 
A literature search was performed using the keywords: surgery, endocrine response, 
systemic inflammatory response, acute phase response, cortisol, IL-6, WCC and CRP was 
made of the US National Library of Medicine (MEDLINE), the Excerpta Medica Database 
(EMBASE), PubMed and the Cochrane Database of Systemic Reviews (CDSR) for articles 
that reported cortisol, IL-6, WCC and CRP following surgery.  From this, titles of studies 
and abstracts were analysed for relevance.  Bibliographies of relevant studies were 
searched and cross referenced to identify any additional studies relevant for inclusion.  
Included studies had to assess the systemic inflammatory response using at least one 
objective marker (cortisol, IL-6, WCC or CRP).  On review the studies were divided into 
those that analysed cortisol, IL-6, WCC and CRP and subsequently into different surgical 
specialties for each analyte.  The number of post-operative sampling points was recorded 
and any study where less than 3 post-operative sampling points were reported was 
excluded as it was not possible to examine the peak of the response.  The number of hours 
post-operatively at which the peak response occurred was documented.  Where more than 
one study was reported for an analyte in a surgical specialty a weighted average peak value 
was calculated.  Where the analyte was reported in different units across different studies 
they were converted to SI units.  Included papers were examined by the authors and any 
conflicts that arose were discussed with the senior author.   
Although there is a continuum between minor and major surgery, for comparison three 
arbitrary categories were made, based on the degree of clinical support.  These were minor 
(requiring general clinical care), moderate (requiring specialist clinical care or short high 
dependency stay) and major surgical injury (requiring specialist clinical care, prolonged 
high dependency or intensive care stay).  For each analyte, the included studies were sorted 
into one of these three categories and then classified according to the surgical procedure in 
order to investigate whether this continuum might well be delineated by the magnitude of 
cortisol, IL-6, WCC and CRP.  
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5.3 Results 
5.3.1 Study Selection Process  
The selection process is summarised in Figure 5.1.  Using the above search criteria, 
abstracts were identified and the bibliographies of these articles were hand searched for 
additional articles.  In total 296 abstracts were identified and full text obtained.  
Subsequent analysis of the full text of these articles resulted in 132 being excluded from 
analysis: 3 were unavailable in English language, 12 were review articles, 5 were animal 
studies, 14 articles involved emergency or trauma procedures, 1 study did not separate 
laparoscopic and open procedures and 84 studies had less than 3 post-operative sampling 
points.  164 studies were available for further analysis: 43 reported the response of cortisol 
(n = 1881), 103 the response of interleukin-6 (n = 4192), 35 the response of WCC (n = 
2064) and 108 the response of CRP (n = 6531).  It should be noted that some studies 
measured more than one analyte.      
5.3.2 Markers of the Systemic Inflammatory Response 
Cortisol Response Following Elective Surgery 
43 studies reported the response of cortisol following elective surgery (n = 1881).  These 
results are shown in Table 5.1.  The time of peak response occurred from 0-4 hours post-
operatively and a peak response was seen in both minor and major procedures.   
In the minor surgical injury category there was a wide range of peak cortisol levels, 
ranging from 459 for rectopexy to 1009 nmol/L for inguinal hernia repair.  In the moderate 
surgical injury group peak cortisol responses again varied from 450 nmol/L in a knee 
replacement to 621 nmol/L for colorectal cancer resection, 772 nmol/L in hip replacement, 
910 nmol/L in spinal surgery and 1018 nmol/L in gastric bypass.  In the major surgical 
injury group there was a range of peak responses ranging from 743 nmol/L for 
oesophagectomy to 1200 nmol/L for aneurysm repair.   
Within minor to major surgery groupings there also appeared to be little difference when 
comparing minimally invasive or laparoscopic procedures with open procedures.  This was 
best seen with laparoscopic and open cholecystectomy (600 vs 750 nmol/L), laparoscopic 
and open inguinal hernia repair (946 vs 1071 nmol/L) and laparoscopic and open gastric 
bypass (993 vs 1048 nmol/L).  Therefore the magnitude of cortisol concentrations 
following elective surgery was variable and was not clearly associated with the magnitude 
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of surgical injury within the surgical category or within the invasiveness of the surgical 
procedure.  
Interleukin-6 (IL-6) Response Following Surgery 
103 studies reported the response of IL-6 following different surgical procedures (n = 
4192). The results are shown in Table 5.2.  The time of peak response occurs between 12 
and 24 hours and a peak response was seen in both minor and major procedures.   
In the minor surgical injury group there was a peak IL-6 response seen with different 
procedures including inguinal hernia repair and cholecystectomy (13 and 77 pg/ml).  In the 
moderate surgical injury group, the response of IL-6 was generally greater than that seen in 
the minor injury group.  Peak response ranged from 62 pg/ml with prostatectomy, to 140 
pg/ml with total hip replacement, 161 pg/ml with colorectal cancer resection and 321 pg/ml 
with total knee replacement.  The magnitude of response was greater again in the major 
surgical injury group, ranging from 248 pg/ml with AAA repair to 345 pg/ml with major 
liver resection and 428 pg/ml with open cardiac surgery.   
Within minor to major surgery groupings there also appeared to be a difference between 
minimally invasive or laparoscopic procedures and open procedures.  This difference was 
best seen with laparoscopic and open rectopexy (21 vs 111 pg/ml), laparoscopic and open 
cholecystectomy (62 vs 95 pg/ml), laparoscopic and open gastrectomy (44 vs 129 pg/ml), 
laparoscopic and open abdominal hysterectomy (19 vs 166 pg/ml), laparoscopic and open 
miscellaneous colorectal resection (140 vs 393 pg/ml), and endovascular and open 
aneurysm repair (116 vs 332 pg/ml).  Therefore, the magnitude of IL-6 concentrations 
following elective surgery was associated with the magnitude of surgical injury and with 
the invasiveness of the surgical procedure.  
White Cell Count (WCC) Response Following Surgery 
35 studies reported the response of WCC following different surgical procedures (n = 
2064).  The results are shown in Table 5.3.  The peak response occurred at approximately 
24 hours post-operatively.   
In the minor injury category there was a range of peak WCC levels, ranging from 10.3 
x10
9
/L with inguinal hernia repair to 11.8 x10
9
/L with cholecystectomy.  In the moderate 
surgical injury group peak WCC responses varied from 7.5 x10
9
/L for breast 
reconstruction to 8.7 x10
9
/L for colorectal cancer resection, 9.0 x10
9
/L for hip replacement 
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and knee replacement, 11.7 x10
9
/L for hysterectomy and 13.3 x10
9
/L for gastric bypass.  
Similar was seen in the major surgical injury group with a range of responses from 9.9 
x10
9
/L in abdominal aortic aneurysm repair to 12.5 x10
9
/L with oesophagectomy and 16.6 
x10
9
/L in endovascular thoracic aneurysm repair. 
Within minor to major surgery groupings there also was little difference in the magnitude 
of response when comparing minimally invasive or laparoscopic with open procedures.  
This was best seen in laparoscopic and open inguinal hernia repair (10.1 vs 10.4 x10
9
/L), 
laparoscopic and open colorectal cancer resection (9.9 vs 8.6 x10
9
/L), laparoscopic and 
open gastrectomy (9.0 vs 10.8 x10
9
/L), and endovascular and open repair of abdominal 
aortic aneurysm (9.7 vs 10.1 x10
9
/L).  Therefore, the magnitude of WCC concentrations 
following elective surgery was variable and was not clearly associated with the magnitude 
of surgical injury associated with the surgical category or with the invasiveness of the 
procedure.  
C - reactive protein (CRP) Response Following Surgery 
108 studies reported the response of CRP following different surgical procedures (n = 
6531).  The results are shown in Table 5.4.  The timing of peak response occurred later 
than that of IL-6, between 24 and 72 hours post operatively and was seen in both minor 
and major procedures.   
In the minor surgical injury group there was a peak CRP response in different procedures 
including inguinal hernia repair and cholecystectomy (40 and 52 mg/L).  In the moderate 
surgical injury group the magnitude of CRP response was greater than in the minor injury 
group and ranged from 74 mg/L with neurosurgical procedures to 123 mg/L with 
colorectal cancer resection, 145 mg/L with hip replacement, 151 mg/L with spinal surgery 
and 153 mg/L with knee replacement.  The magnitude of response of CRP was greater still 
in the major surgical injury group ranging from163 mg/L in those undergoing abdominal 
aortic aneurysm repair to 186 mg/L with oesophagectomy and 189 mg/L in open cardiac 
surgery.   
Within minor to major surgery groupings there also was a difference between minimally 
invasive or laparoscopic and open procedures.  This difference was best seen with 
laparoscopic and open inguinal hernia repair (30 vs 49 mg/L), laparoscopic and open 
cholecystectomy (27 vs 80 mg/L), laparoscopic and open abdominal hysterectomy (29 vs 
99 mg/L), laparoscopic and open colorectal cancer resection (97 vs 133 mg/L), and 
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endovascular and open aneurysm repair (132 vs 180 mg/L).  Therefore, the magnitude of 
CRP concentrations following elective surgery was associated with the magnitude of 
surgical injury, and with the invasiveness of the surgical procedure.  
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5.4 Discussion 
The present review shows that cortisol, IL-6, WCC and CRP all peak following all types of 
elective surgery, minor and major; laparoscopic and open.  The peak responses following 
surgery occur at approximately 0-4 hours for cortisol, 12-24 hours for IL-6, 24-48 hours 
for WCC and 24-72 hours for CRP. Only IL-6 and CRP were consistently associated with 
the magnitude of surgical injury.  Therefore, IL-6 and CRP would appear to be useful 
markers for assessing the magnitude of the SIR following elective surgery.   However, in 
contrast to IL-6, CRP is routinely measured in clinical laboratories worldwide and 
extensively used in clinical practice and therefore may be useful in the monitoring and 
modulation of the SIR following elective surgery.  Indeed, using CRP in this way, from the 
present review of the literature it was identified that laparoscopic surgery was associated 
with a reduction of the SIR.  
The present review has a number of possible limitations.  The conclusions drawn from the 
present study are based on the premise that the peak values of IL-6 and CRP are mainly 
due to the degree of tissue damage and magnitude of the SIR during the surgical procedure.  
However, there are several potential confounding factors that need to be considered. Pre-
operative factors such age, obesity, co-morbid disease, emergency presentation and 
inflammatory status may enhance the peak SIR.  For example, increasing age has been 
reported to be associated with chronic innate immune activation and changes in monocyte 
function (Hearps et al., 2012, Kale and Yende, 2011, Michaud et al., 2013). Also, co-
morbid disease is associated with increased markers of the SIR such as IL-6 and CRP 
(Esser et al., 2014).   
The development of post-operative complications may also be considered as a potential 
confounding factor since the peak SIR may reflect, in part, the development of 
complications.  However, with respect to CRP, day 2 concentrations were similar in both 
those who did and did not go on to develop post-operative complications (Warschkow et 
al., 2012b). Furthermore, with respect to post-operative complications including 
anastomotic leak, CRP concentrations on days 3-5 have been reported to be of most 
importance (Singh et al., 2014, McDermott et al., 2015).   The selection of only studies in 
which surgery was carried out electively would help minimise such potential confounding 
factors. 
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Another limitation was that the data was from a variety of surgical procedures across a 
range of surgical specialties that span several decades.  During this time period there may 
have been changes in the measurement of the analytes and clinical management of surgical 
procedures that might alter the magnitude of the peak values.  However, it is unlikely to 
have altered the timing and relative magnitude of the peak SIR for the analytes considered.  
Also, the timing of blood samples was different across the range of studies included which 
may affect the peak values of the analytes considered. Also, in order to minimise the effect 
of sampling time on results, studies were only included if they included 3 or more 
measurements post operatively and at the time of the known analyte peak. It was of interest 
that the median peak IL-6 and CRP concentrations for the surgical procedures of 
cholecystectomy, colorectal cancer resection and abdominal aortic aneurysm repair were 
not lower in the more recent studies (See Tables 5.2 & 5.4).  Therefore it would appear that 
the magnitude of the post-operative inflammatory response was not associated with the 
more recent surgery and the introduction of perioperative care protocols.  Other than 
laparoscopic surgery, it is not clear whether individual components of these protocols are 
associated with a reduction in the magnitude of IL-6 or CRP.  Indeed, it is anticipated that 
the present review will stimulate more research in this area. 
It remains unclear which aspect of the surgery was responsible for the magnitude of the 
SIR.  However, the lower SIR associated with laparoscopic surgery would suggest that 
certain aspects of this technique, for example smaller wounds, are associated with a 
reduced degree of tissue trauma.  Factors other than the degree of tissue trauma or injury 
may be involved.  Specifically, perioperative hypoxia can result in raised inflammatory 
markers and in certain circumstances can be seen to promote inflammation (Eltzschig and 
Carmeliet, 2011).  Perioperative pain and its management may also be involved.  
Peripherally active opioids can modulate the inflammatory process and wound healing 
(Stein and Kuchler, 2013), whilst improved overall survival has been reported in patients 
with breast cancer who received intra-operative non-steroidal anti-inflammatory agents and 
opiates (Forget et al., 2014).  Despite this, it has been reported that there is no difference in 
the levels of post-operative CRP in patients who receive general or regional anaesthesia 
(Buyukkocak et al., 2006, Kahveci et al., 2014), in patients receiving general or combined 
general and regional anaesthesia (Papadima et al., 2009) and following the use of 2 
different inhalation agents (Marana et al., 2013).  Similarly, there appears to be no 
difference in CRP levels comparing those who receive epidural anaesthesia followed by 
epidural analgesia or spinal anaesthesia followed by morphine analgesia (Chloropoulou et 
al., 2013) and those who receive continuous opiate or intermittent non-opiate analgesia 
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(Avdagic et al., 2010). Therefore, it would appear that the magnitude of the SIR, as 
evidenced by CRP, is mainly determined by the magnitude of surgical insult.  
The results of the present study would indicate that cortisol is rapidly and maximally 
stimulated since the peak values were similar across a variety of elective surgical 
procedures.  Secretion of cortisol by the adrenal gland is stimulated by release of 
corticotrophin from the anterior pituitary gland and levels begin to increase minutes after 
surgery.  In the normal state the body employs a negative feedback mechanism to limit the 
amount of corticotrophin released from the pituitary but following surgical injury this 
mechanism is perturbed such that cortisol concentrations are increased over a period of 
hours before returning to normal (Weissman, 1990). Therefore, the release of cortisol 
following surgical injury is a neuroendocrine response that appears to be an all or none 
phenomenon and appears to be consistent with the present results.  In contrast, the peak IL-
6 and CRP concentrations appear to be responsive to the magnitude of elective surgical 
injuries and procedures.   Consistent with these observations, IL-6 is a pro-inflammatory 
cytokine that is produced by many cells throughout the body in response to injury. IL-6 
levels have been reported to rise from approximately 2 hours following stimulus and peak 
at approximately 12-24 hours.  IL-6 production is primarily regulated by a negative 
feedback mechanism through suppressors of cytokine signaling (Socs) molecules, coded 
by genes of the JAK-STAT pathway (Kishimoto, 2010).  This acts to reduce 
overproduction of IL-6 concentrations following injury.  Circulating IL-6 concentrations 
have been reported to be reduced dramatically by 48-72 hours in those with no post-
operative complications (Baigrie et al., 1992).  IL-6 is thought to be the main inducer of 
acute phase proteins such as CRP from hepatocytes as well as causing differentiation, 
proliferation and maturation of haemopoietic progenitors.  CRP is considered to be an 
opsonin and activator of innate immune cells, in particular neutrophils, as well as having 
both anti and pro-inflammatory properties (Gabay and Kushner, 1999).  Elevations of CRP 
levels begin at approximately 4-6 hours following surgical injury and typically peak at 48 
hours.  Following uncomplicated surgery, the levels of CRP begin to fall, typically 
normalising at 72 – 168 hours (Gabay and Kushner, 1999). Therefore, it is perhaps not 
surprising that, given their relationship and kinetics in plasma, both IL-6 and CRP appear 
to similarly reflect the magnitude of surgical injury.   
Although there are more than 2 dozen interleukins, with IL-12 and IL-18 being uniquely 
inflammatory, these have been rarely assessed in elective surgery and subject to 
intervention studies.  In contrast, the established pro-inflammatory cytokines have been 
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subject to such examination.  There have been attempts to modify or block aspects of the 
systemic inflammatory response, namely via tumour necrosis factor (TNF) and IL-1. TNF 
binding proteins inactivate TNF and are presumed to provide some control of the SIR.  
Indeed, anti-TNF-α therapies (inflixamab and adalimumab) are widely used in patients 
with inflammatory bowel disease with good clinical benefit (Yang et al., 2010, Kopylov et 
al., 2012). Similarly, IL-1 receptor antagonists have been used in patients with sepsis and 
rheumatoid arthritis with only some clinical benefit seen in rheumatoid arthritis (Freeman 
and Buchman, 2001).  Of the pro-inflammatory cytokines, IL-6 has attracted interest since 
IL-6 stimulation and production causes a cascade of effects that result in stimulation of 
acute phase proteins (in particular CRP) and activation of the innate immune system. 
Clinical trials involving IL-6 blockade have reported efficacy in several inflammatory 
conditions including rheumatoid arthritis and juvenile idiopathic arthritis, resulting in their 
use as a monotherapy or in combination with disease modifying antirheumatic drugs 
(Tanaka and Kishimoto, 2012).      
 In the present study, WCC did not appear to reflect the magnitude of the surgical injury. 
However, neutrophils are the major component of the WCC but not normally separately 
identified in the elective surgery literature. They are ‘first responders’ present at the site of 
injury within 1 hour and peak at 24 hours.  Levels begin to wane after 48 hours with 
neutrophils cleared from circulation via the liver, spleen and bone marrow (Kolaczkowska 
and Kubes, 2013).  Moreover, there are other white cells such as lymphocytes, monocytes, 
basophils, and eosinophils that may respond differently to a surgical injury.  To date such 
changes in these white cells following elective surgical injury has been poorly 
documented.   
Over the last decade, minimal access or laparoscopic surgery has become routinely applied 
and has been associated with quicker recovery following surgery, shorter hospital stays, 
better cosmetic results, reduced post-operative pain and quicker return to normal activities 
(Vittimberga et al., 1998, Buunen et al., 2004, Ng et al., 2005).  It has been assumed that 
some of these benefits are due to a reduced SIR caused by reduced surgical injury.  The 
present review, across the elective surgical literature, would appear to confirm the view 
that laparoscopic operations evoke less of an inflammatory response, as evidenced by IL-6 
and CRP, than open operations.   
Anaesthetic practice has also changed in recent times with the development of safer 
anaesthetic agents, improved pain management and better peri-operative monitoring.  A 
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regimen of short acting anaesthetic agents, muscle relaxation if necessary, minimally 
invasive monitoring, multimodal peri-operative analgesia and aggressive anti-emetic 
therapy have been reported to allow quicker return of normal organ functions and fewer 
episodes of organ dysfunction (Kehlet and Dahl, 2003). Widespread use of peri-operative 
monitoring such as the oesophageal Doppler has been undertaken with the perceived 
benefit of allowing the patients cardiac output to be optimised and to guide subsequent 
fluid administration (Abbas and Hill, 2008).  However a recent meta-analysis suggested 
that actually oesophageal Doppler guided fluid therapy did not influence length of stay or 
complication rates following colorectal surgery (Srinivasa et al., 2013).  It remains to be 
determined which such anaesthetic practices do indeed modulate the SIR.    
An extension of such work is Enhanced Recovery after Surgery (ERAS) programmes.  It 
has been reported that they reduce the incidence of post-operative complications, resulting 
in reduced length of hospital stay and improved short term outcomes (Kehlet and Wilmore, 
2005, Wind et al., 2006, Kehlet, 2008, Varadhan et al., 2010, Melnyk et al., 2011, 
Rawlinson et al., 2011) by purportedly reducing the SIR following surgery.  Systematic 
reviews and meta-analyses of several randomized trials across multiple surgical specialties 
indicate that ERAS programmes reduce post-operative morbidity, reduce hospital stay and 
accelerate recovery (Eskicioglu et al., 2009, Varadhan et al., 2010, Rawlinson et al., 2011, 
Spanjersberg et al., 2011, Coolsen et al., 2013a, Coolsen et al., 2013b).  However, with no 
standardised protocol and with no objective measure of response, in particular the SIR, the 
basis of the effect of ERAS is unclear.  A recent systematic review and meta-analysis 
suggested that the quality of reporting in many ERAS studies was poor and that studies 
where fewer ERAS elements were employed showed greater reduction in mortality and 
complications than those with a greater number of ERAS elements (Nicholson et al., 
2014).  Indeed, it might have been expected that the greater number of ERAS elements 
employed, the greater then benefits seen.  However, it may be that only some of the 
elements used in ERAS programmes, such as laparoscopic surgery, actually modify the 
SIR.  It may be that, as in the present review, the use of markers such as CRP would 
objectively determine which components reduce the magnitude of the systemic 
inflammatory response following elective surgery. 
It is therefore of interest that Neville and colleagues recently published a systematic review 
of outcomes used to evaluate enhanced recovery after surgery (Neville et al., 2014) and 
commented that one of the main challenges in evaluating outcomes in ERAS programmes 
is how to measure the effect of the ERAS programme on the systemic inflammatory 
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response.  In many studies, objective markers of the SIR were not monitored.  For 
example, they reported that only 11 out of the 38 included studies (29%) measured 
“immunological factors” such as CRP and interleukins and only 3 out of the 38 included 
studies (9%) used “markers of the stress response” such as cortisol, prolactin and growth 
hormone levels (Neville et al., 2014).  Strategies that can be shown to reduce these peak 
levels of CRP or avoid excessive concentrations could therefore form the basis of an 
evidence based ERAS protocol. 
Therefore, the finding that these markers are a marker for the complexity and severity of a 
given surgery is clear, but it is not clear whether the levels correlate with outcome for a 
particular procedure.  The results of the present review may have a clinical impact out with 
its implication for components of the ERAS programme.  Cancer surgery has long been 
proposed to produce an environment whereby micrometastatic disease is stimulated to 
progress due to the associated immunosuppressive state i.e. a loss of immune equilibrium 
and growth of so-called dormant micrometastases (Baum et al., 2005, Retsky et al., 2008).  
However, confirmatory data supporting this hypothesis has been lacking, in particular, the 
magnitude of the SIR associated with different surgical procedures and its impact on 
immune equilibrium has not been clear.  From the results of the present study it is clear 
that only some surgical operations can significantly perturb the SIR such that immune 
function is compromised.  Therefore, it would be of considerable interest to reinvestigate 
the tumour dormancy hypothesis in the context of this new information.  In this context, it 
is of interest that it has recently been reported that following elective colorectal cancer 
resection, elevated CRP levels are associated with an increased risk of development of 
post-operative complications (Dutta et al., 2011, Welsch et al., 2007, Mackay et al., 2011, 
Matthiessen et al., 2008, Singh et al., 2014), specifically, that peak (day 2) CRP levels 
greater than 190 ml/L are associated with an increased risk of development of infective 
complications (Ramanathan et al., 2013).  However, whether these elevated peak levels 
effect long term outcome has yet to be determined.   
In summary, the results of the present review may allow monitoring of patient recovery 
following surgery and allow surgeons to identify those at increased risk of developing 
infective complications based on the magnitude of the SIR, allowing appropriate decisions 
to be made on their investigation and management.  Moreover, these values may provide a 
therapeutic target that would allow prompt and pre-emptive treatment of potential post-
operative complications, with the resultant benefit to recovery following elective surgery. 
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Papers identified and 
reviewed  
(n = 296) 
Excluded (n = 132) 
 
Full text not in English (n = 3) 
Review Article (n = 12) 
Animal Study (n = 5) 
Emergency/Trauma Articles (n = 14) 
Mixture of techniques (n = 1) 
< 3 post-operative sampling points  
(n = 84) 
 
Studies Included* 
(n = 164) 
Studies of Cortisol 
(n = 43) 
Studies of IL-6 
(n = 103) 
* Some studies assessed more than one marker of the stress response 
Studies of CRP 
(n = 108) 
Studies of WCC 
(n = 35) 
 
Figure 5.1 Flow chart demonstrating the process used for study selection 
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Table 5.1 The timing and magnitude of cortisol concentrations following elective 
surgery 
Surgical Procedure Studies 
(n) 
Patients 
(n) 
Sampling 
Points 
(n) 
Time 
of 
Peak 
(hrs) 
Peak 
Value 
(nmol/L) 
References 
Minor Surgical Injury       
Rectopexy 
 
 Laparoscopic 
 Open 
1 39 
 
20 
19 
3 4 459 
 
343 
582 
(Solomon et 
al., 2002) 
Cholecystectomy 
 
 Laparoscopic 
 Open 
 
12 418 
 
254 
164 
3-10 0-12 659 
 
600 
750 
 
(Joris et al., 
1992, 
McMahon et 
al., 1993, 
Deuss et al., 
1994, 
Jakeways et 
al., 1994, 
Milheiro et 
al., 1994, 
Glaser et al., 
1995, Ortega 
et al., 1996, 
Karayiannakis 
et al., 1997, 
Yamauchi et 
al., 1998, 
Kristiansson 
et al., 1999, 
Yoshida et al., 
2000, Crema 
et al., 2005) 
Inguinal Hernia Repair 
 
 Laparoscopic 
 Open 
2 
 
70 
 
35 
35 
3-6 3-24 1009 
 
946 
1071 
(Akhtar et al., 
1998, 
Uzunkoy et 
al., 2000) 
Moderate Surgical Injury       
Primary Total Knee 
Replacement 
1 12 3 6 450 (Smith et al., 
2006) 
Prostatectomy 
 
 TURP 
 Endoscopic Laser Ablation 
 Radical Retropubic 
3 94 
 
24 
24 
46 
3-4 0-0.5 484 
 
515 
435 
494 
(Bedalov et 
al., 2008, 
Hong et al., 
2011, Fant et 
al., 2013) 
Hysterectomy 
 
 Laparoscopic  
 Open  
 Laparoscopic Assisted 
Vaginal 
4 127 
 
20 
87 
20 
3-5 2-24 595 
 
300 
591 
909 
(Yuen et al., 
1998, 
Rorarius et 
al., 2001, 
Maciejczyk-
Pencula et al., 
2004, 
Pirbudak et 
al., 2004) 
Misc.  Colorectal Resection  
 
 Laparoscopic 
 Open 
2 103 
 
52 
51 
4-7 4-24 610 
 
610 
610 
(Harmon et 
al., 1994, 
Braga et al., 
2002) 
Colorectal Cancer Resection 
 
 Laparoscopic 
 Open 
4 449 
 
47 
402 
4-7 4-24 621 
 
851 
594 
(Ozawa et al., 
2000, 
Delgado et al., 
2001, 
Borgdorff et 
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al., 2004, Ren 
et al., 2012) 
Exploratory Gyn. Surgery 
 
 Laparoscopy 
 Mini-laparotomy 
 Laparotomy 
3 90 
 
60 
10 
20 
3-4 0-2 693 
 
539 
579 
1214 
(Muzii et al., 
1996, Marana 
et al., 2003, 
Marana et al., 
2013) 
Primary Total Hip Replacement 4 152 4-6 0-8 772 (Hogevold et 
al., 2000, Hall 
et al., 2001, 
Bjornsson et 
al., 2007, Al 
Oweidi et al., 
2010) 
Spinal Surgery  1 85 3 0 910 (Ezhevskaya 
et al., 2013) 
Open Gastrectomy 1 20 3 3 998 (Servis et al., 
2008) 
Gastric Bypass 
 
 Laparoscopic 
 Open 
1 48 
 
26 
22 
4 1 1018 
 
993 
1048 
(Nguyen et 
al., 2002) 
Mastectomy 1 5 3 0 1112 (Yamauchi et 
al., 1998) 
Major Surgical Injury       
Oesophagectomy 
 
 Minimally Invasive 
 Open 
2 34 
 
14 
20 
3-4 0-24 743 
 
714 
764 
(Yamauchi et 
al., 1998, 
Maas et al., 
2013) 
Coronary Artery Bypass  2 120 3 6-24 754 (Roth-Isigkeit 
et al., 1998, 
Velissaris et 
al., 2004) 
Pulmonary Lobectomy 1 5 3 0 1007 (Yamauchi et 
al., 1998) 
Open Abdominal Aortic 
Aneurysm Repair 
1 10 4 12 1200 (Smeets et al., 
1993) 
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Table 5.2 The timing and magnitude of interleukin-6 (IL-6) concentrations following 
elective surgery 
Surgical Procedure Studies 
(n) 
Patients 
(n) 
Sampling 
Points 
(n) 
Time 
Peak 
(hrs) 
Peak 
Value 
(pg/ml) 
References 
Minor Surgical Injury       
Inguinal Hernia Repair 
 
 Laparoscopic 
 Open 
5 104 
 
49 
55 
3-8 4-24 13 
 
11 
15 
(Baigrie et al., 
1992, Takahara 
et al., 1995, 
Schrenk et al., 
1996, Jess et 
al., 2000, Suter 
et al., 2002) 
Rectopexy 
 
 Laparoscopic 
 Open 
1 39 
 
20 
19 
3 4-24 65 
 
21 
111 
(Solomon et 
al., 2002) 
Cholecystectomy 
 
 Single Incision 
 Laparoscopic 
 Open 
15 593 
 
31 
291 
271 
3-9 4-24 77 
 
54 
62 
95 
(Cruickshank 
et al., 1990, 
Joris et al., 
1992, 
McMahon et 
al., 1993, Cho 
et al., 1994, 
Jakeways et 
al., 1994, 
Glaser et al., 
1995, 
Yamauchi et 
al., 1998, 
Kristiansson et 
al., 1999, 
Yoshida et al., 
2000, 
Schietroma et 
al., 2001, 
Schietroma et 
al., 2004a, 
Schietroma et 
al., 2004b, Han 
et al., 2012, 
Sista et al., 
2013a, Sista et 
al., 2013b) 
Moderate Surgical Injury       
Spinal Surgery  1 85 3 24 10 (Ezhevskaya et 
al., 2013) 
Mastectomy 2 15 3-5 0-48 27 (Yamauchi et 
al., 1998, Khan 
et al., 1999) 
Exploratory Gyn. Surgery 
 
 Laparoscopic 
 Open 
1 40 
 
25 
15 
3 4 28 
 
20 
40 
(Torres et al., 
2007) 
Prostatectomy 
 
 Laparoscopic 
 Open 
2 429 
 
163 
266 
3-6 6-24 62 
 
70 
57 
(Jurczok et al., 
2007, Fant et 
al., 2013) 
Nephrectomy 
 
 Laparoscopic Single Site 
 Laparoscopic 
 Open 
2 104 
 
31 
35 
38 
4 6-24 73 
 
60 
65 
90 
(Adler et al., 
1998, Greco et 
al., 2012) 
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Restrictive Gastric Surgery 
 
 Laparoscopic 
 Open 
2 40 
 
15 
25 
4-5 6-24 94 
 
83 
100 
(Kragsbjerg et 
al., 1995, 
Zengin et al., 
2002) 
Gastrectomy 
 
 Laparoscopic 
 Open 
3 149 
 
49 
100 
3-5 3-24 101 
 
44 
129 
(Adachi et al., 
2000, Fujita 
and Yanaga, 
2007, Servis et 
al., 2008) 
Gastric Bypass 
 
 Laparoscopic 
 Open 
1 48 
 
26 
22 
4 24 102 
 
72 
137 
(Nguyen et al., 
2002) 
Hysterectomy 
 
 Laparoscopic  
 Open  
 Laparoscopic Vaginal 
 Open Vaginal 
7 295 
 
58 
121 
74 
42 
3-4 2-24 117 
 
19 
166 
163 
27 
(Yuen et al., 
1998, Harkki-
Siren et al., 
2000, Malik et 
al., 2001, 
Rorarius et al., 
2001, Ribeiro 
et al., 2003, 
Hou et al., 
2011, Roy et 
al., 2012) 
Lumbar Discectomy 2 26 5-6 12-24 124 (Huang et al., 
2005, 
Kumbhare et 
al., 2009) 
Total Hip Replacement 
 
 Primary 
 Revision 
9 205 
 
201 
4 
3-7 4-24 140 
 
142 
40 
(Cruickshank 
et al., 1990, 
Hogevold et 
al., 1992, 
Wilson et al., 
1993, 
Kragsbjerg et 
al., 1995, 
Hogevold et 
al., 2000, 
Wirtz et al., 
2000, Hall et 
al., 2001, 
Minetto et al., 
2006, 
Bjornsson et 
al., 2007) 
Colorectal Cancer Resection 
 
 Laparoscopic 
 Open 
20 1110 
 
347 
763 
4-7 3-24 161 
 
177 
154 
(Cruickshank 
et al., 1990, 
Schulze et al., 
1992, Stage et 
al., 1997, 
Hewitt et al., 
1998, Leung et 
al., 2000, 
Ozawa et al., 
2000, Schwenk 
et al., 2000, 
Delgado et al., 
2001, Mehigan 
et al., 2001, 
Nishiguchi et 
al., 2001, 
Ordemann et 
al., 2001, 
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Wichmann et 
al., 2005, 
Catena et al., 
2009, Evans et 
al., 2009, 
Persec et al., 
2009, Vignali 
et al., 2009, 
Pascual et al., 
2011, Ren et 
al., 2012, 
Wang et al., 
2012, 
Kvarnstrom et 
al., 2013) 
Open Minor Liver Resection 3 37 3-7 2-48 179 (Lan et al., 
2003, Jansen et 
al., 2008, Strey 
et al., 2011) 
Nissen Fundoplication 
 
 Laparoscopic 
 Open 
2 69 
 
61 
8 
3-4 4-6 233 
 
240 
180 
(Zieren et al., 
2000, 
Schietroma et 
al., 2013) 
Misc. Colorectal Resection 
 
 Laparoscopic 
 Open 
2 66 
 
33 
33 
3-6 6 267 
 
140 
393 
(Harmon et al., 
1994, 
Hildebrandt et 
al., 2003) 
Total Knee Replacement 
 
 Primary Unilateral 
 Primary Bilateral 
3 35 
 
20 
15 
3-6 6-24 321 
 
261 
400 
(Kragsbjerg et 
al., 1995, 
Wirtz et al., 
2000, Jules-
Elysee et al., 
2011) 
Major Surgical Injury       
Thoracic Surgery 
 
 Video-assisted (VATS) 
 Open 
7 180 
 
37 
143 
3-5 0-24 85 
 
51 
94 
(Yamauchi et 
al., 1998, Yim 
et al., 2000, 
Nagahiro et al., 
2001, Franke 
et al., 2005, 
Wang et al., 
2005, Friscia et 
al., 2007, 
Avdagic et al., 
2010) 
Oesophagectomy 
 
 Minimally Invasive 
 Open 
2 34 
 
14 
20 
3-4 0-24 180 
 
116 
225 
(Yamauchi et 
al., 1998, Maas 
et al., 2013) 
Abdominal Aortic Aneurysm 
Repair 
 
 Endovascular (EVAR) 
 Open 
13 297 
 
 
116 
181 
3-9 4-24 248 
 
 
116 
332 
(Cruickshank 
et al., 1990, 
Baigrie et al., 
1992, Parry-
Billings et al., 
1992, Swartbol 
et al., 1996, 
Norman and 
Fink, 1997, 
Syk et al., 
1998, 
Holzheimer et 
al., 1999, 
Boyle et al., 
127 
 
 
 
2000, 
Elmarasy et al., 
2000, Galle et 
al., 2000, 
Odegard et al., 
2000, Bolke et 
al., 2001, 
Rowlands and 
Homer-
Vanniasinkam, 
2001) 
Renal Transplant 1 46 3 2 268 (Hadimioglu et 
al., 2012) 
Open Major Liver Resection 5 59 3-9 2-48 345 (Badia et al., 
1998, Wiezer 
et al., 1999, 
Schmidt et al., 
2007, Jansen et 
al., 2008, Strey 
et al., 2011) 
Open Cardiac Surgery 4 112 3-6 0-8 428 (Kragsbjerg et 
al., 1995, 
Fransen et al., 
1998, Mollhoff 
et al., 1999, 
Franke et al., 
2005) 
Endovascular Thoracic Aneurysm 
Repair 
1 9 5 36 700 (Chang et al., 
2009) 
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Table 5.3 The timing and magnitude of white cell count (WCC) concentrations 
following elective surgery 
Surgical Procedure Studies 
(n) 
Patients 
(n) 
Sampling 
Points 
(n) 
Time 
of 
Peak 
(hrs) 
Peak 
Value 
(X10
9
/L) 
References 
Minor Surgical Injury       
Inguinal Hernia Repair 
 
 Laparoscopic 
 Open 
4 129 
 
64 
65 
3 4-24 10.3 
 
10.1 
10.4 
(Takahara et 
al., 1995, 
Schrenk et al., 
1996, Uzunkoy 
et al., 2000, 
Suter et al., 
2002) 
Cholecystectomy 
 
 Laparoscopic 
 Open 
1 30 
 
15 
15 
3 4 11.8 
 
11.0 
12.5 
(Joris et al., 
1992) 
Moderate Surgical Injury
  
      
Breast Reconstruction 
 
 Lateral Thoracodorsal 
Flap 
 Latissimus Dorsi Flap 
 Transverse Rectus 
Abdominus 
Myocutaneous Flap 
1 51 
 
11 
 
21 
19 
3 24 7.5 
 
7.4 
 
6.9 
8.1 
(Blomqvist et 
al., 1998) 
Prostatectomy 
 
 TURP 
 Endoscopic Laser 
Ablation 
 Radical Retropubic 
2 74 
 
24 
24 
 
26 
3-4 24 8.0 
 
8.4 
6.9 
 
8.7 
(Bedalov et al., 
2008, Fant et 
al., 2013) 
Colorectal Cancer Resection 
 
 Laparoscopic 
 Open 
4 397 
 
47 
350 
3-6 6-24 8.7 
 
9.9 
8.6 
(Nishiguchi et 
al., 2001, 
Ordemann et 
al., 2001, 
Kvarnstrom et 
al., 2013, 
Warschkow et 
al., 2011) 
Primary Total Hip Replacement 4 123 3-5 4-24 9.0 (Shih et al., 
1987, 
Hogevold et 
al., 1992, 
Moreschini et 
al., 2001, 
Bjornsson et 
al., 2007) 
Primary Unilateral Total Knee 
Replacement 
1 18 3 24 9.0 (Moreschini et 
al., 2001) 
Lumbar Discectomy 1 197 4 48 9.9 (Kraft et al., 
2011) 
Gastrectomy 
 
 Laparoscopic 
 Open 
5 316 
 
145 
171 
3-4 3-24 10.0 
 
9.0 
10.8 
(Adachi et al., 
2000, Usui et 
al., 2005, 
Servis et al., 
2008, 
Kawamura et 
al., 2009, 
Sakuramoto et 
al., 2009) 
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Spinal Surgery  2 253 3-4 24 10.2 (Chung et al., 
2011, Kraft et 
al., 2011) 
Hysterectomy 
 
 Laparoscopic  
 Open  
 Laparoscopic Assisted 
Vaginal 
2 84 
 
20 
44 
20 
3-4 2-24 11.7 
 
9.0 
11.5 
14.8 
(Yuen et al., 
1998, Rorarius 
et al., 2001) 
Nissen Fundoplication 
 
 Laparoscopic 
 Open 
2 50 
 
34 
16 
3-4 1-2 12.9 
 
12.3 
14.1 
(Sietses et al., 
1999, Zieren et 
al., 2000) 
Gastric Bypass 
 
 Laparoscopic 
 Open 
1 176 
 
59 
117 
3 24 13.3 
 
14.0 
13.0 
(Csendes et al., 
2009) 
Major Surgical Injury       
Abdominal Aortic Aneurysm 
Repair 
 
 Endovascular (EVAR) 
 Open 
4 89 
 
 
47 
42 
5-7 6-48 9.9 
 
 
9.7 
10.1 
(Swartbol et 
al., 1996, 
Boyle et al., 
2000, Galle et 
al., 2000, 
Odegard et al., 
2000) 
Open Major Liver Resection 1 12 8 24 11.3 (Wiezer et al., 
1999) 
Oesophagectomy 
 
 Minimally Invasive 
 Open 
1 27 
 
14 
13 
4 24 12.5 
 
10.9 
14.3 
(Maas et al., 
2013) 
Endovascular Thoracic 
Aneurysm Repair 
1 38 4 24 16.6 (Chang et al., 
2009) 
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Table 5.4 The timing and magnitude of C-reactive protein (CRP) concentrations 
following elective surgery 
Surgical Procedure Studies 
(n) 
Patients 
(n) 
Sampling 
Points 
(n) 
Time 
of 
Peak 
(hrs) 
Peak 
Value 
(mg/L) 
References 
Minor Surgical Injury       
Inguinal Hernia Repair 
 
 Laparoscopic 
 Open 
5 149 
 
74 
75 
3-6 24-48 40 
 
30 
49 
(Takahara et al., 
1995, Schrenk et 
al., 1996, Akhtar et 
al., 1998, Uzunkoy 
et al., 2000, Suter 
et al., 2002) 
Anterior Cruciate Ligament 
Reconstruction 
1 25 4 48 45 (Orrego et al., 
2005) 
Cholecystectomy 
 
 Laparoscopic 
 Open 
 
 
 
13 459 
 
241 
218 
3-10 24-48 52 
 
27 
80 
(Cruickshank et 
al., 1990, Joris et 
al., 1992, Roumen 
et al., 1992, 
McMahon et al., 
1993, Cho et al., 
1994, Jakeways et 
al., 1994, Bruce et 
al., 1999, 
Kristiansson et al., 
1999, Yoshida et 
al., 2000, 
Schietroma et al., 
2004b, Schietroma 
et al., 2007, Sista 
et al., 2013a, Sista 
et al., 2013b) 
Rectopexy 
 
 Laparoscopic 
 Open 
1 39 
 
20 
19 
3 48 90 
 
70 
112 
(Solomon et al., 
2002) 
Moderate Surgical Injury       
Nissen Fundoplication 
 
 Laparoscopic 
 Open 
2 51 
 
43 
8 
3 6-24 58 
 
54 
82 
(Sietses et al., 
1999, Schietroma 
et al., 2013) 
Lumbar Discectomy 4 270 3-5 24-72 73 (Larsson et al., 
1992, Huang et al., 
2005, Orrego et al., 
2005, Kraft et al., 
2011) 
Neurosurgical Procedures 
 
 Craniotomy 
 Ventricular-
Peritoneal Shunt 
 Cerebral Biopsy 
 Cerebral Tumour 
Debulking 
3 103 
 
46 
4 
 
14 
39 
5-6 24-48 74 
 
32 
35 
 
60 
133 
(Bengzon et al., 
2003, Mirzayan et 
al., 2007, Al-Jabi 
and El-Shawarby, 
2010) 
Hysterectomy 
 
 Laparoscopic  
 Open  
 Laparoscopic Assisted 
Vaginal 
 Open Vaginal 
6 200 
 
38 
107 
30 
 
25 
3-5 36-48 75 
 
29 
99 
45 
 
75 
(Yuen et al., 1998, 
Harkki-Siren et al., 
2000, Malik et al., 
2001, Rorarius et 
al., 2001, Aka et 
al., 2004, 
Maciejczyk-
Pencula et al., 
2004) 
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Breast Reconstruction 
Surgery 
 
 Lateral 
Thoracodorsal Flap 
 Latissimus Dorsi 
Flap 
 Transverse Rectus 
Abdominus 
Myocutaneous Flap 
1 51 
 
 
11 
 
21 
 
19 
3 72 88 
 
 
44 
 
74 
 
130 
(Blomqvist et al., 
1998) 
Miscellaneous Colorectal 
Resection 
 
 Laparoscopic 
 Open 
2 121 
 
 
61 
60 
3-6 48 110 
 
 
109 
112 
(Braga et al., 2002, 
Hildebrandt et al., 
2003) 
Gastrectomy 
 
 Laparoscopic 
 Open 
6 343 
 
145 
198 
3-5 48-96 115 
 
98 
127 
(Adachi et al., 
2000, Usui et al., 
2005, Fujita and 
Yanaga, 2007, 
Servis et al., 2008, 
Kawamura et al., 
2009, Sakuramoto 
et al., 2009) 
Open Restrictive Gastric 
Surgery 
1 10 6 96 121 (Kragsbjerg et al., 
1995) 
Colorectal Cancer Resection 
 
 Laparoscopic 
 Open 
 
15 775 
 
248 
527 
3-7 24-72 123 
 
97 
133 
(Cruickshank et 
al., 1990, Schulze 
et al., 1992, Stage 
et al., 1997, Leung 
et al., 2000, 
Schwenk et al., 
2000, Delgado et 
al., 2001, Mehigan 
et al., 2001, 
Nishiguchi et al., 
2001, Wichmann 
et al., 2005, Catena 
et al., 2009, He et 
al., 2009, Vignali 
et al., 2009, Wang 
et al., 2012, 
Kvarnstrom et al., 
2013, Warschkow 
et al., 2011) 
Gastric Bypass 
 
 Laparoscopic 
 Open 
3 614 
 
475 
139 
3-5 48-72 124 
 
123 
126 
(Nguyen et al., 
2002, Csendes et 
al., 2009, 
Warschkow et al., 
2012a) 
Nephrectomy 
 
 Laparoscopic Single 
Site 
 Laparoscopic 
 Open 
2 104 
 
31 
 
35 
38 
4 48-72 128 
 
140 
 
120 
125 
(Adler et al., 1998, 
Greco et al., 2012) 
Prostatectomy 
 
 TURP 
 Laparoscopic 
 Open 
3 453 
 
24 
163 
266 
3-6 48-72 133 
 
70 
120 
146 
(Nielsen et al., 
1999, Jurczok et 
al., 2007, Fant et 
al., 2013) 
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Breast Surgery 
 
 Mastectomy 
 Breast Implant 
Exchange 
 Breast Augmentation 
 Breast Reduction 
2 100 
 
10 
30 
 
30 
30 
5-6 24-
120 
141 
 
100 
136 
 
149 
153 
(Khan et al., 1999, 
Toman et al., 
2008) 
Total Hip Replacement 
 
 Primary 
 Revision 
16 894 
 
885 
9 
3-7 24-72 145 
 
145 
136 
(Aalto et al., 1984, 
Shih et al., 1987, 
Cruickshank et al., 
1990, Hogevold et 
al., 1992, Larsson 
et al., 1992, 
Kragsbjerg et al., 
1995, Niskanen et 
al., 1996, Okafor 
and MacLellan, 
1998, White et al., 
1998, Wirtz et al., 
2000, Bilgen et al., 
2001, Hall et al., 
2001, Moreschini 
et al., 2001, Orrego 
et al., 2005, 
Neumaier et al., 
2006, Bjornsson et 
al., 2007) 
Open Minor Liver Resection 2 25 3-7 48-72 146 (Lan et al., 2003, 
Jansen et al., 2008) 
Spinal Surgery  
 
 With Instrumentation 
 Without 
Instrumentation 
6 577 
 
438 
139 
3-6 48-72 151 
 
114 
267 
(Takahashi et al., 
2001, Munoz et al., 
2004, Mok et al., 
2008, Chung et al., 
2011, Kraft et al., 
2011, Kong et al., 
2012) 
Primary Total Knee 
Replacement 
9 416 3-6 48-72 153 (Larsson et al., 
1992, Kragsbjerg 
et al., 1995, 
Niskanen et al., 
1996, White et al., 
1998, Wirtz et al., 
2000, Bilgen et al., 
2001, Moreschini 
et al., 2001, Orrego 
et al., 2005, Smith 
et al., 2006) 
Open Mixed Gastro-
oesophageal Cancer Resection 
1 31 10 48 171 (Warschkow et al., 
2012b) 
Abdominoplasty 1 30 6 120 196 (Toman et al., 
2008) 
Major Surgical Injury       
Thoracic Surgery 
 
 Video-assisted 
(VATS) 
 Open 
3 143 
 
19 
 
124 
3-6 48-72 85 
 
15 
 
96 
(Craig et al., 2001, 
Franke et al., 2005, 
Avdagic et al., 
2010) 
Open Major Liver Resection 3 158 3-7 72 94 (Schmidt et al., 
2007, Jansen et al., 
2008, Rahman et 
al., 2008) 
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Cerebral Aneurysm Surgery 
 
 Endovascular Repair 
 Clipping 
2 20 
 
8 
12 
5 48-72 112 
 
41 
160 
(Bengzon et al., 
2003, Al-Jabi and 
El-Shawarby, 
2010) 
Abdominal Aortic Aneurysm 
Repair 
 
 Endovascular 
(EVAR) 
 Open 
9 234 
 
 
81 
 
180 
5-8 24-72 163 
 
 
132 
 
180 
(Cruickshank et 
al., 1990, Baigrie 
et al., 1992, 
Swartbol et al., 
1996, Syk et al., 
1998, Galle et al., 
2000, Morikage et 
al., 2000, Odegard 
et al., 2000, Bolke 
et al., 2001, 
Kucukakin et al., 
2010) 
Oesophagectomy 
 
 Minimally Invasive 
 Open 
1 27 
 
14 
13 
4 72 186 
 
189 
183 
(Maas et al., 2013) 
Open Cardiac Surgery 4 109 3-7 24-72 189 (Boralessa et al., 
1986, Kragsbjerg 
et al., 1995, 
Mollhoff et al., 
1999, Franke et al., 
2005) 
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6 Comparison of the components of a white cell 
count and acute phase proteins as markers of 
the magnitude of injury and the development of 
infective complications following elective 
surgery for colorectal cancer 
6.1 Introduction 
Following surgical intervention, a cascade of different processes occurs throughout the 
body that results in the elaboration of the systemic inflammatory response (Chapter 5). It 
has long been proposed that cancer surgery, due to the profound immunosuppression it 
causes, may promote progression of dormant micrometastatic disease (Baum et al., 2005, 
Retsky et al., 2008, O'Leary et al., 2016). Indeed, post-operative CRP and the NLR have 
been reported to predict the development of post-operative complications (Cook et al., 
2007, Forget et al., 2015, Singh et al., 2014). Therefore, it is of interest that, of the routine 
clinically available markers, the magnitude of the post-operative systemic inflammatory 
response was best assessed by circulating concentrations of CRP (Chapter 5). In contrast, 
WCC did not appear to accurately reflect the magnitude of the systemic inflammatory 
response following surgery. Whilst the majority of white cells are neutrophils, there are 
other cells that are included in the WCC such as lymphocytes, monocytes, basophils and 
eosinophils and these may compromise its value. Therefore, it is possible that these 
different cell types may each respond differently following surgical intervention. The aim 
of the present study was to compare white cells with acute phase proteins as markers of the 
magnitude of surgical injury and the development of infective complications following 
elective surgery for colorectal cancer.  
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6.2 Methods 
6.2.1 Patients 
This was a retrospective study of patients with histologically proven colorectal cancer 
(based on pre-operative endoscopic biopsies, pre-operative computed tomography and 
confirmed on laparotomy findings) who were considered to have undergone elective, 
potentially curative resection between December 2003 and June 2013 in one of two 
University teaching hospitals in Glasgow (n = 378).  Patient characteristics were collected 
in a prospectively maintained database and all patient data was anonymised.  
All tumours were staged according to conventional tumour, node, metastasis classification. 
All resections were performed electively and were performed using open (n = 291) or 
laparoscopic (n = 87) surgery. Patients with metastatic disease or who underwent 
emergency surgery were excluded from the analysis.  
Pre-operatively all patients received thromboembolic prophylaxis and antibiotic 
prophylaxis as per the local protocol. Surgery was performed by specialist colorectal 
surgeons, experienced in treating patients with colorectal cancer, either by traditional open 
method or laparoscopic method utilising a small lower abdominal extraction wound. Blood 
samples were taken for routine laboratory analysis of C-reactive protein and white cell 
count (neutrophil, lymphocyte, monocyte, eosinophil and basophil count) during the pre 
and post-operative period (days 1-4). Post-operatively, patients had a daily clinical 
assessment and investigations carried out as clinically indicated. Patients were discharged 
after day 4 when the surgical team felt this was clinically indicated. Patients were assessed 
for both infective and non-infective complications. Infective complications can be 
classified as either surgical site infections (SSI) or remote site infections (RSI). The criteria 
used to define these infective complications were the same as has been previously 
described (Ramanathan et al., 2013) and is as follows: a wound infection included the 
presence of pus that discharged spontaneously or required drainage; an intra-abdominal 
abscess was confirmed by imaging such as computed tomography (CT) and required either 
conservative therapy with antibiotics or drainage; an anastomotic leak, defined as a fistula 
to the bowel anastomosis, was confirmed radiologically or diagnosed at re-laparotomy; 
pneumonia was diagnosed as the presence of x-ray changes and fever that required 
antibiotic therapy and urinary tract infection as positive urine culture in presence of 
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symptoms that required antibiotic therapy. The West of Scotland research ethics committee 
approved this study.  
6.2.2 Statistical Analysis  
Data is presented as the median (range). Comparison of post-operative values with pre-
operative values was performed using Wilcoxon signed-rank test and comparison of 
continuous data was performed using a Mann Whitney U test. Receiver Operating Curves 
(ROC) were used to identify optimal thresholds for predicting the development of infective 
complications. A p value of <0.05 was considered statistically significant. Statistical 
analysis was performed using SPSS version 22.0 for Windows (IBM, SPSS, IL, USA).
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6.3  Results 
378 patients were included in this study and their baseline characteristics are shown in 
Table 6.1. The majority of patients were aged over 65 years old (71%) with similar 
numbers of males and females and the majority having TNM stage II disease (43%). 23% 
underwent a laparoscopic procedure and 28% developed an infective post-operative 
complication. 
Of the components of a WCC, only the neutrophil and monocyte count significantly 
increased following surgery, both peaking on post-operative day 1 (Table 6.2). On the first 
post-operative day the neutrophil count increased by 89% and monocyte count by 17%. 
The neutrophil count and monocyte counts on post-operative day 1 were significantly 
different to the pre-operative value (p < 0.001). Lymphocytes showed a reduction of 42% 
on the first post-operative day, reducing further on post-operative day 3 and the counts 
were statistically different on all post-operative days compared to pre-operative values (p < 
0.001). Similarly, the basophil and platelet counts all decreased following surgery and with 
no real discernible nadir demonstrated but with the counts on all post-operative days 
statistically different to pre-operative values (p < 0.001). Eosinophils decreased by 100% 
on post-operative day 1 before beginning to rise back to pre-operative levels. The 
eosinophil count on post-operative day 1 was significantly different to the pre-operative 
value (p < 0.001). In comparison, CRP increased profoundly following surgery, its peak 
value being 2800% greater than the pre-operative concentration (p < 0.001) and albumin 
fell by 29% (p < 0.001). 
Comparison of the components of the differential WCC in open and laparoscopic 
procedures is shown in Table 6.2. Neutrophil and lymphocyte counts evoked a smaller 
response in laparoscopic procedures, however this response was only statistically different 
for the neutrophil count pre-operatively (p = 0.002) and on post-operative day 2 (p = 
0.006) and for lymphocyte count on all days (all p < 0.05). The monocyte count was 
greater in laparoscopic procedures and was significantly different on all post-operative 
days (all p < 0.01). Eosinophil and platelet counts were not statistically different in 
laparoscopic or open groups. In comparison, CRP was lower in laparoscopic procedures 
both pre-operatively and on post-operative days 1-3 (p < 0.001) and albumin higher in 
laparoscopic procedures on post-operative days 1-3 (p < 0.001). Both appeared superior to 
the neutrophil count in this regard (Figure 6.1).  
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Comparison of the components of the WCC in patients who developed post-operative 
infective complications and no complications following both open and laparoscopic 
surgery is shown in Table 6.3 In those patients undergoing open surgery, only the 
neutrophil count, on post-operative day 3, was significantly greater in those who developed 
an infective complication (p < 0.05). In comparison, CRP concentrations were significantly 
higher and albumin concentrations significantly lower from day 2 onwards (p < 0.001). In 
those patients undergoing laparoscopic surgery, the neutrophil count on days 2, 3 and 4 
was significantly greater (p < 0.05) and the basophil count on day 3 significantly reduced 
(p <0.05) in those developing infective complications. In comparison, CRP concentrations 
were significantly greater on all post-operative days in those developing infective 
complications (p < 0.05) and appeared superior to the neutrophil count to this regard 
(Figure 6.2). 
The correlation between the neutrophil count and CRP (Table 6.4) and between the 
neutrophil count and albumin (Table 6.5) was examined. There was a significant 
correlation between the neutrophil count and CRP which appeared to happen 
contemporaneously, with day 2 neutrophil count most closely correlated with day 2 CRP 
concentration and the same with day 3 and day 4. There was also a significant correlation 
between the neutrophil count and albumin, particularly on day 3 and day 4. 
Receiver Operating Curves (ROC) were used to determine the optimal neutrophil threshold 
for the development of infective complications on day 3 and day 4 (Figures 6.3 (a) & 6.4 
(a)). On day 3 the area under the curve was 0.617 (95% CI 0.55-0.69, p = 0.001) and the 
optimal threshold value was 7.5 x10
9
/L. On day 4 the area under the curve was 0.608 (95% 
CI 0.53-0.68, p = 0.005) and the optimal threshold value was 6.5 x10
9
/L. When compared 
to the ROC for CRP on days 3 and 4 (Figures 6.3 (b) and 6.4 (b)) the neutrophil count is 
inferior with regards to the area under the curve (Day 3 – CRP AUC 0.748, p < 0.001; Day 
4 – CRP AUC 0.749, p , 0.001). Using the established neutrophil threshold of 7.5 x109/L 
on day 3, the rate of infective complications ranges from 23% in those with a low 
neutrophil count to 42% in those with a high neutrophil count (p = 0.001). This results in a 
sensitivity of 44%, specificity of 66%, positive predictive value of 42% and negative 
predictive value of 77%. Using the neutrophil threshold of 6.5 x10
9
/L on day 4, the rate of 
infective complications ranges from 26% on those with a low neutrophil count to 48% in 
those with a high neutrophil count (p < 0.001). This results in a sensitivity of 58%, 
specificity of 66%, positive predictive value of 48% and negative predictive value of 74%. 
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6.4 Discussion 
The results of the present study show that of the components of a WCC, only the 
neutrophil count consistently reflected the impact of the magnitude of injury and 
development of infective complications. Therefore, if a WCC is to be used to monitor the 
course of the systemic inflammatory response following surgery, especially the 
development of infective complications, then particular attention should be paid to the 
neutrophil count. 
It was of interest that the components of the WCC behaved in a similar fashion to other 
components of the systemic inflammatory response with regards to the method of surgery, 
be that open or laparoscopic. Laparoscopic surgery resulted in a relatively lower neutrophil 
count, which is in keeping with similar work looking at CRP in colorectal cancer surgery  
and a range of surgical procedures (Chapter 5) (Ramanathan et al., 2015).  Indeed, there 
was a correlation between the neutrophil count and both CRP and albumin. This 
correlation (neutrophil and CRP) appears to happen contemporaneously, with day 2 
neutrophil count most closely correlated with day 2 CRP concentration and the same with 
day 3 and day 4. This was also evident with the neutrophil count and albumin on day 3 and 
day 4. Moreover, similar to that of CRP and albumin, a neutrophil count above the 
established threshold on day 3 (>7.5 x10
9
/L) was associated with the development of 
infective complications. Taken together this would suggest that they play a coordinated 
role in the initiation and maintenance of the systemic inflammatory response following 
surgery. 
Infective complications, including anastomotic leak, have previously been reported to have 
a negative impact on long term outcomes and quality of life following surgery for 
colorectal cancer (Brown et al., 2014, Artinyan et al., 2015). Furthermore, CRP has been 
reported to be able to predict the development of these complications using defined 
thresholds on different post-operative days, (Platt et al., 2012, Singh et al., 2014) with 
concentrations on days 3 and 4 thought to be most clinically relevant. In the present study, 
of the components of a white cell count, only the neutrophil count was significantly 
increased in the group with infective complications and would appear to predict infective 
complications, particularly on post-operative days 3 and 4. However, compared with CRP 
and albumin, the neutrophil count was inferior in this regard. Clinical signs such as fever, 
abdominal pain and tachycardia can be absent early in complication development and 
therefore the use of CRP, albumin and neutrophil thresholds on day 3 may allow a more 
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objective assessment of the patient’s condition and provide a ‘tip-off’ to the likely safe 
discharge of the patient (Singh et al., 2014). 
The molecular basis of the observations of the present study is not clear. However, it is of 
interest that interleukin-6 (IL-6) is known to stimulate production of both neutrophils and 
CRP, which are both components of the innate immune response. Indeed, immature 
granulocytes, a subset of neutrophils that are released prematurely from the bone marrow 
during periods of infection and inflammation, may offer further insight into the exact role 
IL-6 plays. Such myeloid derived suppressor cells (MDSCs) are known to be involved in 
chronic inflammation induced immunosuppression both locally and systemically (Baniyash 
et al., 2014) and to invoke tumour-mediated adaptive immune suppression in patients with 
different tumour types (Diaz-Montero et al., 2009). Furthermore, levels of MDSCs have 
been reported to be correlated with tumour stage and metastatic tumour burden (Diaz-
Montero et al., 2009). It has previously been reported that MDSC recruitment was 
associated with increased IL-6 levels and that the levels of both MDSCs and IL-6 predicted 
prognosis in patients with oesophageal cancer (Chen et al., 2014). Pharmacological 
methods of reducing MDSC levels therefore may be of benefit in the treatment of patients 
with cancer, perhaps by targeting the inhibition of IL-6/ JAK/ STAT pathway (Roxburgh 
and McMillan, 2016).  
In the present study, it was of interest that the lymphocyte count fall following surgery, 
was less affected in laparoscopic surgery and was not associated with the development of 
infective complications. These results may have implications for the prognostic value of 
the neutrophil-lymphocyte ratio (NLR) in the post-operative period (Cook et al., 2007, 
Forget et al., 2015).  
Laparoscopic surgery is being increasingly utilised as a method of curative surgery for 
colorectal cancer and has been reported to shorten hospital stay, reduce morbidity and 
reduce post-operative pain (Reza et al., 2006, Lourenco et al., 2008). More recently it has 
also been reported to evoke a reduced systemic inflammatory response as evidenced by 
CRP concentrations (Ramanathan et al., 2015) and IL-6 concentrations (Chapter 5) . In the 
present study, in addition to the post-operative CRP concentrations being significantly 
reduced in those undergoing laparoscopic procedures, the neutrophil count was also 
significantly reduced and therefore can be considered to reliably reflect the magnitude of 
surgical injury. Therefore, in addition to drug interventions, different operative techniques 
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may make it possible to reduce circulating IL-6, CRP and MDSCs, causing relative 
adaptive immunosuppression and thus potentially improve long term outcomes.    
The present study has some potential limitations that should be considered. Plasma 
cytokine levels were not measured in these patients and as such no comment can be made 
on specific mediators of the systemic inflammatory response following surgery. Measures 
of pre-operative morbidity were also not carried out and therefore it is not clear whether 
co-morbidity would have had any bearing on the overall results.  Nevertheless, 
comparative measures of the perioperative systemic inflammatory response were 
examined.  Furthermore, Clavien-Dindo classification was not available for all included 
cases. However, it has recently been reported that post-operative CRP concentrations were 
associated with the severity of complications (McSorley et al., 2015).  Therefore, it may be 
hypothesised that the neutrophil count may also be associated with the severity of 
complications but further research is required. 
In summary, of the components of a WCC, only the neutrophil count reflected both the 
magnitude of injury and the impact on the development of infective complications. 
Although the neutrophil count would appear to be inferior to CRP and albumin in this 
regard, it confirms that the development of the systemic inflammatory response following 
surgery for colorectal cancer is principally due to an upregulation of the innate immune 
response.   
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Table 6.1 Clinicopathological characteristics of patients undergoing elective resection 
for colorectal cancer  
Characteristic No. of patients (%) 
Age: <65/ 65-74/ >=75 109 (29)/ 127 (33)/ 142 (38) 
Sex: Male/ Female 197 (52)/ 181 (48) 
Operation: Colon/ Rectum 272 (72)/ 105 (28) 
Laparoscopic: No/ Yes 291 (77)/ 87 (23) 
TNM Stage: I/ II/ III 75 (20)/ 162 (43)/ 120 (32) 
All Complications: No/ Yes 231 (61)/ 147 (39) 
Infective Complication: No/ Yes 272 (72)/ 106 (28) 
Results given as number (%) 
CRP, C-reactive protein; TNM, tumour node metastasis 
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Table 6.2 Changes in the concentrations of components of the differential white cell count and acute phase proteins in patients undergoing elective 
surgery for colorectal cancer 
Overall Cohort Comparison of Open and Laparoscopic Surgery 
Characteristic Median (range) Percentage 
change from pre-
operative value 
(%) 
p-value
a
 Open  
Median 
Laparoscopic 
Median 
Percentage 
difference (%) 
p-value 
White Cell         
Pre-operative 7.5 (3.5 – 23.5) 0  7.8 7.2 -8 0.106 
POD 1 10.8 (0.7 – 33.8) 44 <0.001 10.9 10.4 -5 0.471 
POD 2 10.7 (1.4 – 52.9) 43 <0.001 10.9 9.9 -9 0.217 
POD 3 9.1 (2.7 – 45.6) 21 <0.001 9.1 8.8 -3 0.447 
POD 4 8.2 (1.6 – 38.3) 9 <0.001 8.3 8.2 -1 0.800 
Neutrophil        
Pre-operative 4.7 (1.1 – 12.8) 0  5.0 4.1 -18 0.002 
POD 1 8.9 (0.4 – 23.3) 89 <0.001 9.1 8.4 -8 0.086 
POD 2 8.6 (0.8 – 25.4) 83 <0.001 9.0 7.6 -16 0.006 
POD 3 7.2 (1.7 – 26.7) 53 <0.001 7.3 6.6 -10 0.100 
POD 4 6.0 (1.4 – 22.8) 28 <0.001 6.3 5.7 -10 0.743 
Lymphocytes        
Pre-operative 1.7 (0.3 – 19.1) 0  1.6 1.8 13 0.003 
POD 1 1.0 (0.1 – 24.3) -42 <0.001 1.0 1.1 10 0.001 
POD 2 1.0 (0.2 – 38.4) -42 <0.001 1.0 1.2 20 <0.001 
POD 3 0.9 (0.2 – 36.7) -47 <0.001 0.9 1.2 33 0.001 
POD 4 0.9 (0.1 – 32.7) -47 <0.001 0.9 1.2 33 0.001 
Monocytes        
Pre-operative 0.6 (0.2 – 2.0) 0  0.6 0.6 0 0.761 
POD 1 0.7 (0.1 – 2.0) 17 <0.001 0.7 0.9 29 0.001 
POD 2 0.7 (0 – 2.5) 17 <0.001 0.7 0.8 14 0.003 
POD 3 0.6 (0.1 – 1.8) 0 0.117 0.6 0.7 17 <0.001 
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POD 4 0.6 (0.1 – 1.6) 0 0.040 0.6 0.7 17 0.007 
Eosinophils        
Pre-operative 0.19 (0 – 1.18) 0  0.20 0.15 -25 0.906 
POD 1 0 (0 – 1.98) -100 <0.001 0.01 0.00 -100 0.180 
POD 2 0.09 (0 – 0.61) -53 <0.001 0.10 0.07 -30 0.796 
POD 3 0.19 (0 – 2.07) 0 0.982 0.20 0.14 -30 0.198 
POD 4 0.20 (0 – 1.30) 5 0.018 0.20 0.20 0 0.904 
Basophils        
Pre-operative 0.02 (0 – 0.20) 0  0.02 0.03 50 0.001 
POD 1 0.01 (0 – 0.32) -50 <0.001 0.01 0.01 0 0.058 
POD 2 0.01 (0 – 0.10) -50 <0.001 0.01 0.01 0 <0.001 
POD 3 0.01 (0 – 0.10) -50 <0.001 0.01 0.01 0 <0.001 
POD 4 0.01 (0 – 0.10) -50 <0.001 0.01 0.02 100 <0.001 
Platelets        
Pre-operative 275 (94 – 811) 0  278 269 -3 0.385 
POD 1 227 (71 – 732) -17 <0.001 233 216 -7 0.552 
POD 2 219 (78 – 649) -20 <0.001 223 218 -2 0.809 
POD 3 231 (73 – 761) -16 <0.001 236 226 -4 0.642 
POD 4 266 (59 – 861) -3 <0.001 268 265 -1 0.146 
C-reactive 
Protein 
       
Pre-operative 6 (0.4 – 249) 0  8.2 3.3 -60 <0.001 
POD 1 98 (1.9 – 284) 1533 <0.001 104 71 -32 <0.001 
POD 2 173 (17 – 358) 2783 <0.001 185 126 -32 <0.001 
POD 3 161 (2.3 – 430) 2583 <0.001 173 131 -24 <0.001 
POD 4 113 (6.0 – 425) 1783 <0.001 120 87 -28 0.296 
Albumin        
Pre-operative 38 (17-49) 0  38 37 -3 0.212 
POD 1 27(12-40) -29 <0.001 26 29 12 <0.001 
POD 2 27 (11-44) -29 <0.001 26 29 12 <0.001 
POD 3 27 (9-40) -29 <0.001 26 29 12 <0.001 
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POD 4 27 (11-40) -29 <0.001 26 28 8 0.146 
a
 Comparison of post-operative median value with pre-op median value. POD, post-operative day 
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Table 6.3 Components of the differential white cell count and acute phase proteins in 
patients developing no complications and infective complications following 
open and laparoscopic surgery for colorectal cancer 
 Open Surgery (n = 291) Laparoscopic Surgery (n = 87) 
Characteristic No 
Complications  
(n = 206) 
Infective 
Complications  
(n = 85) 
p-value No 
Complications  
(n = 66) 
Infective 
Complications  
(n = 21) 
p-value 
White Cell        
Pre-
operative 
7.4 7.7 0.396 7.1 7.5 0.629 
POD 1 11.1 10.9 0.635 10.5 11.5 0.036 
POD 2 10.6 10.7 0.649 8.9 11.2 0.004 
POD 3 8.6 9.8 0.040 8.3 10.2 0.022 
POD 4 8.0 8.6 0.132 8.0 9.2 0.014 
Neutrophil       
Pre-
operative 
5.0 5.0 0.728 4.3 4.1 0.612 
POD 1 9.1 9.1 0.653 8.0 9.2 0.073 
POD 2 8.8 8.9 0.698 7.0 9.0 0.007 
POD 3 6.7 7.7 0.021 5.9 7.7 0.016 
POD 4 6.0 6.8 0.065 5.4 7.1 0.006 
Lymphocytes       
Pre-
operative 
1.5 1.6 0.294 1.8 1.9 0.363 
POD 1 1.0 1.0 0.822 1.2 1.3 0.124 
POD 2 0.9 0.9 0.812 1.4 1.2 0.820 
POD 3 0.9 0.9 0.826 1.2 1.0 0.171 
POD 4 0.9 0.8 0.270 1.3 1.0 0.619 
Monocytes       
Pre-
operative 
0.6 0.6 0.070 0.6 0.5 0.563 
POD 1 0.7 0.7 0.115 0.9 0.9 0.470 
POD 2 0.6 0.7 0.406 0.7 0.9 0.378 
POD 3 0.5 0.6 0.064 0.7 0.8 0.487 
POD 4 0.6 0.7 0.092 0.7 0.7 0.520 
Eosinophils       
Pre-
operative 
0.17 0.20 0.085 0.15 0.28 0.003 
POD 1 0.01 0.01 0.794 0.01 0.01 0.689 
POD 2 0.10 0.08 0.361 0.08 0.11 0.457 
POD 3 0.20 0.20 0.658 0.14 0.25 0.094 
POD 4 0.20 0.20 0.775 0.19 0.21 0.286 
Basophils       
Pre-
operative 
0.02 0.03 0.071 0.03 0.03 0.511 
POD 1 0.00 0.01 0.180 0.01 0.01 0.089 
POD 2 0.00 0.01 0.192 0.01 0.02 0.274 
POD 3 0.01 0.01 0.937 0.02 0.01 0.024 
POD 4 0.01 0.01 0.793 0.02 0.02 0.936 
Platelets       
Pre-
operative 
280 273 0.321 278 283 0.474 
POD 1 245 222 0.393 236 230 0.533 
POD 2 238 214 0.065 232 219 0.427 
POD 3 244 221 0.142 265 226 0.242 
POD 4 288 258 0.072 270 266 0.386 
C-reactive       
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Protein 
Pre-
operative 
7 10 0.222 3 3 0.309 
POD 1 102 113 0.158 55 96 0.002 
POD 2 163 211 <0.001 87 151 <0.001 
POD 3 143 213 <0.001 87 175 0.003 
POD 4 94 179 <0.001 76 206 0.016 
Albumin       
Pre-
operative 
39 37 0.208 37 38 0.320 
POD 1 27 26 0.038 29 30 0.190 
POD 2 27 25 <0.001 29 30 0.850 
POD 3 27 24 <0.001 29 27 0.122 
POD 4 28 24 <0.001 29 27 0.122 
POD, post-operative day 
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Table 6.4 Correlations between the neutrophil count and CRP concentrations on post-
operative days 1-4 
 Day 1 CRP 
Concentration 
Day 2 CRP 
Concentration 
Day 3 CRP 
Concentration 
Day 4 CRP 
Concentration 
Day 1 
Neutrophil 
Count 
rs = 0.070 
p = 0.198  
rs = 0.031  
p = 0.569 
rs = 0.015 
p = 0.781 
 rs = -0.006 
p = 0.911  
Day 2 
Neutrophil 
Count 
rs = 0.163 
p = 0.003  
rs = 0.226 
p < 0.001 
rs = 0.204 
p < 0.001 
rs = 0.072 
p = 0.210 
Day 3 
Neutrophil 
Count 
rs = 0.109 
p = 0.053  
rs = 0.147 
p = 0.008  
rs = 0.251 
p < 0.001  
rs = 0.195 
p = 0.001 
Day 4 
Neutrophil 
Count 
rs = 0.075 
p = 0.213  
rs = 0.093 
p = 0.122  
rs = 0.219 
p < 0.001  
rs = 0.219 
p < 0.001  
 
 
 
Table 6.5 Correlations between neutrophil count and albumin concentrations on post-
operative days 1-4 
 Day 1 Albumin 
Concentration 
Day 2 Albumin 
Concentration 
Day 3 Albumin 
Concentration 
Day 4 Albumin 
Concentration 
Day 1 
Neutrophil 
Count 
rs = 0.101 
p = 0.084 
rs = 0.072 
p = 0.215 
rs = -0.001 
p = 0.983 
 rs = 0.22 
p = 0.723 
Day 2 
Neutrophil 
Count 
rs = -0.118 
p = 0.045 
rs = -0.058 
p = 0.321 
rs = -0.130 
p = 0.030 
rs = -0.141 
p = 0.024 
Day 3 
Neutrophil 
Count 
rs = -0.139 
p = 0.024 
rs = -0.163 
p = 0.008 
rs = -0.126 
p = 0.038 
rs = -0.238 
p = <0.001 
Day 4 
Neutrophil 
Count 
rs = -0.148 
p = 0.022 
rs = -0.162 
p = 0.012 
rs = -0.216 
p = 0.001 
rs = -0.216 
p = 0.001 
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Figure 6.1 The magnitude of the neutrophil count, CRP and albumin in both open and 
laparoscopic elective colorectal cancer resection 
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Figure 6.2 The magnitude of the neutrophil count, CRP and albumin in patients 
developing infective complications and no complications following elective 
colorectal cancer resection 
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Figure 6.3 (a) ROC curve of the day 3 neutrophil count and development of infective 
complications and (b) ROC curve of the day 3 CRP and the development of 
infective complications.  
(a)The area under the curve (AUC) is 0.617 (95% CI 0.55-0.69; p=0.001) and 
(b) the area under the curve (AUC) is 0.748 (95% CI 0.69-0.81; p<0.001). 
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Figure 6.4 (a) ROC curve of the day 4 neutrophil count and development of infective 
complications and (b) ROC curve of the day 4 CRP and the development of 
infective complications. 
(a) The area under the curve (AUC) is 0.6089 (95% CI 0.53-0.68; p=0.005) and 
(b) the area under the curve (AUC) is 0.749 (95% CI 0.69-0.81; p<0.001). 
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7 A post-operative systemic inflammation score 
predicts short and long term outcomes in 
patients undergoing surgery for colorectal 
cancer 
7.1 Introduction 
In those deemed to have non-metastatic disease, surgery is the primary modality of cure. 
However, there has been a longstanding concern that although surgery provides the means 
of a potential cure for patients with colorectal cancer, the injury associated with it may 
stimulate tumour growth and dissemination (Abramovitch et al., 1999, Mynster et al., 
2000, McArdle et al., 2005, Retsky et al., 2008). Despite various infection control 
measures and the use of pre-operative antibiotic prophylaxis following surgery, a 
significant proportion of patients develop post-operative complications, with the majority 
of these being infective in nature. Recently, it has become apparent these complications, as 
well as having an adverse effect on patients quality of life (Brown et al., 2014) are 
associated with both increased risk of cancer recurrence and poorer long term survival 
(McArdle et al., 2005, Mirnezami et al., 2011, Richards et al., 2011, Pucher et al., 2014, 
Artinyan et al., 2015). 
Therefore, there has been considerable interest in objectively identifying, early in the post-
operative phase, which patients are at increased risk of developing infective complications 
in order to facilitate prompt investigation, treatment or alternatively facilitate safe 
discharge.  In particular, the stereotypical marker of the systemic inflammatory response 
(SIR), C-reactive protein (CRP) has been extensively examined and concentrations greater 
than approximately 150mg/l on days 3-5 have been shown to be useful (Singh et al., 2014).  
In particular, it has been proposed that in patients undergoing resection for colorectal 
cancer, CRP concentrations of <150 mg/L on post-operative days 3-5 are unlikely to 
develop of infective complications facilitating safe early discharge (McDermott et al., 
2015). 
Recently, McSorley et al. reported in 377 patients that the post-operative systemic 
inflammatory response, evidenced by CRP concentrations greater than 150 mg/L, were 
associated with both complication severity and long term outcome (McSorley et al., 
2016b). However, whether this observation provides the basis for a post-operative scoring 
system to predict both short term and long term outcomes is not clear. 
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Therefore, the aim of the present study was to examine whether the combination of post-
operative markers of the SIR, namely CRP and albumin, are useful in predicting the 
development of post-operative infective complications and long term survival in a large 
cohort of patients undergoing potentially curative surgery for colorectal cancer. 
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7.2 Methods 
7.2.1 Patients 
Patients with histologically proven colorectal cancer who, on the basis of intra-operative 
findings and pre-operative computed tomography, were considered to have undergone 
potentially curative resection at a single centre between March 1999 and May 2013 were 
included in the analyses (n=813). All patient data was anonymised and all tumours were 
staged according to conventional tumour, node, metastasis (TNM5) classification, as per 
the Royal College of Pathologists guidelines (RCPath, 2014) and additional pathological 
data obtained from the pathology reports issued at the time of the resection. Patients were 
grouped into 2 cohorts, in both cohorts patient characteristics were collected in a 
prospective manner. In the test cohort (surgery from March 1999 to November 2007; 
n=402) post-operative complication data was collected retrospectively from electronic 
records. In the validation cohort (surgery from January 2008 to May 2013; n=411) post-
operative complication data was collected prospectively from patient records following 
discharge. Due to the prospective method of data collection, Clavien-Dindo classification 
of complications was also recorded for this validation cohort. 
Pre-operatively, all patients received thromboembolism prophylaxis and antibiotic 
prophylaxis as per local protocols. Blood samples were taken for routine laboratory 
analysis pre and post-operatively. The pre-operative SIR was assessed using the modified 
Glasgow Prognostic Score (McMillan, 2013b) (mGPS, Table 7.1).  
The post-operative SIR was assessed using the post-operative Glasgow Prognostic Score 
(poGPS, Table 7.1). In essence, a post-operative CRP concentration below 150 mg/L, 
regardless of albumin concentration scored 0, a CRP concentration ≥150 mg/L and 
albumin >25 g/L scored 1 and CRP ≥150 mg/L and albumin <25 g/L scored 2. The 
creation of this score was initially performed in the retrospective test cohort and an attempt 
to subsequently validate this in the prospective validation cohort then performed.  
Post-operatively all patients underwent daily clinical assessment. Clinicians were not 
blinded to these daily blood results and additional investigations and management were 
instigated at the surgical team’s discretion based on the relevant clinical findings.  
Patients were assessed for both non-infective (ileus, acute coronary syndrome, acute 
myocardial infarction, pulmonary embolism and arrhythmias) and infective complications 
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(wound, intra-abdominal abscess, anastomotic leak, urinary tract infection and 
pneumonia). The criteria used to define these complications were the same as has been 
previously described (Platt et al., 2012, Ramanathan et al., 2013). In short, a wound 
infection included the presence of pus that discharged spontaneously or required drainage; 
an intra-abdominal abscess was confirmed by imaging and required either conservative 
therapy with antibiotics or drainage; an anastomotic leak was defined as a fistula to the 
bowel anastomosis that was confirmed radiologically or diagnosed at re-laparotomy; 
pneumonia was diagnosed as the presence of x-ray changes and fever that required 
antibiotic therapy and urinary tract infection as positive urine culture in presence of 
symptoms that required antibiotic therapy. Patients were routinely followed up for 5 years 
following resection as per national guidelines. Date and cause of death were crosschecked 
with the cancer registration system and Registrar General (Scotland).  The West of 
Scotland research ethics committee approved this study.  
7.2.2 Statistical Analysis 
The comparison of categorical variables was performed using Chi square test and of 
continuous variables using the Mann Whitney U test. Univariate survival analysis was 
performed using Cox proportional hazards regression in order to calculate hazard ratios 
(HR) and 95% confidence intervals (95% CI). A two sided p value of <0.05 was 
considered statistically significant. Statistical analysis was performed using SPSS version 
22.0 for Windows (IBM, SPSS, IL, USA). 
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7.3 Results 
In both the test cohort (n=402) and the validation cohort (n=411), the majority of patients 
were aged >65 years old, were male, had a colonic tumour and had an elective operation. 
Comparison of the clinicopathological characteristics in both cohorts is shown in Table 
7.2. There were significantly fewer emergency procedures (p<0.05), more T1 tumours and 
less T3 tumours (p<0.005), greater overall complication rate (p<0.001) and greater 
infective complication rate (p<0.001) in the validation cohort. Median follow up of 
survivors in the test cohort was 116 months (range 76-180) and in the validation cohort 
was 31 months (range 10-71 months).  
7.3.1 Test Cohort 
With regards to short term outcomes, 87 patients (22%) developed an infective 
complication. In this cohort, of the pre-operative factors, emergency presentation (p<0.01) 
and raised pre-operative CRP concentrations (p<0.05) were associated with the 
development of infective complications. Moreover, rectal surgery (p<0.01), exceeding the 
post-operative thresholds for CRP on days 3 and 4 (both p<0.001) and for albumin on days 
3 and 4 (both p<0.001) and the day 3 and 4 poGPS (both p<0.001) were also associated 
with the development of infective complications (Table 7.3).  
In patients undergoing surgery for colon cancer (n=259), 46 patients (18%) of patients 
developed an infective complication. In these patients, emergency presentation (p<0.001), 
exceeding the post-operative day 3 and 4 thresholds of CRP (p<0.001) and albumin 
(p<0.005) and the day 3 and 4 poGPS (both p<0.001) were associated with the 
development of infective complications (Table 7.4).  
When using the post-operative scoring system (Table 6.6), post-operative Glasgow 
Prognostic Score (poGPS), an incremental increase in the day 3 poGPS from 0 to 1 to 2 
resulted in an increase in the infective complication rate from 10.3% to 31.0% to 56.6% 
(p<0.001) and using the day 4 poGPS from 17.0% to 50.0% to 73.9% (p<0.001).  
7.3.2 Validation Cohort 
In this cohort there were similar findings to those in the test cohort. With regards to short 
term outcomes, 106 patients (26%) developed an infective complication. Male sex 
(p<0.005), exceeding the post-operative thresholds for CRP on days 3 and 4 (both 
158 
 
 
 
p<0.001) and for albumin on days 3 and 4 (both p<0.005) and the day 3 and 4 poGPS (both 
p<0.001) were also associated with the development of infective complications (Table 
7.5).  
When using the post-operative scoring system (Table 7.6) an incremental increase in the 
day 3 poGPS resulted in an increase in the infective complication rate from 14.4% to 
28.9% to 41.9% (p<0.001) and using the day 4 poGPS from 17.9% to 32.2% to 53.7% 
(p<0.001). Increase in the day 3 poGPS score resulted in an increase in severity of Clavien-
Dindo Scores (p<0.001) as did an increase in the day 4 poGPS (p<0.001).  
7.3.3 Overall Cohort  
With regards to long term outcomes, univariate survival analysis between the 
clinicopathological characteristics, the pre-operative and post-operative SIR is shown in 
Table 7.7. There were 175 cancer deaths and 139 non-cancer deaths. Age (p<0.001), TNM 
stage (p<0.001), venous invasion (p<0.005), margin involvement (p<0.001), peritoneal 
involvement (p<0.001), adjuvant therapy (p<0.05) and mGPS (p<0.001) as well as 
exceeding the post-operative day 3 and 4 threshold for CRP (both p<0.05) and for albumin 
(both p<0.05) and the day 3 and 4 poGPS (p<0.05) were associated with OS.  
Furthermore, in patients undergoing resection of colon cancer (Table 7.8), age, (p<0.01), 
emergency presentation (p<0.05), TNM stage (p<0.001), venous invasion (p<0.05), margin 
involvement (p<0.001), and adjuvant therapy (p<0.05) as well as the mGPS (p<0.001), 
exceeding day 3 and 4 threshold for CRP (p<0.05) and albumin (p<0.001) and the day 3 
and 4 poGPS (p<0.005) were associated with overall survival. 
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7.4 Discussion 
The results of the present study confirm that the development of post-operative 
complications, in particular infective complications, were associated with the post-
operative SIR in patients undergoing surgery for colorectal cancer. Furthermore, an 
objective post-operative scoring approach (poGPS) was capable of stratifying the risk of 
developing post-operative infective complications, ranging from approximately 12% with a 
score of 0 to approximately 30% with a score of 1 and approximately 50% with a score of 
2. These results have been demonstrated in a retrospective ‘test cohort’ and subsequently 
validated in the prospective ‘validation’ cohort.  Moreover, the post-operative SIR, 
evidenced by the poGPS, was associated with survival in patients undergoing surgery for 
colorectal cancer.  
This study appears to finally tie the SIR to outcomes following surgery for colorectal 
cancer.  Specifically, the present study builds on work by McSorley et al. who reported in a 
cohort of 377 patients that the magnitude of the post-operative SIR was significantly 
associated with long term outcomes, independent of complications and tumour stage 
(McSorley et al., 2016b). These findings, along with the present study would appear to 
suggest that the mechanisms behind the development of post-operative complications and 
poor long term survival are linked by the SIR.  Therefore a plausible hypothesis is that the 
cancer itself elicits an SIR in a significant proportion of patients while the added surgical 
injury produces an immunological hit in all patients that leads to homeostatic 
decompensation in some. The nature and the consequences of that decompensation may be 
the same as seen in patients with untreated or metastatic disease, perhaps even stimulating 
the growth of residual cancer cells (micrometastatic disease). Moreover, it would appear 
that the SIR involves both a dimension of magnitude and duration, both of which affect the 
prognosis. Consistent with this hypothesis, it has recently been reported that serum and 
peritoneal fluid samples from patients undergoing colorectal cancer surgery who had post-
operative peritoneal infection increased the in-vitro invasiveness capacity of cancer cell 
lines, causing increased tumour dissemination and tumour cell survival (Salvans et al., 
2014).  If this were to prove to be the case then it may be that colorectal cancer surgery 
should be practiced in such a way to minimise the post-operative SIR. This study lays the 
foundation for further work in this field.   
In the present study it was of interest that elevated poGPS scores were significantly 
associated with emergency presentation and the presence of a SIR pre-operatively.  It has 
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now been established that patients who present as an emergency for surgery for colorectal 
cancer have poorer 5 year survival (McArdle and Hole, 2004, Oliphant et al., 2014a, 
Oliphant et al., 2014b). In the present study, when only patients who had elective surgery 
and had a mGPS 0 were examined the poGPS stratified the post-operative infective 
complication rate on both day 3 (poGPS0 rate was 13.7%, poGPS1 rate was 32.8% and 
poGPS2 rate was 50.7%; p<0.001) and day 4 (poGPS0 rate was 17.3, poGPS1 rate was 
43.1% and poGPS2 rate was 71.4%; p<0.001).  Also, the poGPS stratified the 5 year 
survival rates on day 3 (poGPS0 rate was 74%, poGPS1 rate was 67% and poGPS2 rate 
was 60%; p = 0.039). Therefore, the results of the present study would indicate a role for a 
post-operative SIR scoring system in predicting both short and long term outcomes in 
patients undergoing surgery for colorectal cancer.  
Recently, it was reported that the depletion of skeletal muscle mass following surgery for 
colorectal cancer was greater with older age, female sex, open surgery and an elevated pre-
operative SIR, as evidenced by the neutrophil lymphocyte ratio (Malietzis et al., 2016). 
Therefore, consistent with the present results, it may be hypothesised that this was related 
to a greater post-operative SIR.  Given the above it would be of interest to examine 
whether approaches to minimise the poGPS, other than laparoscopic surgery, such as peri-
operative steroids (McSorley et al., 2016a) would reduce the loss of skeletal muscle mass 
following surgery for colorectal cancer. 
This study has several potential clinical benefits: In those with a low score, it may provide 
the clinician with reassurance regarding the development of infective complications and 
allow prompt discharge, particularly in an enhanced recovery setting. In contrast, in those 
with a high score it may provide an early warning to the clinician and prompt re-
assessment and management of the patient. Also, by enabling objective comparison of the 
impact of different surgical approaches and techniques on the magnitude of the post-
operative SIR following surgery it may be possible to identify individuals or techniques 
that minimise the poGPS score (Chapter 5) .  Finally, by acting as a therapeutic target, the 
use of post-operative anti-inflammatory agents has the potential to improve short term 
outcomes. The use of anti-inflammatory agents in the post-operative period, particularly 
following colorectal surgery continues to be a subject of intense debate, with studies 
reporting conflicting outcomes (Klein et al., 2012, Bhangu et al., 2014, STARSURG, 
2014).  Cautious use in the post-operative period may provide benefit to patients with an 
exaggerated post-operative SIR but more work is required to test this.  
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The magnitude of surgical injury in different colorectal procedures may be different e.g. 
for colonic resections and rectal resections.  This may also vary across surgical centres, 
with differences in patient cohorts and in operative expertise.  Therefore, the present 
results require external validation.  However, given the simplicity of the measurement of 
post-operative SIR developed such validation can be readily tested.  
In the present study thresholds for CRP and albumin were examined using ROC analysis 
and post-operative infective complications as an end point.  On day 3 they were 153mg/l 
and 26g/l respectively. On day 4 they were 125mg/l and 27g/l respectively.  These were 
similar to that established from previous meta-analysis (CRP >150mg/l and albumin 
<25g/l) and therefore the latter thresholds were used in the analysis. A limitation of the 
present study was that there are intrinsic and extrinsic factors not accounted for that may 
potentially affect the relationship between the post-operative SIR and long and short term 
outcomes in patients undergoing surgery for colorectal cancer.  For example, 
comorbidities, the quality and type of anaesthesia/surgery, blood loss and blood transfusion 
may all affect this relationship.  Nevertheless, the poGPS provide an objective framework 
against which such factors to be investigated. 
In summary, the magnitude of the post-operative SIR, as evidenced by the poGPS, was 
associated with an incremental increase in the post-operative infective complication rates 
and a reduction in survival.  Elevated systemic inflammation whether prior to or following 
surgery is associated with poor outcome in patients with colorectal cancer.   
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Table 7.1 The pre-operative modified Glasgow Prognostic Score (mGPS) and the post-
operative Glasgow Prognostic Score (poGPS) 
The modified Glasgow Prognostic Score (mGPS) Score 
C-reactive protein ≤10 mg/L and Albumin ≥35 g/L 0 
C-reactive protein ≤10 mg/L and Albumin <35 g/L 0 
C-reactive protein >10 mg/L and Albumin ≥35 g/L 1 
C-reactive protein >10 mg/L and Albumin <35 g/L 2 
  
The post-operative Glasgow Prognostic Score (poGPS)  
C-reactive protein ≤150 mg/L and Albumin ≥25 g/L 0 
C-reactive protein ≤150 mg/L and Albumin <25 g/L 0 
C-reactive protein >150 mg/L and Albumin ≥25 g/L 1 
C-reactive protein >150 mg/L and Albumin <25 g/L 2 
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Table 7.2 Comparison of clinicopathological characteristics in both the test and 
validation cohort 
mGPS, modified Glasgow Prognostic Score; TNM, Tumour, Node, Metastasis; CRP, C-
reactive protein 
  
Characteristic  Test Cohort 
(n = 402) 
Validation Cohort 
(n = 411) 
 
  n (%) n (%) p-
value 
Age    0.153 
 <65 131 (33) 137 (33)  
 65-74 131 (33) 155 (38)  
 >74 140 (34) 119 (29)  
Sex    0.828 
 Female 184 (46) 185 (45)  
 Male 218 (54) 226 (55)  
Emergency 
Presentation 
   0.047 
 No 354 (88) 379 (92)  
 Yes 48 (12) 32 (8)  
Tumour Site    0.933 
 Colon 261 (65) 268 (65)  
 Rectum 141 (35) 143 (35)  
TNM Stage    0.002 
 0 1 (1) 10 (2)  
 I 52 (13) 80 (20)  
 II 179 (44) 177 (43)  
 III 170 (42) 144 (35)  
All 
complications 
   <0.001 
 No 298 (74) 254 (62)  
 Yes 100 (25) 156 (38)  
Infective 
Complications 
   <0.001 
 No 298 (74) 254 (62)  
 Yes 87 (22) 106 (26)  
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Table 7.3 The clinical characteristics, pre-operative systemic inflammation and post-
operative complications in the test cohort 
Characteristic  No Complication 
(n = 298) 
Infective 
Complications 
(n = 87) 
 
  n (%) n (%) p-value 
Age    0.359 
 <65 yrs 102 (79) 27 (21)  
 65-74 yrs 89 (73) 33 (21)  
 >74 yrs 107 (80) 27 (20)  
Sex    0.356 
 Female 140 (79) 36 (21)  
 Male 158 (76) 51 (24)  
Emergency 
Presentation 
   0.006 
 No 269 (80) 69 (20)  
 Yes 29 (62) 18 (38)  
Tumour Site    0.007 
 Colon 204 (82) 46 (18)  
 Rectum 94 (70) 41 (30)  
TNM Stage    0.255 
 0 0 (0) 1 (100)  
 I 39 (75) 13 (25)  
 II 131 (77) 40 (23)  
 III 128 (79) 33 (21)  
Pre-op CRP    0.040 
 ≤10 mg/L 174 (81) 40 (19)  
 >10 mg/L 124 (72) 47 (28)  
Pre-op Albumin    0.677 
 ≥35 g/L 239 (78) 68 (22)  
 <35 g/L 59 (76) 19 (24)  
Pre-op mGPS    0.119 
 0 174 (81) 40 (19)  
 1 84 (73) 31 (27)  
 2 40 (71) 16 (29)  
Post-op Day 3     <0.001 
 CRP ≤150 mg/L  165 (89) 20 (11)  
 CRP >150 mg/L 99 (60) 66 (40)  
Post-op Day 3     <0.001 
 Alb ≥25 g/L 183 (82) 41 (18)  
 Alb <25 g/L 68 (60) 45 (40)  
D3 poGPS    <0.001 
 0 165 (89) 20 (11)  
 1 74 (67) 36 (33)  
 2 22 (42) 30 (58)  
Post-op Day 4     <0.001 
 CRP ≤150 mg/L  202 (82) 44 (18)  
 CRP >150 mg/L 23 (40) 35 (60)  
Post-op Day 4     <0.001 
 Alb ≥ 25 g/L  176 (82) 38 (18)  
 Alb < 25 g/L 42 (52) 39 (48)  
D4 poGPS    <0.001 
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mGPS, modified Glasgow Prognostic Score; TNM, Tumour, Node, Metastasis; CRP, C-
reactive protein 
 
  
 0 202 (82) 44 (18)  
 1 15 (45) 18 (55)  
 2 5 (23) 17 (77)  
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Table 7.4 Clinical characteristics and post-operative complications of patients 
undergoing resection for colon cancer in test cohort 
Characteristic  No 
Complication 
(n = 204) 
Infective 
Complications 
(n = 46) 
 
  n (%) n (%) p-value 
Age    0.985 
 <65 yrs 60 (81) 14 (19)  
 65-74 yrs 69 (82) 15 (18)  
 >74 yrs 75 (81) 17 (19)  
Sex    0.910 
 Female 95 (82) 21 (18)  
 Male 109 (81) 25 (19)  
Emergency 
Presentation 
   <0.001 
 No 176 (86) 29 (14)  
 Yes 28 (62) 17 (38)  
TNM Stage    0.393 
 I 20 (74) 7 (26)  
 II 99 (85) 18 (15)  
 III 85 (80) 21 (20)  
Pre-op CRP    0.075 
 ≤10 mg/L 105 (86) 17 (14)  
 >10 mg/L 99 (77) 29 (23)  
Pre-op 
Albumin 
   0.083 
 ≥35 g/L 158 (84) 30 (16)  
 <35 g/L 46 (74) 16 (26)  
Pre-op mGPS    0.097 
 0 105 (86) 17 (14)  
 1 66 (80) 16 (20)  
 2 33 (72) 13 (28)  
Post-op Day 3     <0.001 
 CRP ≤150 mg/L  107 (90) 12 (10)  
 CRP >150 mg/L 71 (68) 34 (32)  
Post-op Day 3     0.001 
 Alb ≥25 g/L 40 (89) 5 (11)  
 Alb <25 g/L 5 (45) 6 (6 (55)  
D3 poGPS    <0.001 
 0 107 (90) 12 (10)  
 1 56 (78) 16 (22)  
 2 12 (40) 18 (60)  
Post-op Day 4     <0.001 
 CRP ≤150 mg/L  136 (84) 26 (16)  
 CRP >150 mg/L 17 (55) 14 (45)  
Post-op Day 4     <0.001 
 Alb ≥ 25 g/L  123 (88) 17 (12)  
 Alb < 25 g/L 24 (52) 22 (48)  
D4 poGPS    <0.001 
 0 136 (84) 26 (16)  
 1 12 (63) 7 (37)  
 2 3 (30) 7 (70)  
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mGPS, modified Glasgow Prognostic Score; TNM, Tumour, Node, Metastasis; CRP, C-
reactive protein 
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Table 7.5 Clinical characteristics and post-operative complications of patients 
undergoing resection of colorectal cancer in the validation cohort 
Characteristic  No 
Complication 
(n = 254) 
Infective 
Complications 
(n = 106) 
 
  n (%) n (%) p-
value 
Age    0.853 
 <65 yrs 88 (69) 39 (31)  
 65-74 yrs 99 (72) 38 (28)  
 >74 yrs 67 (70) 29 (30)  
Sex    0.003 
 Female 132 (78) 37 (22)  
 Male 122 (64) 69 (36)  
Emergency 
Presentation 
   0.135 
 No 239 (72) 95 (28)  
 Yes 15 (58) 11 (42)  
Tumour Site    0.055 
 Colon 173 (74) 61 (26)  
 Rectum 81 (64) 45 (36)  
TNM Stage    0.221 
 0 8 (80) 2 (20)  
 I 54 (76) 17 (24)  
 II 112 (73) 42 (27)  
 III 80 (64) 45 (36)  
Pre-op CRP    0.688 
 ≤10 mg/L 185 (71) 75 (29)  
 >10 mg/L 69 (69) 31 (31)  
Pre-op 
Albumin 
   0.594 
 ≥35 g/L 168 (71) 67 (29)  
 <35 g/L 86 (69) 39 (31)  
Pre-op mGPS    0.902 
 0 185 (71) 75 (29)  
 1 26 (70) 11 (30)  
 2 43 (68) 20 (32)  
Post-op Day 3     <0.001 
 CRP ≤150 mg/L  131 (83) 26 (17)  
 CRP >150 mg/L 108 (59) 75 (41)  
Post-op Day 3     0.003 
 Alb ≥25 g/L 142 (77) 42 (23)  
 Alb <25 g/L 97 (62) 59 (38)  
D3 poGPS    <0.001 
 0 131 (83) 26 (17)  
 1 54 (67) 26 (33)  
 2 53 (52) 49 (48)  
Post-op Day 4     <0.001 
 CRP ≤150 mg/L  142 (79) 38 (21)  
 CRP >150 mg/L 63 (50) 64 (50)  
Post-op Day 4     <0.001 
 Alb ≥ 25 g/L  130 (78) 37 (22)  
 Alb < 25 g/L 75 (54) 64 (46)  
169 
 
 
 
 
mGPS, modified Glasgow Prognostic Score; TNM, Tumour, Node, Metastasis; CRP, C-
reactive protein 
 
D4 poGPS    <0.001 
 0 142 (79) 38 (21)  
 1 36 (65) 19 (35)  
 2 26 (37) 44 (63)  
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Table 7.6 The day 3 and day 4 poGPS and the development of post-operative complications in patients undergoing resection for colorectal cancer in 
both test and validation cohorts 
Post-operative 
Day 
CRP 
(mg/L) 
Albumin (g/L) poGPS No. of 
patients 
No Complications/Infective 
Complications 
(n) 
Infective Complication 
Rate  
(%) 
Clavien-
Dindo Grade 
(0/1-2/3-5)
#
 
Test Cohort 
(n=402) 
       
3        
 ≤150 <25 OR ≥25 0 194 165/20 10.3 - 
 >150 ≥25 1 116 74/36 31.0 - 
 >150 <25 2 53 22/30 56.6 - 
4        
 ≤150 <25 OR ≥25 0 259 202/44 17.0 - 
 >150 ≥25 1 36 15/18 50 - 
 >150 <25 2 23 5/17 73.9 - 
Validation 
Cohort (n=411) 
       
3        
 ≤150 <25 OR ≥25 0 180 131/26 14.4 72/22/6 
 >150 ≥25 1 90 54/26 28.9 61/30/9 
 >150 <25 2 117 53/49 41.9 45/41/14 
4        
 ≤150 <25 OR ≥25 0 212 142/38 17.9 67/25/8 
 >150 ≥25 1 59 36/19 32.2 61/34/5 
 >150 <25 2 82 26/44 53.7 32/47/21 
CRP, C-reactive protein; poGPS, post-op Glasgow Prognostic Score 
#
 only available in validation cohort 
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Table 7.7 The relationship between clinicopathological factors and the pre- and post-operative systemic inflammatory response in patients 
undergoing resection for colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mGPS, modified Glasgow Prognostic Score; poGPS, post-operative Glasgow Prognostic Score; TNM, Tumour, Node, Metastasis;  
CRP, C-reactive protein  
Clinicopathological Characteristic Cancer-specific Survival Overall Survival 
Univariate Analysis 
(95% CI) 
p-value Univariate Analysis  
(95% CI) 
p-value 
     
Age (<65/65-74/>74) 1.20 (1.00-1.44) 0.056 1.57 (1.36-1.81) <0.001 
Sex (Female/Male) 1.32 (0.98-1.79) 0.071 1.21 (0.96-1.51) 0.100 
Site (Colon/Rectum) 1.06 (0.78-1.44) 0.712 0.89 (0.70-1.13) 0.332 
Emergency (No/ Yes) 1.75 (1.16-2.63) 0.008 1.33 (0.95-1.86) 0.094 
TNM Stage (0/I/II/III) 2.26 (1.77-2.89) <0.001 1.53 (1.30-1.80) <0.001 
Venous Invasion (No/Yes) 1.75 (1.29-2.39) <0.001 1.44 (1.15-1.80) 0.002 
Margin involvement (No/Yes) 4.85 (3.34-7.03) <0.001 3.13 (2.25-4.35) <0.001 
Peritoneal involvement (No/Yes) 2.22 (1.63-3.01) <0.001 1.68 (1.32-2.14) <0.001 
Tumour perforation (No/Yes) 2.21 (1.09-4.50) 0.028 1.51 (0.80-2.83) 0.201 
Adjuvant therapy (No/Yes) 1.07 (0.76-1.50) 0.695 0.75 (0.57-0.99) 0.045 
     
Pre-operative Systemic Inflammation     
mGPS (0/1/2) 1.36 (1.13-1.65) 0.001 1.36 (1.18-1.57) <0.001 
     
Post-operative Systemic Inflammation     
Day 3 CRP > 150 mg/L (No/Yes) 1.31 (0.96-1.79) 0.088 1.41 (1.12-1.78) 0.004 
Day 3 Albumin <25 g/L (No/Yes) 1.38 (1.00-1.90) 0.047 1.42 (1.11-1.81) 0.005 
Day 3 poGPS (0/1/2) 1.20 (0.99-1.46) 0.059 1.27 (1.10-1.47) 0.001 
     
Day 4 CRP > 150 mg/L (No/Yes) 1.31 (0.93-1.84) 0.129 1.33 (1.02-1.74) 0.035 
Day 4 Albumin <25 g/L (No/Yes) 1.36 (0.98-1.90) 0.068 1.48 (1.15-1.91) 0.002 
Day 4 poGPS (0/1/2) 1.22 (0.99-1.50) 0.065 1.21 (1.03-1.42) 0.024 
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Table 7.8 The relationship between clinicopathological factors and pre- and post-operative systemic inflammatory response in patients undergoing 
resection for colon cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mGPS, modified Glasgow Prognostic Score; poGPS, post-operative Glasgow Prognostic Score; TNM, Tumour, Node, Metastasis;  
CRP, C-reactive protein 
Clinicopathological Characteristic Cancer-specific Survival Overall Survival 
Univariate Analysis 
(95% CI) 
p-value Univariate Analysis (95% 
CI) 
p-value 
     
Age (<65/65-74/>74) 1.23 (0.97-1.56) 0.086 1.60 (1.34-1.91) <0.001 
Sex (Female/Male) 1.07 (0.74-1.55) 0.726 1.01 (0.77-1.32) 0.958 
Emergency (No/ Yes) 2.13 (1.38-3.28) 0.001 1.47 (1.04-2.08) 0.031 
TNM Stage (0/I/II/III) 2.78 (1.99-3.90) <0.001 1.53 (1.24-1.90) <0.001 
Venous Invasion (No/Yes) 2.03 (1.36-3.02) <0.001 1.40 (1.06-1.84) 0.018 
Margin involvement (No/Yes) 4.51 (2.61-7.80) <0.001 3.15 (1.96-5.06) <0.001 
Peritoneal involvement (No/Yes) 2.86 (1.97-4.15) <0.001 1.79 (1.35-2.36) <0.001 
Tumour perforation (No/Yes) 2.86 (1.97-4.15) <0.001 1.63 (0.83-3.18) 0.154 
Adjuvant therapy (No/Yes) 1.09 (0.72-1.65) 0.679 0.64 (0.45-0.90) 0.011 
     
Pre-operative Systemic Inflammation     
mGPS (0/1/2) 1.61 (1.29-2.02) <0.001 1.54 (1.30-1.82) <0.001 
     
Post-operative Systemic Inflammation     
Day 3 CRP > 150 mg/L (No/Yes) 1.43 (0.96-2.12) 0.082 1.50 (1.12-2.01) 0.006 
Day 3 Albumin <25 g/L (No/Yes) 2.22 (1.47-3.34) <0.001 2.00 (1.47-2.72) <0.001 
Day 3 poGPS (0/1/2) 1.36 (1.06-1.75) 0.015 1.42 (1.18-1.72) <0.001 
     
Day 4 CRP > 150 mg/L (No/Yes) 1.38 (0.89-2.14) 0.149 1.55 (1.12-2.14) 0.009 
Day 4 Albumin <25 g/L (No/Yes) 1.86 (1.22-2.83) 0.004 1.87 (1.37-2.56) <0.001 
Day 4 poGPS (0/1/2) 1.35 (1.03-1.77) 0.030 1.40 (1.14-1.71) 0.002 
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8 Enhanced Recovery after Surgery (ERAS); 
which components, if any, impact on the 
systemic inflammatory response following 
colorectal surgery? – A systematic review 
 
8.1 Introduction 
Surgery for colorectal disease is associated with variable short term outcomes. Recent 
advances in peri-operative care methods have attempted to improve these outcomes. The 
development and widespread application of enhanced recovery or fast track surgical 
protocols (ERAS), in combination with laparoscopic surgery, represents a paradigm shift 
in peri-operative care (Lassen et al., 2009).  ERAS involves multimodal, protocol driven 
perioperative care which proponents have asserted reduce the SIR to surgery (Wilmore and 
Kehlet, 2001).  
The trauma of surgery leads to well understood metabolic, neuroendocrine and immune 
responses, the aims of which are to promote physiological stability and wound healing 
(Cuthbertson, 1979).  The cellular response to surgical injury is to activate neutrophils and 
macrophages of the innate immune system by the production of pro-inflammatory 
cytokines such as tumour necrosis factor (TNF) alpha, and the interleukins (IL) e.g. IL-1 
and IL-6 (Baigrie et al., 1992, Marik and Flemmer, 2012).  Pro-inflammatory cytokines 
alter the levels of circulating acute phase proteins, e.g. C-reactive protein (CRP), albumin, 
ferritin, transferrin and fibrinogen, through their action on hepatocytes (Gabay and 
Kushner, 1999).  Indeed, it has been reported that concentrations of circulating acute phase 
proteins and cytokines are associated with the magnitude of the stress response i.e. the 
systemic inflammatory response to surgery (Chapter 5).  Furthermore, CRP and IL-6 have 
been reported to have the strongest association with the magnitude of the surgical injury, 
although CRP is perhaps the most clinically useful of these (Chapter 5) . Moreover, this 
knowledge forms the basis of an objective examination of the evidence for the impact of 
ERAS protocols and their components.    
Although it is recognised that laparoscopic surgery generates a reduced post-operative 
systemic inflammatory response following colorectal surgery, the impact of individual 
components of ERAS protocols, in terms of the systemic inflammatory response, have not 
been examined in a systematic manner. The aim of the present review was to examine the 
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evidence in relation to ERAS protocols and their components having an effect on objective 
markers of the post-operative systemic inflammatory response.  
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8.2 Methods 
Recent separate guidelines on ERAS recommendations following elective colonic and 
elective rectal/pelvic surgery have been published (Gustafsson et al., 2012a, Nygren et al., 
2012). The present systematic review focuses on the components reported in the ERAS 
Group consensus review in colorectal surgery (Lassen et al., 2009). These 
recommendations for patients undergoing colorectal surgery are summarised in Table 8.1. 
A systematic literature search of the US National Library of Medicine (MEDLINE), the 
Excerpta Medica Database (EMBASE), PubMed and the Cochrane Database of Systemic 
Reviews (CDSR) was made using the following search criteria: ‘ERAS component’ AND 
(systemic inflammation OR systemic inflammatory response OR stress response OR C-
reactive protein OR CRP OR IL-6) AND surgery. This was performed independently by 
the 2 lead authors and any conflicts that were encountered were discussed with the senior 
authors. From this search, abstracts of articles were analysed for relevance and the 
bibliographies of relevant studies as well as the bibliography of the consensus review of 
perioperative care following colorectal surgery (Lassen et al., 2009) were hand-searched 
for any additional studies. Included studies had to assess the impact of the selected ERAS 
component on the systemic inflammatory response using either CRP or interleukin-6 (IL-
6).  Both prospective clinical trials and observational trials were included.   
The selection process is summarised in Figure 8.1.  Using the aforementioned search 
strategy relevant abstracts were obtained for each ERAS component.  Articles were 
excluded if they were animal studies, not in the English language, were review articles, 
were not related to colorectal surgery or did not use either CRP or IL-6 as the marker of the 
systemic inflammatory response. Table 8.2 summarises the included studies for each 
ERAS component and the marker of the systemic inflammatory response analysed.  
Evidence relating to other outcomes of ERAS programmes such as length of stay or post-
operative complications were obtained from the most recent Cochrane Reviews or meta-
analyses on the specific topic.  Meta-analysis of included studies was not performed due to 
significant heterogeneity amongst study methodology, populations and outcomes 
measured. 
Subjective assessment of study validity was carried out by two authors independently (DW 
and SM) using the Cochrane Collaboration tool provided by Review Manager version 5.3 
(RevMan 5.3, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 
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Denmark).  Any uncertainties were resolved by consensus following discussion with the 
senior authors (PG and DM). Both prospective clinical trials and observational trials were 
included. 
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8.3 Results 
8.3.1 Assessment of included study validity 
The validity of included studies is summarised in Figure 8.2.  The present systematic 
review included 15 randomised controlled trials (RCT), 1 controlled clinical trial (CCT), 
and 3 observational studies.  The included studies were of varying methodological quality.  
In particular those RCTs investigation the impact of laparoscopic vs. open surgery on 
postoperative IL-6 or CRP had issues relating to blinding to both patients and clinicians.  
All included studies examined the impact of ERAS components on patients undergoing 
elective colorectal surgery. No studies including emergency surgery or presentation. 
 
8.3.2 Enhanced Recovery after Surgery (ERAS) protocols  
Amongst the published literature surrounding ERAS there is considerable variation in the 
number and nature of the ERAS components applied and also in the outcomes measured 
(Ahmed et al., 2012, Neville et al., 2014, Nicholson et al., 2014).  Indeed, a recent meta-
analysis reported that using fewer ERAS components was associated with a greater 
reduction in mortality and complications compared to those with a greater number of 
components (Nicholson et al., 2014). Some evidence suggests that only the provision of 
laparoscopic surgery, early enteral nutrition and early mobilisation shorten length of stay 
following colorectal surgery within the ERAS framework (Vlug et al., 2012).  Two studies 
including 249 patients examined the impact of ERAS protocols when compared to standard 
perioperative care and laparoscopic surgery when compared to open procedures, on 
postoperative CRP and IL-6 (Veenhof et al., 2012, Wang et al., 2012).  Wang and 
colleagues reported that, in 170 patients, CRP and IL-6 on post-operative days 1 and 3 
were lower in those cared for using an ERAS protocol, independent of the mode of 
surgery.  Veenhof and coworkers, in their study of 79 patients, reported that no observed 
difference in postoperative CRP or IL-6 could be attributed solely to the use of an ERAS 
protocol.  No studies examined the impact of ERAS protocols as a whole versus standard 
perioperative care on the post-operative systemic inflammatory response in colorectal 
surgery without the inclusion of a laparoscopic surgery vs. open surgery arm, making the 
interpretation of the impact of ERAS protocols alone difficult.         
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Laparoscopic Surgery 
Laparoscopic colorectal surgery has been reported to shorten length of stay and reduce 
postoperative pain when compared to open surgery (Schwenk et al., 2005).  Furthermore, it 
has been reported to produce equivalent oncological outcomes when compared to open 
surgery (Kuhry et al., 2008, Vennix et al., 2014).  Ten studies including a total of 1,040 
patients have demonstrated lower post-operative CRP following laparoscopic colorectal 
surgery when compared to open procedures (Schwenk et al., 2000, Delgado et al., 2001, 
Braga et al., 2002, Dunker et al., 2003, Ng et al., 2009, Gustafsson et al., 2012b, 
Tsimogiannis et al., 2012, Veenhof et al., 2012, Wang et al., 2012, Ramanathan et al., 
2015).  Furthermore, a recent review has also reported similar findings in both benign and 
malignant colorectal disease (Chapter 5). Four studies, including 206 patients, reported no 
difference in postoperative serum CRP when those undergoing laparoscopic colorectal 
surgery were compare to those undergoing open procedures (Han et al., 2010, Tsamis et 
al., 2012, Wu et al., 2003, Veenhof et al., 2011).  Therefore, laparoscopic surgery appears 
to be associated with a reduction in the post-operative systemic inflammatory response, as 
evidenced by circulating concentrations of CRP, following colorectal surgery and is likely 
to reduce the SIR as part of an ERAS protocol.  
Post-operative Analgesia 
Systemic opioids provide effective analgesia but are associated with side effects, including 
nausea, vomiting, gut dysfunction, respiratory depression and drowsiness, which are likely 
to prolong hospital stay (Kehlet, 2005, Marret et al., 2007). Methods of analgesia which 
minimise the amount of opioids used are therefore key components of ERAS programmes. 
Epidural analgesia is an effective method of analgesia that can be used with local 
anaesthetic and low dose opioids. However, they are associated with a failure rate of 
approximately 30%, epidural haematoma and hypotension (Hermanides et al., 2012). In a 
recent meta-analysis comparing epidural analgesia (EA) versus opioid analgesia in patients 
undergoing colorectal surgery, the use of EA decreased the duration of postoperative ileus, 
allowed more intensive post-operative physiotherapy and mobilisation and resulted in a 
reduction in pain scores without a significant reduction in length of stay (Marret et al., 
2007). EA have been reported to result in a decrease in CRP levels following colorectal 
surgery (Chen et al., 2015). 
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Local anaesthesia techniques such as the Transversus Abdominis Plane block (TAP) have 
been reported to be successful in multiple surgical specialties and operations (Johns et al., 
2012). Subsequent meta-analysis of the use of TAP blocks showed a reduction in morphine 
use 24 hours postoperatively and reduced postoperative nausea and vomiting (Johns et al., 
2012). A continuous infusion of local anaesthetic (LA) delivered directly into the surgical 
wound via a catheter allows longer benefit from the local anaesthetic, is easy to insert and 
associated with few complications and a low failure rate (Thornton and Buggy, 2011). 
When compared to EA, wound catheters were reported to be of equal efficacy in terms of 
pain scores at 48 hours postoperatively with a lower rate of urinary retention (Ventham et 
al., 2013).  However, there would appear to be no literature examining the impact of this 
strategy on the systemic inflammatory response following colorectal surgery.  
Non-steroidal anti-inflammatory drugs (NSAIDs) can be used to good effect in the post-
operative period. Some studies have suggested that combining NSAIDs and opioid 
medications results in decreased opioid consumption over a 24 hour period (Maund et al., 
2011). If an EA has been used, the combination of paracetamol and an NSAID provides 
good analgesia during the period around EA removal. However, there would appear to be 
no literature examining the impact of this strategy on the systemic inflammatory response 
following colorectal surgery. In summary, there is some evidence that epidural anaesthesia 
but not local anaesthesia or NSAIDs can reduce the SIR as part of an ERAS protocol.  
Pre-operative Fasting & Carbohydrate Loading 
Surgery performed in a fasted state is thought to worsen the catabolic state and delay 
patient recovery.  A recent Cochrane review reported that pre-operative carbohydrate 
loading was only associated with a small reduction in length of stay and had no effect on 
complication rates (Smith et al., 2014).  One study reported no effect on systemic 
inflammation, as evidenced by CRP and IL-6, in patients undergoing major abdominal 
surgery (Mathur et al., 2010). Therefore, there is no evidence that carbohydrate loading can 
reduce the SIR as part of an ERAS protocol.  
Mechanical Bowel Preparation 
A recent Cochrane review has reported that there is no statistically significant evidence 
that the use of mechanical bowel preparation (MBP) alone prevents post-operative 
complications such as anastomotic leak in patients undergoing colorectal surgery (Guenaga 
et al., 2011).   
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The benefits of MBP in rectal surgery remains unclear with some studies reporting no 
difference in anastomotic leak rates (Van't Sant et al., 2010) and others finding that MBP 
reduced infective complication rates (Bretagnol et al., 2010). However, recent work from 
the United States has reported that MBP in combination with oral antibiotics was 
associated with significantly reduced surgical site infections, anastomotic leak, hospital 
readmission and ileus (Kiran et al., 2015, Scarborough et al., 2015, Klinger et al., 2017). 
Despite these reported benefits, no studies analysed whether MBP had an impact on the 
systemic inflammatory response. Therefore, there is no evidence that MBP can reduce the 
SIR as part of an ERAS protocol.  
Goal directed fluid therapy 
Goal directed therapy is the use of intravenous fluids and vasoactive drugs to meet defined 
targets for blood flow to achieve optimal oxygen delivery (Abbas and Hill, 2008).  A 
recent Cochrane Review of goal directed therapy, including 5,291 patients from 31 studies 
across several surgical specialities, demonstrated a modest reduction in postoperative 
complications and hospital stay when compared to conventional fluid regimens (Grocott et 
al., 2013).  Two studies have demonstrated a reduction in postoperative complications 
following the use of goal directed therapy in colorectal surgery (Wakeling et al., 2005, 
Noblett et al., 2006).  One study demonstrated a significant reduction in postoperative 
serum interleukin-6 when goal directed therapy was compared to conventional fluid 
management in colorectal surgery (Noblett et al., 2006), however this has not been 
reproduced in other studies (Wakeling et al., 2005).  No study has specifically examined 
the impact of goal directed therapy on CRP following colorectal surgery. Therefore, there 
is no evidence that goal directed fluid therapy can reduce the SIR as part of an ERAS 
protocol.  
Prevention of Post-operative Ileus 
Post-operative ileus is a common problem following colorectal surgery and often results in 
the patient feeling nauseous and bloated and can delay discharge from hospital (Fitzgerald 
and Ahmed, 2009). The exact cause of an ileus is unknown but it is thought to be multi-
factorial (Luckey et al., 2003). The use of thoracic epidural analgesia instead of opioids has 
been shown to improve gut motility and reduce the length of postoperative ileus (Jorgensen 
et al., 2000, Miedema and Johnson, 2003, Marret et al., 2007). Avoidance of gut oedema 
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due to fluid overloading during can improve gut function postoperatively can be improved 
(Lobo et al., 2002) as can the use of laparoscopic surgery (Tjandra and Chan, 2006).  
Other strategies that have been reported to reduce post-operative ileus include the use of 
chewing gum and the use of intravenous lignocaine intra-operatively. Some studies report 
that the use of chewing gum in the postoperative period reduced postoperative ileus and 
inpatient stay (Fitzgerald and Ahmed, 2009, Li et al., 2013) whilst others reported only a 
mild reduction in time to flatus with no difference in length of stay or complication rate 
(Su'a et al., 2015). In one study analysing the effect of intravenous lignocaine given intra-
operatively, they reported a reduction in post-operative analgesic requirements as well as 
improved time to flatus and reduced post-operative nausea and vomiting (Sridhar et al., 
2014). As previously stated, there is little reported evidence on the effects of different 
analgesic methods on the systemic inflammatory response following colorectal surgery. 
One study reported that those receiving intravenous lignocaine had lower post-operative 
levels of both CRP and IL-6 following major abdominal surgery (Sridhar et al., 2014). 
Therefore, there is some evidence that strategies to reduce post-operative ileus such as 
intravenous lidocaine and epidural anaesthesia but not chewing gum can reduce the SIR as 
part of an ERAS protocol.  
Early post-operative enteral nutrition 
A Cochrane Review of 14 trials including 1,224 patients undergoing colorectal surgery 
(Andersen et al., 2006) reported a non-significant trend toward fewer complications, in 
particular infections, in patients allowed enteral nutrition within 24 hours of surgery. 
However, there would appear to be no literature examining the impact of this strategy on 
the systemic inflammatory response following colorectal surgery. Therefore, there is no 
evidence that early post-operative enteral nutrition can reduce the SIR as part of an ERAS 
protocol.  
Avoidance of nasogastric tubes 
A Cochrane Review of nasogastric tube decompression, including 5,240 patients from 33 
studies undergoing abdominal surgery, reported earlier return of bowel function and fewer 
pulmonary complications in those without routine nasogastric tube (Nelson et al., 2007).  
There was no significant increase in other complications.  A recent meta-analysis, 
including 1,416 patients from 7 trials, in patients undergoing elective colorectal surgery 
reported similar results (Rao et al., 2011).  However, there would appear to be no literature 
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examining the impact of this strategy on the systemic inflammatory response following 
colorectal surgery. Therefore, there is no evidence that avoidance of nasogastric tubes can 
reduce the SIR as part of an ERAS protocol.  
Avoidance of Peritoneal Drains 
There is no evidence to support the routine use of peritoneal drains following colorectal 
surgery to either reduce the incidence or severity of anastomotic leaks nor to reduce the 
development of intra-abdominal collections  (Jesus et al., 2004, Karliczek et al., 2006, 
Nygren et al., 2012, Puleo et al., 2013). Moreover, there would appear to be no literature 
examining the impact of this strategy on the systemic inflammatory response following 
colorectal surgery. Therefore, there is no evidence that avoidance of peritoneal drains can 
reduce the SIR as part of an ERAS protocol.  
Early removal of urinary catheter 
A meta-analysis of patients undergoing abdominal surgery reported reduced rates of 
bacteriuria and discomfort when suprapubic catheters were compared to transurethral 
catheters (Mcphail et al., 2006).  A systematic review of urinary catheter management 
following colorectal surgery suggests removal of urinary catheters on the first 
postoperative day in colonic resections and from postoperative day 3 to 6 in rectal 
surgeries (Hendren, 2013).  This is associated with a lower incidence of urosepsis and a 
non-significant increase in urinary retention and re-catheterisation, however this is based 
on a single small RCT and several observational studies (Benoist et al., 1999, Basse et al., 
2000, Kahokehr et al., 2010, Zmora et al., 2010).  However, there would appear to be no 
literature examining the impact of this strategy on the systemic inflammatory response 
following colorectal surgery. Therefore, there is no evidence that early removal of urinary 
catheter can reduce the SIR as part of an ERAS protocol.  
Surgical Incisions 
A Cochrane Review, including 3,464 patients from 19 trials comparing transverse and 
vertical midline abdominal incisions across several surgical specialities, reported reduced 
rates of incisional hernia, analgesia requirement and improved pulmonary function when 
transverse incisions were employed (Brown and Goodfellow, 2005).   Similar results were 
reported in a more recent meta-analysis of 24 trials which also included para-median 
incisions, however, neither study reported a significant reduction in pulmonary 
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complications or recovery time (Bickenbach et al., 2013).  Two small randomised 
controlled trials included in the above review articles focused on colorectal surgery, 
describe conflicting results with regards to the impact of transverse or midline incisions on 
postoperative pulmonary function and pain (Lindgren et al., 2001, Brown et al., 2004).  
However, there would appear to be no literature examining the impact of this strategy on 
the systemic inflammatory response following colorectal surgery. Therefore, there is no 
evidence that different surgical incisions can reduce the SIR as part of an ERAS protocol.  
Early mobilisation 
Within an enhanced recovery programme following colorectal surgery, mobilisation on 
postoperative days 1 to 3 was associated with a reduced length of hospital stay (Maessen et 
al., 2007, Vlug et al., 2012).  There is no specific evidence for early mobilisation following 
colorectal surgery out with the context of enhanced recovery programmes.  However, there 
would appear to be no literature examining the impact of this strategy on the systemic 
inflammatory response following colorectal surgery. Therefore, there is no evidence that 
early mobilisation can reduce the SIR as part of an ERAS protocol.  
Thromboprophylaxis 
Patient with cancer have a 4-6 fold higher risk than the general population of developing 
venous thromboembolism (Imberti et al., 2008).  Pharmacological methods (low-molecular 
weight heparin (LMWH) or unfractionated heparin) and mechanical methods (intermittent 
pneumatic compression; graduated compression stockings) are used either solely (Levine 
et al., 2001, Borly et al., 2005) or in combination with each other (Wille-Jorgensen, 1991).  
No studies have analysed thromboprophylaxis in an ERAS setting, although conclusions 
regarding the benefits can be drawn from non-ERAS patient groups. Furthermore, no 
studies reported whether the use of thromboprophylaxis had any impact on the systemic 
inflammatory response. Therefore, whilst the use of LMWH is effective in reducing VTE 
rates, there would appear to be no literature examining the impact of this strategy on the 
systemic inflammatory response following colorectal surgery. Therefore, there is no 
evidence that thromboprophylaxis can reduce the SIR as part of an ERAS protocol.  
Antibiotic Prophylaxis 
A recent Cochrane Review (Nelson et al., 2014) of antimicrobial prophylaxis in colorectal 
surgery, including 43,451 patients from 260 trials, has demonstrated a significant reduction 
in postoperative wound infections when prophylactic antibiotics are compared to placebo 
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(RR 0.34, 95% CI 0.28-0.41).  Furthermore, additional benefit in terms of wound infection 
reduction was reported when combination oral and intravenous antibiotics were used and 
when antibiotics with anaerobic cover were used (Nelson et al., 2014).  Although it is 
understood that an exaggerated postoperative systemic inflammatory response, determined 
by measuring serum CRP, is associated with the development of infective complications 
(Platt et al., 2012, Singh et al., 2014), there would appear to be no literature examining the 
impact of this strategy on the systemic inflammatory response following colorectal 
surgery. Therefore, there is no evidence that antibiotic prophylaxis can reduce the SIR as 
part of an ERAS protocol.  
Maintenance of intraoperative normothermia 
The development of hypothermia in the perioperative period is multifactorial, and can be 
attributed to general anaesthesia, surgical technique and the theatre environment (Sessler, 
2000).  In the context of colorectal surgery, warming with forced air blankets and 
intravenous fluids to maintain normothermia has been shown to reduce wound infection 
rates (Kurz et al., 1996), blood transfusion requirements and complication rates (Wong et 
al., 2007).  However, there would appear to be no literature examining the impact of this 
strategy on the systemic inflammatory response following colorectal surgery. Therefore, 
there is no evidence that maintenance of intra-operative normothermia can reduce the SIR 
as part of an ERAS protocol.  
Pre-operative Counselling 
Preoperative patient counselling has been reported to reduce a patient’s anxiety (Kiyohara 
et al., 2004)  and allow quicker recovery and discharge (Halaszynski et al., 2004, Lassen et 
al., 2009) following surgery. If patients are aware of what is likely to happen during their 
hospital stay and are given targets postoperatively then their recovery and hospital 
discharge are perceived to be quicker (Fearon et al., 2005). However, there would appear 
to be no literature examining the impact of this strategy on the systemic inflammatory 
response following colorectal surgery. Therefore, there is no evidence that pre-operative 
counselling can reduce the SIR as part of an ERAS protocol.  
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8.4 Discussion 
The results of the present review shows that although there is evidence of the benefits of 
ERAS protocols in terms of reducing length of hospital stay and the reduction of post-
operative complications following colorectal surgery, evidence of an effect on the SIR is 
surprisingly limited. Moreover, with the exception of laparoscopic surgery, evidence of an 
effect of individual components of ERAS protocols on the SIR is also limited. Without 
such information, establishment of an optimal ERAS protocol will be based on subjective 
evidence rather than evidence of a beneficial effect on the SIR.  
In the present review only laparoscopic surgery was shown to have substantial evidence 
demonstrating its beneficial effect on the reduction of markers of the post-operative 
systemic inflammatory response. It is of interest therefore that it has recently been reported 
that of the recommended ERAS components, only laparoscopic surgery, early oral intake, 
and early mobilisation were identified as independent determinants of early recovery (Vlug 
et al., 2012). It could be considered from a clinical point of view that ERAS protocols were 
developed to reduce pain and hospital stay and to reduce the time to return to work. 
Implicit in this is the assumption that the SIR would also be reduced. From our review it is 
clear, with respect to laparoscopic surgery, there is evidence that these aims have been 
achieved. However, it would appear that there is no evidence that other components of 
ERAS protocols fulfil the above criteria. Future studies could utilise an objective marker of 
the post-operative systemic inflammatory response, such as CRP, which has been reported 
to be reflective of the magnitude of surgical trauma (Chapter 5), to assess which individual 
components of ERAS programmes modulated the systemic inflammatory response. These 
elements could then form future ERAS protocols which would have the proven ability to 
reduce the SIR. On the basis of the present review, these new protocols would likely be 
more streamlined and would perhaps allow easier implementation of the ERAS approach 
in clinical practice. 
Initial studies into enhanced recovery were mainly performed in patients undergoing 
colorectal surgery but ERAS is now used in many different surgical specialties and 
procedures. Indeed there are now consensus guidelines from the ERAS society for patients 
undergoing upper gastrointestinal surgery (Mortensen et al., 2014), urological surgery 
(Cerantola et al., 2013), colorectal surgery (Lassen et al., 2009, Nygren et al., 2012, 
Gustafsson et al., 2012a), hepato-biliary and pancreatic surgery (Lassen et al., 2012). This 
guidance has resulted in the widespread acceptance of the ERAS principles and adoption 
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of these programmes in surgical units across the UK and Europe. However, no standard 
protocol exists for such programmes and as such the number of components used varies 
between units, making comparison of different ERAS studies problematic (Neville et al., 
2014).  
Furthermore, it has previously been presumed that the greater the number of elements in an 
ERAS programme the better the outcomes. However, often studies make no distinction 
between the number of elements intended to be included versus the number that were 
actually successfully implemented (Vlug and Bemelman, 2015). Indeed, it has recently 
been reported that increasing compliance with ERAS protocols improves outcomes in 
patients undergoing elective colorectal cancer resection (ECG, 2015). It has also been 
reported that studies with fewer ERAS components were associated with greater reduction 
in mortality and complications (Nicholson et al., 2014). This finding raises the possibility 
that some of the components of ERAS programmes offer little additional benefit to the 
overall outcomes.  
The recently reported LAFA-study was designed to identify whether laparoscopic or open 
surgery, in combination with ERAS or standard care, was the optimal approach for 
colorectal surgery (Vlug et al., 2011). Interestingly, the authors reported that length of stay 
was shortest in the laparoscopic/ERAS group (5 days), followed by the 
laparoscopic/standard group (6 days) and then by both open groups (7 days). These 
findings would appear to imply that while ERAS and laparoscopic surgery work 
synergistically, perhaps the majority of the benefit seen in these programmes is due to the 
use of laparoscopic surgery (Vlug and Bemelman, 2015).  Additional evidence for this 
hypothesis, in the context of the post-operative systemic inflammatory response, is 
provided by the finding that the two groups undergoing laparoscopic surgery had a lower 
postoperative CRP than either open surgery group regardless of perioperative care methods 
(Veenhof et al., 2012).   
Despite laparoscopic surgery appearing to be the key component in ERAS protocols, the 
majority of patients undergoing resection for colorectal cancer are still likely to receive an 
open procedure. Recent data from the National Bowel Cancer Audit 2014 has reported 
that, of the 19 4533 patients who underwent resection of colorectal cancer, less than half 
(45%) had laparoscopic surgery (HQUIP, 2014). Therefore, rather than increased efforts to 
deliver ERAS protocols it may be more appropriate to increase the number of laparoscopic 
procedures carried out.      
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In the present study a potential confounding factor would be the duration of operation since 
this may vary with surgical approach. However, few of the included studies that examined 
the impact of laparoscopic vs. open colorectal surgery on the postoperative systemic 
inflammatory response reported operation duration.  In a recent audit of our centre there 
was no association between operation duration and the postoperative systemic 
inflammatory response following either laparoscopic or open surgery for colorectal cancer. 
In conclusion, the present systematic review shows that, with the exception of laparoscopic 
surgery, objective evidence of the effect of individual components of ERAS protocols in 
reducing the SIR following colorectal surgery is limited. This review, examining the 
literature pertaining to a known indicator of surgical trauma and predictor of post-operative 
complication severity, may be the first step in stimulating further research in this area.  
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Table 8.1 Components of Enhanced Recovery after Surgery – ERAS Group 
Recommendations 
ERAS Component Recommendation 
Pre-operative counselling Should receive oral and written 
information about admission, what to 
expect and their role in recovery 
 
Pre-operative fasting and carbohydrate 
loading 
Fasting - 2 hours for liquids and 6 hours 
for solids 
Patients should receive carbohydrate 
loading pre-operatively 
 
Mechanical bowel preparation Patients should not routinely receive 
mechanical bowel preparation 
 
Thromboprophylaxis Patients should wear compression 
stockings, have intermittent pneumatic 
compression and pharmacological 
prophylaxis with LMWH 
 
Antibiotic prophylaxis Single-dose antibiotic prophylaxis 30-60 
minutes prior to surgery 
 
Maintenance of intra-operative 
normothermia 
Intra-operative maintenance of 
normothermia with an upper body forced 
air warmer should be used routinely 
 
Goal directed fluid therapy Balanced crystalloids preferred.  
Goal-directed fluid therapy should be 
considered on an individual basis 
 
Surgical incisions Midline or transverse laparotomy incision 
of minimal length should be used 
 
Laparoscopic surgery Laparoscopic surgery recommended if 
the appropriate expertise is available 
 
Avoidance of nasogastric tubes Should not be used routinely post-
operatively 
 
Post-operative analgesia Thoracic epidural analgesia or spinal 
analgesia with local anaesthetic and 
opioids 
Paracetamol and NSAIDs used following 
epidural withdrawal 
 
Prevention of post-operative ileus Mid thoracic epidural analgesia 
Avoidance of fluid overload 
Laparoscopic surgery (if available) 
 
Avoidance of peritoneal drains Not indicated routinely for resections 
above peritoneal reflection 
Short term (<24 hrs) may be appropriate 
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after low rectal resections 
 
Early removal of urinary catheter For colonic surgery, both suprapubic and 
urethral techniques appropriate. 
Suprapubic catheter should be used for 
pelvic surgery 
 
Early post-operative enteral nutrition Patients should be encouraged to 
commence oral diet as early as possible 
after surgery 
Oral nutrition supplements should be 
given until normal diet has been resumed 
 
Early mobilisation Patients should be nursed in environment 
that encourages mobilisation 
LMWH, Low-molecular weight heparin; NSAID, non-steroidal anti-inflammatories 
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Studies identified 
by search strategy 
(n = 2,051) 
Excluded:  (n = 915) 
Animal study (n = 408) 
Non-English (n = 262) 
Review article (n = 245) 
Abstracts reviewed for 
relevance 
(n = 1,136) 
Excluded:   
Irrelevant  (n = 1,117) 
(Not colorectal surgery, or 
did not use CRP/IL-6) 
  
Studies included 
(n = 19) 
Preoperative counselling (n = 0) 
Carbohydrate loading (n = 1) 
Mechanical bowel prep (n = 0) 
Venous thromboprophylaxis (n = 0) 
Antibiotic prophylaxis (n = 0) 
Intraoperative normothermia (n = 0) 
Goal directed therapy (n = 2) 
Transverse vs midline incisions (n = 0) 
Laparoscopic surgery (n = 14) 
Nasogastric decompression (n = 0) 
Perioperative analgesia (n = 1) 
Prevention of ileus (n = 1) 
Avoidance of peritoneal drains (n = 0) 
Early removal of urinary catheter (n = 0) 
Early mobilisation (n = 0) 
Early enteral nutrition (n = 0) 
 
  
Figure 8.1 PRISMA flowchart demonstrating study selection 
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Table 8.2 Summary of included studies for each ERAS component and the marker of the systemic inflammatory response analysed 
ERAS Component Included 
studies 
Author(s) Year of 
publication 
Journal Country Study 
Type 
No. of 
patients 
Marker of 
SIR 
analysed 
Pre-operative 
counselling 
0 - - - -  - - 
Pre-operative fasting 
and carbohydrate 
loading 
1 Mathur, S et al. 2010 British Journal of 
Surgery 
New 
Zealand 
RCT 142 CRP 
Mechanical bowel 
preparation 
0 - - - -  - - 
Thromboprophylaxis 0 - - - -  - - 
Antibiotic prophylaxis 0 - - - -  - - 
Intra-operative 
normothermia 
0 - - - -  - - 
Goal directed fluid 
therapy 
2 Noblett, SE et al. 2006 British Journal of 
Surgery 
UK RCT 108 IL-6 
  Wakeling, HG et 
al. 
2005 British Journal of 
Anaesthesia 
UK RCT 128 IL-6 
Surgical incision 0 - - - -  - - 
Laparoscopic surgery 13 Schwenk, W et al. 2000 Langenbecks 
Archives of 
Surgery 
Germany RCT 60 CRP & IL-6 
  Delgado, S et al. 2001 Diseases of the 
Colon & Rectum 
Spain RCT 97 CRP & IL-6 
  Braga, M et al. 2002 Diseases of the 
Colon & Rectum 
Italy RCT 79 CRP 
  Dunker, MS et al. 2003 Diseases of the The RCT 34 CRP & IL-6 
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Colon & Rectum Netherlands 
  Wu, FP et al. 2003 Diseases of the 
Colon & Rectum 
The 
Netherlands 
RCT 26 IL-6 
  Ng, SS et al. 2009 Diseases of the 
Colon & Rectum 
Hong Kong RCT 153 CRP 
  Han, SA et al. 2010 International 
Journal of 
Colorectal 
Disease 
Korea CCT 74 CRP 
  Veenhof, AA et 
al. 
2011 International 
Journal of 
Colorectal 
Disease 
The 
Netherlands 
RCT 40 CRP & IL-6 
  Gustafsson, UO et 
al. 
2012 World Journal of 
Surgery 
Sweden Obs 114 CRP 
  Tsamis, D et al. 2012 Surgical 
Endoscopy 
Greece MCC 30 CRP & IL-6 
  Tsimogiannis, KE 
et al. 
2012 Surgical 
Endoscopy 
Greece RCT 40 CRP 
  Veenhof, AA et 
al. 
2012 Annals of Surgery The 
Netherlands 
RCT 79 CRP 
  Wang, G et al. 2012 Journal of 
Gastrointestinal 
Surgery 
China RCT 163 CRP & IL-6 
  Ramanathan, ML 
et al. 
2015 Annals of 
Surgical 
Oncology 
UK Obs 344 CRP 
Avoidance of 
nasogastric tubes 
0 - - - -  - - 
Post-operative analgesia 1 Chen, WK et al. 2015 International 
Journal of 
China RCT 53 CRP 
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Colorectal 
Disease 
Prevention of post-
operative ileus 
1 Sridhar, P et al. 2014 ANZ Journal of 
Surgery 
India RCT 134 CRP & IL-6 
Avoidance of peritoneal 
drains 
0 - - - -  - - 
Early removal of 
urinary catheter 
0 - - - -  - - 
Early post-operative 
enteral nutrition 
0 - - - -  - - 
Early mobilisation 0 - - - -  - - 
SIR, systemic inflammatory response; RCT, randomized controlled trial; CCT, controlled clinical trial; MCC, matched case control study; Obs, 
observational study 
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Figure 8.2 Cochrane risk of bias summary 
  Green = low risk of bias; red = high risk of bias; yellow = unclear risk of bias 
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9 Clinicopathological determinants of an elevated 
systemic inflammatory response following 
elective potentially curative resection for 
colorectal cancer 
9.1 Introduction 
Colorectal cancer is the second most common cause of cancer death in the United 
Kingdom, accounting for 16,000 deaths annually (CRUK, 2014a).  It has been recognised 
that the pre-operative systemic inflammatory response is related to long term outcome in 
patients following potentially curative surgery for colorectal cancer (Moyes et al., 2009, 
Roxburgh and McMillan, 2010, Mohri et al., 2014).   
Moreover, it has also been reported that the post-operative systemic inflammatory response 
can be a useful early predictor of the development of post-operative infective 
complications and anastomotic leak following colorectal cancer resection (Platt et al., 
2012, Ramanathan et al., 2013, Singh et al., 2014), regardless of surgical approach 
(Ramanathan et al., 2015). Indeed, C-reactive protein (CRP) concentrations >150mg/L on 
post-operative days 3-5 have been consistently reported to be associated with post-
operative complications (McDermott et al., 2015). With this in mind, a post-operative 
systemic inflammation score, based on the combination of CRP and albumin was 
developed and termed the post-operative Glasgow Prognostic Score (poGPS). This score 
has recently been reported to predict the development and severity of post-operative 
infective complications as well as long term survival (Chapter 6).  
With the expansion in the use of enhanced recovery after surgery (ERAS) programmes to 
improve short term outcomes following surgery and promote timely discharge, ERAS 
programmes have been proposed to reduce the surgical stress response. However, in a 
recent systematic review, it was concluded that of the components of an ERAS 
programme, only the use of laparoscopic surgery was consistently associated with a lower  
post-operative systemic inflammatory response (Chapter 8) . Therefore, clinicopathological 
factors that influence the post-operative systemic inflammatory response, as evidenced by 
the poGPS, are of considerable interest as they may be modifiable and could therefore 
potentially be considered as future therapeutic targets. The aim of the present study was to 
examine the clinicopathological determinants of the post-operative systemic inflammatory 
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response, as evidenced by the poGPS on postoperative days 3 and 4, in patients following 
resection of colorectal cancer. 
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9.2  Methods 
9.2.1 Patients 
Patients with a histologically proven diagnosis of colorectal cancer who, based on 
preoperative investigations and operative findings, were considered to have undergone 
potentially curative resection at a single centre during a period from 1999 to 2013 were 
initially included in the study (n=834). All procedures were performed at Glasgow Royal 
Infirmary, a University teaching hospital where procedures were performed by consultant 
surgeons with a subspecialist interest in colorectal surgery or by trainees who were 
supervised by these consultants.  Patient characteristics, including perioperative C-reactive 
protein concentrations, were recorded routinely in a prospective departmental audit 
database. All patient data were anonymised. 
All tumours were staged according to the conventional tumour, node, metastasis (TNM, 5
th
 
edition) classification. Patients with metastatic disease were excluded from analysis. Daily 
blood samples were obtained, as per hospital routine, during the perioperative period and 
were standard care for all patients.  Prior to surgery, all patients received 
thromboprophylaxis and antibiotic prophylaxis as per hospital policy at the time. Lesions 
from the caecum to the sigmoid colon were classified as colon cancers, lesions of the recto-
sigmoid junction and rectum were classified as rectal cancers.  
The pre-operative systemic inflammatory response was assessed using the modified 
Glasgow Prognostic Score (mGPS), an extensively validated and independently prognostic 
systemic inflammation based score. Briefly, mGPS patients with a normal C-reactive 
protein (<10mg/l) were allocated a score of ‘0’, those with an elevated C-reactive protein 
(>10mg/l) allocated a score ‘1’ and those with an elevated C-reactive protein (>10mg/l) 
and hypoalbuminaemia (<35g/l) were allocated a score of ‘2’. 
The poGPS was calculated as previously described (Chapter 7) and is as follows: a 
postoperative CRP concentration below 150 mg/L, regardless of albumin concentration, 
scored 0, a CRP concentration > 150 mg/L and albumin > 25 g/L scored 1, and CRP > 150 
mg/L and albumin < 25 g/L scored 2. 
Emergency presentation was determined if the patient presented via an unplanned hospital 
admission and underwent surgery during the same admission.  
198 
 
 
 
Patient co-morbidity was classified using the American Society of Anaesthesiologists 
(ASA) grading system, where ‘1’ represents a normal healthy patient, ‘2’ a patient with 
mild systemic disease, ‘3’ a patient with severe systemic disease and ‘4’ a patient with 
severe systemic disease that is a constant threat to life.  This assessment was carried out by 
an anaesthetist preoperatively.  Body Mass Index (BMI) was categorised as normal weight 
(<25), overweight (≥25-30), and obese (>30). BMI was obtained from the patients’ 
electronic pre-operative assessment record and ASA grade from the Opera Theatre 
Management system (OPERA v4.0, CHCA, Canada). The study was approved by the West 
of Scotland Research Ethics Committee, Glasgow. 
 
9.2.2 Statistical Analysis 
The relationship between clinicopathological variables and the day 3 and 4 poGPS were 
examined using the χ2 test for categorical variables. Binary logistic regression was used to 
examine the relationship between clinicopathological factors and the presence of a post-
operative systemic inflammatory response, indicated by a poGPS score of >1 on both days 
3 and 4 and calculate an OR and 95% CI.  Clinicopathological factors that on univariate 
analysis had a p value <0.10 were taken into a multivariate model using a backward 
conditional model to identify independently significant factors. A p value of <0.05 was 
considered significant.   Statistical analysis was performed using SPSS version 22.0 for 
Windows (IBM Corporation, Armonk, NY, USA). 
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9.3 Results 
Baseline characteristics of the 752 patients who underwent elective surgery for colorectal 
cancer are shown in Table 7.1.  The majority of patients were 65 or older (64%), male 
(54%), were overweight or obese (58%), had colonic tumours (62%), were not 
systemically inflamed (68% mGPS 0; 52% NLR ≤3) and had node negative disease (63%).  
Most patients underwent open resection (85%). Overall, 23% of patients developed an 
infective complication.   
The relationships between day 3 and day 4 poGPS and clinicopathological characteristics 
are shown in Table 7.2.  The day 3 poGPS was significantly associated with male sex 
(p<0.05), later year of operation (p<0.001), ASA grade (p<0.01), BMI (p<0.001), mGPS 
(p<0.001), pre-op NLR (<0.001), rectal cancer (p<0.01), laparoscopic surgery (p<0.01) and 
T stage (p<0.01). The day 4 poGPS was significantly associated with later year of 
operation (p<0.001), BMI (p<0.05), mGPS (p<0.01), NLR (p<0.005) and laparoscopic 
surgery (p<0.005). Moreover, when year of operation was further divided into 3 groups 
(1999-2003/ 2004-2008/ 2009-2013) the poGPS of both day 3 and day 4 remained 
significantly associated with year of operation (both p<0.001). The day 3 poGPS was 
significantly associated with an increase in infective complications from 12% to 31% to 
45% and the day 4 poGPS was significantly associated with an increase in infective 
complication rates from 16% to 39% to 58%. 
Binary logistic regression of the factors significantly associated with low poGPS (poGPS 
0) versus a high poGPS (poGPS 2) on day 3 and day 4 are shown in Tables 7.3 and 7.4 
respectively. A high day 3 poGPS was independently associated with year of operation 
(HR 4.63; CI 2.28-9.42; p<0.001), ASA (HR 2.02; CI 1.25-3.26; p=0.004), mGPS (HR 
1.97; CI 1.29-3.01; p=0.002), tumour site (HR 2.62; CI 1.32-5.17; p=0.006) and 
laparoscopic surgery (HR 0.20; CI 0.05-0.73; p = 0.015). When year of operation was 
removed from the binary logistic regression analysis only ASA grade (HR 1.96; CI 1.25-
3.09; p=0.003), BMI (HR 1.60; CI 1.07-2.38; p=0.001), mGPS (HR 2.03; CI 1.35-3.03; 
p=0.001) and tumour site (HR 2.99; CI 1.56-5.71; p<0.001) were independently associated 
with a high day 3 poGPS. 
A high day 4 poGPS was independently associated with year of operation (HR 5.32; CI 
2.49-11.34; p<0.001), ASA (HR 1.61; CI 1.02-2.55; p=0.043), mGPS (HR 1.98; CI 1.32-
2.96; p=0.001), NLR (HR 0.47; CI 0.24-0.93; p=0.031) and tumour site (HR 2.97; CI 1.49-
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5.91; p=0.002). When year of operation was removed from the binary logistic regression 
analysis only ASA grade (HR 1.65; CI 1.06-2.57; p=0.028), mGPS (HR 1.81; CI 1.22-
2.68; p=0.003), NLR (HR 0.50; CI 0.26-0.95; p=0.034) and tumour site (HR 2.90; CI 1.49-
5.65; p=0.002) were independently associated with a high day 4 poGPS.  
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9.4 Discussion 
The results of the present study showed that, in elective surgery, year of operation, ASA 
grade, the pre-operative modified Glasgow Prognostic Score (mGPS) and tumour site were 
independently associated with the post-operative systemic inflammatory response, as 
evidenced by the poGPS on both post-operative day 3 and 4. Therefore, in a large cohort, 
the present results establish the main clinicopathological factors determining an elevated 
systemic inflammatory response following elective potentially curative resection for 
colorectal cancer.   
In the present study it was of interest that the more recent time period (2007-2013) was 
significantly associated with a greater magnitude of the post-operative systemic 
inflammatory response, as evidenced by the poGPS.  This was unexpected since it might 
have been anticipated that with more recent surgical and anaesthetic techniques fewer 
patients would exceed poGPS thresholds.  On further analysis, patients in the more recent 
time period had higher BMI (p<0.001) and mGPS (p<0.001) values. Indeed, the median 
BMI in the cohort operated on in 1999-2006 was 25.4 and on those operated on in 2007-
2013 was 27.5. The median BMI of the general population has been increasing over the 
last two decades and this would also appear to be represented in patients attending for 
colorectal surgery. Various lifestyle factors may account for this such as poor diet, 
increased consumption of processed foods and lack of exercise. This increase in average 
BMI may also explain why those in the more recent cohort are more likely to be 
systemically inflamed. Regardless of the causative factors, these findings would suggest 
that elective surgery for colorectal cancer is increasingly being carried out in obese and 
systemically inflamed patients.  However, these factors were adjusted for in the present 
analysis and it may be that other factors, related or unrelated, account for the greater 
magnitude of the post-operative systemic inflammatory response in the more recent time 
period. 
The present results may have implications for future clinical care, particularly with respect 
to minimising the magnitude of the post-operative systemic inflammatory response.  For 
example, ASA and BMI are problematic therapeutic targets in that it would be difficult to 
treat these directly in the relatively short time between diagnosis and elective surgery. 
However, the post-operative systemic inflammatory response could be targeted.  For 
example, patients who have a high BMI or ASA may selectively receive laparoscopic 
surgery and peri-operative care that minimises the post-operative systemic inflammatory 
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response. Included in such care would be the use of anti-inflammatory agents such as 
corticosteroids (McSorley et al., 2016a, McSorley et al., 2017).  However, such targeted 
peri-operative care is in its infancy and the optimal timings, the agents and the doses to 
minimise the magnitude of the post-operative systemic inflammatory response that will 
result in improved post-operative outcomes remains to be determined (Roxburgh et al., 
2013).  
In the present study, an elevated BMI was associated with an increased poGPS. To our 
knowledge this relationship has not been previously reported.  However, a direct 
relationship between BMI and C-reactive protein concentrations has been widely reported 
(Choi et al., 2013) and both are established risk factors for the development of colorectal 
cancer.  The mechanism underlying the relationship between BMI and the magnitude of 
the post-operative systemic inflammatory response is not clear.  However, it may be that 
surgical injury to an increased amount of subcutaneous fat leads to a more profound 
systemic inflammatory response.  This relationship is worthy of further study.   
Multiple NLR Thresholds have been used to define high and low NLR states. The majority 
of these have been shown to be of prognostic benefit (Guthrie et al. 2013a). In chapter 3 of 
this thesis, an NLR threshold of greater than 5 was used to define a high NLR value. This 
was associated with poorer survival in patients with node negative colorectal cancer. In the 
present chapter a threshold of greater than 3 was used to define a high NLR value, in 
keeping with recent work in the literature (Enriquez et al. 2017, Feliciano et al. 2017) and 
this was also significantly associated with an elevated poGPS. Regardless of the threshold 
value used, an elevated NLR appears to be prognostic in determining poor short and long 
term outcomes in patients with colorectal cancer.  
The laparoscopic surgical approach, compared with the open approach, has been 
repeatedly shown to attenuate the systemic inflammatory response (Lane et al., 2013, 
Srinivasa et al., 2011, Wang et al., 2012). In the present study, laparoscopic surgery was 
independently associated with the post-operative SIR on day 3 but not day 4.  The basis of 
this differential response to laparoscopic surgery is not clear.  However, it may relate to the 
transient effect of this surgical approach or the interaction between laparoscopic surgery, 
ASA grade and BMI.  For example, patients who undergo a laparoscopic resection for 
colon cancer may have less comorbidity and be less obese. Indeed, it would therefore 
appear that the benefit of laparoscopic surgery is more pronounced in the immediate post-
operative period. The significance of this is not clear but perhaps highlights the important 
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role the systemic inflammatory response plays early in the post-operative period. Given the 
increasing use of the laparoscopic approach (approximately 45% of colorectal cancer 
resections, (HQUIP, 2014)) these relationships warrant further study.   
The present study has some potential limitations that should be considered. Many pre-
operative factors associated with a greater post-operative systemic inflammatory response 
such as obesity, diabetes and other comorbidities are inter-related and therefore potential 
confounding is an important issue in the analysis of the present study.  Nevertheless, an 
objective measurement of the post-operative systemic inflammatory response, such as the 
poGPS will, in future studies, facilitate the dissection of factors that have independent 
influence.  
In conclusion, the mGPS, ASA grade, BMI and tumour site were independently associated 
with a greater magnitude of the post-operative systemic inflammatory response in patients 
undergoing elective surgery for colorectal cancer.  
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Table 9.1 Clinicopathological characteristics of patients undergoing elective, 
potentially curative resection for colorectal cancer 
Characteristic No. of patients (%) 
Age (<65/ 65-74/ ≥75) 245 (33)/ 272 (33)/ 235 (31) 
Sex (female/ male) 344 (46)/ 408 (54) 
Year of Operation (1999-2006/2007-2013) 311 (41)/ 408 (54) 
ASA (1/ 2/ 3/ 4)
a
 58 (11)/ 214 (42)/ 219 (42)/ 24 (5) 
BMI (<25/ >25-30/ >30)
b
 186 (34)/ 223 (41)/ 131 (24) 
  
TNM Stage (0/ I/ II/ III) 12 (2)/ 141 (19)/ 321 (43)/ 278 (37) 
T Stage (I/II/III/IV) 62 (8)/ 106 (14)/ 411 (55)/ 161 (21) 
N Stage (0/I/II) 474 (63)/ 206 (27)/ 72 (10) 
Tumour site (colon/ rectum) 467 (62)/ 285 (38) 
Laparoscopic (No/ Yes) 640 (85)/ 112 (15) 
  
Pre-op mGPS 498 (68)/ 134 (18)/ 100 (14) 
Pre-op NLR (≤3/ >3) 391 (52)/ 358 (48) 
  
Day 3 poGPS (0/1/2) 361 (53)/ 186 (27)/ 135 (20) 
Day 4 poGPS (0/1/2) 439 (72)/ 87 (14)/ 86 (14) 
  
Infective Complications (No/ Yes) 580 (77)/ 169 (23) 
 
ASA, American Society of Anaesthesiology Grading System; BMI, Body Mass Index; 
mGPS, modified Glasgow Prognostic Score; TNM, Tumour Node Metastases; CRP, C-
reactive protein 
a
 n = 516 
b
 n = 540 
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Table 9.2 Relationship between clinicopathological characteristics and day 3 & 4 poGPS in patients undergoing elective, potentially curative surgery 
for colorectal cancer 
Characteristic  n Day 3 poGPS (0/1/2) p-value Day 4 poGPS (0/1/2) p-value 
Age    0.247  0.662 
 <65 245 117 (53)/ 62 (28)/ 41 (19)  135 (70)/ 28 (14)/ 31 (16)  
 65-74 272 120 (49)/ 76 (31)/ 47 (19)  155 (70)/ 35 (16)/ 30 (14)  
 ≥75 235 124 (57)/ 48 (22)/ 47 (21)  149 (75)/ 24 (12)/ 25 (13)  
Sex    0.012  0.109 
 Female 344 181 (57)/ 69 (22)/ 66 (21)  200 (75)/ 29 (11)/ 38 (14)  
 Male 408 180 (49)/ 117 (32)/ 69 (19)  239 (69)/ 58 (17)/ 48 (14)  
Year of 
Operation 
   <0.001  <0.001 
 1999-2006 311 160 (58)/ 87 (32)/ 28 (10)  196 (82)/ 28 (12)/ 14 (6)  
 2007-2013 441 201 (49)/ 99 (24)/ 107 (26)  243 (65)/ 59 (16)/ 72 (19)  
Year of 
Operation 
   <0.001  <0.001 
 1999-2003 172 89 (61)/ 49 (33)/ 9 (6)  102 (84)/ 15 (12)/ 5 (4)  
 2004-2008 228 113 (52)/ 60 (28)/ 43 (20)  148 (76)/ 22 (11)/ 24 (12)  
 2009- 
2013 
352 159 (50)/ 77 (24)/ 83 (26)  189 (64)/ 50 (17)/ 57 (19)  
ASA    0.008  0.446 
 1 58 37 (72)/ 8 (16)/ 6 (12)  30 (79)/ 5 (13)/ 3 (8)  
 2 214 109 (56)/ 64 (33)/ 22 (11)  132 (75)/ 28 (16)/ 15 (9)  
 3 219 107 (51)/ 57 (27)/ 44 (21)  137 (71)/ 30 (16)/ 25 (13)  
 4 24 7 (33)/ 7 (33)/ 7 (33)  15 (68)/ 2 (9)/ 5 (23)  
BMI    <0.001  0.003 
 <25 186 103 (60)/ 33 (19)/ 35 (21)  97 (70)/ 15 (11)/ 26 (19)  
 >25-30 223 107 (53)/ 70 (35)/ 23 (12)  138 (73)/ 35 (19)/ 15 (8)  
 >30 131 45 (40)/ 39 (34)/ 29 (26)  62 (59)/ 25 (24)/ 18 (17)  
mGPS    <0.001  0.007 
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 0 498 260 (56)/ 128 (28)/ 75 (16)  302 (74)/ 54 (13)/ 50 (12)  
 1 134 50 (41)/ 45 (37)/ 26 (22)  71 (68)/ 21 (20)/ 13 (12)  
 2 100 43 (48)/ 13 (14)/ 34 (38)  55 (61)/ 12 (13)/ 23 (26)  
NLR    <0.001  0.002 
 ≤3 391 177 (49)/ 122 (33)/ 66 (18)  216 (66)/ 60 (18)/ 51 (16)  
 >3 358 184 (59)/ 62 (20)/ 68 (21)  222 (78)/ 27 (10)/ 34 (12)  
Tumour site    0.009  0.076 
 Colon 467 225 (54)/ 126 (30)/ 69 (16)  264 (72)/ 58 (16)/ 43 (12)  
 Rectum 285 136 (52)/ 60 (23)/ 66 (25)  175 (71)/ 29 (12)/ 43 (17)  
Laparoscopic    0.006  0.002 
 No 640 299 (51)/ 158 (27)/ 127 (22)  390 (73)/ 66 (12)/ 79 (15)  
 Yes 112 62 (63)/ 28 (29)/ 8 (8)  49 (64)/ 21 (27)/ 7 (9)  
T Stage    0.007  0.578 
 I 62 23 (42)/ 26 (47)/ 6 (11)  31 (63)/ 11 (22)/ 7 (14)  
 II 106 61 (62)/ 23 (24)/ 14 (14)  62 (71)/ 16 (16)/ 11 (13)  
 III 411 186 (50)/ 102 (27)/ 85 (23)  241 (71)/ 48 (14)/ 49 (15)  
 IV 161 84 (58)/ 34 (23)/ 27 (19)  95 (75)/ 14 (11)/ 18 (14)  
N Stage    0.346  0.065 
 0 474 229 (53)/ 109 (25)/ 94 (22)  275 (72)/ 49 (13)/ 59 (15)  
 I 206 100 (54)/ 58 (31)/ 29 (15)  129 (75)/ 27 (16)/ 15 (9)  
 II 72 32 (51)/ 19 (30)/ 12 (19)  35 (60)/ 11 (19)/ 12 (21)  
Infective 
Complications 
   <0.001  <0.001 
 No 580 316 (61)/ 129 (25)/ 74 (14)  364 (80)/ 53 (12)/ 36 (8)  
 Yes 169 42 (26)/ 57 (36)/ 61 (38)  72 (46)/ 34 (22)/ 50 (32)  
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Table 9.3 Binary logistic regression of clinicopathological factors associated with low poGPS (poGPS 0) versus high poGPS (poGPS 2) on post-
operative day 3 
  
Characteristic Univariate Analysis  Multivariate Analysis  
 HR (95% CI) p-value HR (95% CI) p-value 
Age (<65/ 65-74/ ≥75) 1.04 (0.81-1.32) 0.760 - - 
Sex (Female/ Male) 1.05 (0.71-1.56) 0.804 - - 
Year of Operation 
(99-06/ 07-13) 
3.04 (1.91-4.84) <0.001 4.63 (2.28-9.42) <0.001 
ASA (1/ 2/ 3/ 4) 1.87 (1.31-2.69) 0.001 2.02 (1.25-3.26) 0.004 
BMI 
(<25/ 25-30/>30) 
1.36 (1.02-1.80) 0.033 1.44 (0.94-2.20) 0.090 
mGPS (0/ 1/ 2) 1.67 (1.30-2.15) <0.001 1.97 (1.29-3.01) 0.002 
NLR (≤3/ >3) 0.99 (0.67-1.47) 0.965 - - 
Tumour site 
(Colon/ Rectum) 
1.58 (1.06-2.36) 0.024 2.62 (1.32-5.17) 0.006 
Laparoscopic (No/ Yes) 0.30 (0.14-0.65) 0.002 0.20 (0.05-0.73) 0.015 
T Stage (I/ II/ III/ IV) 1.09 (0.86-1.36) 0.482 - - 
N Stage (0/ I/ II) 0.86 (0.63-1.18) 0.348 - - 
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Table 9.4 Binary logistic regression of clinicopathological factors associated with low poGPS (poGPS 0) versus high poGPS (poGPS 2) on post-
operative day 4  
 
 
Characteristic Univariate Analysis  Multivariate Analysis  
 HR (95% CI) p-value HR (95% CI) p-value 
Age (<65/ 65-74/ ≥75) 0.85 (0.64-1.14) 0.285 - - 
Sex (Female/ Male) 1.06 (0.66-1.68) 0.815 - - 
Year of Operation 
(99-06/ 07-13) 
4.15 (2.27-7.58) <0.001 5.32 (2.49-11.34) <0.001 
ASA (1/ 2/ 3/ 4) 1.55 (1.01-2.38) 0.045 1.61 (1.02-2.55) 0.043 
BMI 
(<25/ 25-30/>30) 
1.03 (0.75-1.43) 0.838 - - 
mGPS (0/ 1/ 2) 1.54 (1.16-2.04) 0.003 1.98 (1.32-2.96) 0.001 
NLR (≤3/ >3) 0.65 (0.40-1.04) 0.073 0.47 (0.24-0.93) 0.031 
Tumour site 
(Colon/ Rectum) 
1.51 (0.95-2.40) 0.082 2.97 (1.49-5.91) 0.002 
Laparoscopic (No/ Yes) 0.71 (0.31-1.61) 0.408 - - 
T Stage (I/ II/ III/ IV) 1.02 (0.79-1.32) 0.865 - - 
N Stage (0/ I/ II) 1.00 (0.70-1.43) 0.998 - - 
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10 Pre-operative aspirin and statin prescription          
and the post-operative systemic inflammatory 
response following surgery for colorectal 
cancer 
10.1 Introduction 
It has been well established that following surgical intervention, the development of a 
systemic inflammatory response (SIR) is considered part of the normal homeostatic 
mechanisms and is an essential component of repair and healing. Furthermore, the 
magnitude of this systemic inflammatory response can be measured using stereotypical 
markers of the systemic inflammatory response such as C-reactive protein (CRP) or 
interleukin-6 (Chapter 5) . 
Despite the use of different skin preparations, the use of prophylactic antibiotics and the 
increased use of laparoscopic surgery and enhanced recovery after surgery (ERAS) 
protocols, infective complications following surgery remains a significant problem. 
Subsequently, attention has focused on early identification of patients who are likely to 
develop or at risk of developing post-operative complications. Recent work has reported 
that a CRP of greater than 150 mg/L on post-operative days 3-5 was associated with the 
development of complications (McDermott et al., 2015). Furthermore, an exaggerated SIR, 
evidenced by the post-operative Glasgow Prognostic Score (poGPS), has been reported to 
be associated not only with the development of infective complications and their severity, 
but also with poorer long term outcomes (McSorley et al., 2016b) (Chapter 7).  
Drugs such as aspirin and statins are commonly prescribed for their anti-platelet function 
to patients with ischaemic heart disease and to treat patients with hypercholesterolaemia. 
Corticosteroids such as dexamethasone are also commonly given around the peri-operative 
period for their anti-emetic properties and have become a staple component of modern 
peri-operative practices. However, these drugs also have anti-inflammatory properties. 
Recently, it has been reported that the use of corticosteroids in the peri-operative period 
causes a reduction in the post-operative systemic inflammatory response and a reduction in 
complications following surgery for gastrointestinal cancer (McSorley et al., 2016a). It 
could therefore be hypothesised that pre-operative use of aspirin and statins may be 
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capable of modulating the post-operative SIR, with the possible benefit of reducing post-
operative complication rates and improving outcomes following surgery for colorectal 
cancer but there is little evidence currently to support this. 
Therefore, the aim of the present study was to determine whether pre-operative use of 
aspirin and statins were associated with a reduced post-operative systemic inflammatory 
response in patients undergoing surgery for colorectal cancer. 
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10.2 Methods 
10.2.1 Patients 
Patients with histologically proven colorectal cancer who, on the basis of intra-operative 
findings and pre-operative computed tomography, were considered to have undergone 
potentially curative resection at a single centre between January 2010 and June 2014 were 
included in the analyses (n = 446). Patient characteristics were collected in a prospectively 
maintained database and all patient data was anonymised. All tumours were staged 
according to conventional tumour, node, metastasis classification and additional 
pathological data obtained from the pathology reports issued at the time of the resection.  
Pre-operatively, all patients received thromboembolism prophylaxis and antibiotic 
prophylaxis as per local protocols. Blood samples were taken as part of routine care of 
patients both pre-operatively and post-operatively. The pre-operative systemic 
inflammatory response was assessed using the modified Glasgow Prognostic Score 
(mGPS) and the post-operative systemic inflammatory response assessed using the post-
operative Glasgow Prognostic Score (poGPS) (Chapter 6).  
Electronic patient case notes were reviewed for pre-operative use of aspirin and statin use.  
Primary care referral letters were the primary source of prescribing data, and pre-operative 
anaesthetic assessment documents and medical clerk-in documents completed on 
admission to hospital were also used if referral letters did not include the appropriate 
information.  For the purposes of the present study, patients who were prescribed aspirin or 
statins at the time of surgery were considered as aspirin or statin users.  Patient co-
morbidity using ASA Physical Status grade, smoking status and body mass index (BMI) 
were all obtained from pre-operative anaesthetic assessments. The West of Scotland 
research ethics committee approved this study.  
10.2.2 Statistical Analysis 
The comparison of categorical variables was performed using Chi square test and of 
continuous variables using the Mann Whitney U test. A two sided p value of <0.05 was 
considered statistically significant. Binary logistic regression was used to examine the 
relationship between aspirin and statin use, clinicopathological characteristics and the 
presence of a systemic inflammatory response, as characterised by poGPS≥1, by 
calculating ORs and 95% CIs.  Variables with P- value ≤0.1 on univariate analysis were 
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entered into a multivariate model using a backwards conditional method.  Statistical 
analysis was performed using SPSS version 22.0 for Windows (IBM, SPSS, IL, USA). 
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10.3 Results 
The clinicopathological characteristics of the 446 included patients are shown in Table 
10.1. The majority of patients were over the age of 65 years old (64%), male (57%), had 
elective surgery (91%), had colon cancer (59%) and had node negative disease (63%). The 
majority of patients had a BMI >25 (74%) and had open surgery (63%). The majority of 
patients were not systemically inflamed pre-operatively (mGPS = 0, 75%). 120 patients 
were prescribed aspirin and 187 patients prescribed a statin with 100 patients prescribed 
both aspirin and a statin. 
The relationship between aspirin and statin use and clinicopathological characteristics is 
shown in Table 10.1. Aspirin prescription was significantly associated with increasing age 
(p<0.001), male sex (p<0.05), less pre-operative systemic inflammation (p<0.05) and 
increasing ASA grade (p<0.05). Statin prescription was significantly associated with 
increasing age (p<0.001) and increasing ASA grade (p<0.001). 
The relationship between aspirin and statin prescription, the post-operative systemic 
inflammatory response and post-operative complications is shown in Table 10.2. On post-
operative day 3, 50% had a poGPS 0, 23% a poGPS 1 and 27% a poGPS 2. Neither aspirin 
nor statin prescription was significantly associated with the day 3 poGPS. On post-
operative day 4, 61% had a poGPS 0, 17% a poGPS 1 and 22% a poGPS 2. Neither aspirin 
nor statin prescription was significantly associated with the day 4 poGPS. Aspirin 
prescription was associated with the development of more complications of any type as 
was statin prescription (p≤0.05). Statin prescription was also associated with the 
development of more non-infective complications (p<0.05). 
The relationship between aspirin and statin prescription, the post-operative systemic 
inflammatory response and post-operative complications in patients who were systemically 
inflamed preoperatively (mGPS≥1) is shown in Table 10.3. On day 3, 36% had a poGPS 0, 
17% a poGPS 1 and 47% poGPS 2. Neither aspirin prescription nor statin prescription was 
significantly associated with the day 3 poGPS . On day 4, 48% had a poGPS 0, 18% a 
poGPS 1 and 33% a poGPS 2. Neither aspirin prescription nor statin prescription was 
significantly associated with the day 4 poGPS.  In this cohort of systemically inflamed 
patients, neither aspirin nor statin prescription was associated with the development of 
complications.       
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The relationship between aspirin and statin prescription and an elevated day 3 poGPS is 
shown in Table 10.4. On binary logistic regression, emergency presentation and open 
surgery, were significantly associated with an elevated poGPS. On multivariate analysis, 
open surgery, emergency presentation and male sex were independently associated with an 
elevated poGPS. Neither aspirin nor statin prescription was associated with an elevated day 
3 poGPS.  
The relationship between aspirin and statin prescription and an elevated day 4 poGPS is 
shown in Table 10.5. On binary logistic regression, none of the factors examined were 
associated with an elevated day 4 poGPS.  
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10.4 Discussion 
The results of the present study showed that the prescription of aspirin, but not statin, prior 
to surgery was associated with a lower pre-operative systemic inflammatory response in 
patients undergoing surgery for colorectal cancer.  However, the prescription of aspirin and 
statin was not associated with moderation of the post-operative systemic inflammatory 
response even when adjusted for the presence of systemic inflammation prior to surgery.  
Therefore, it would appear that at therapeutic doses given in patients with colorectal 
cancer, aspirin and statin are unlikely to be useful in the moderation of the post-operative 
systemic inflammatory response. 
Although this is the first study, to our knowledge, to examine the effect of aspirin and 
statins on post-operative systemic inflammation and outcomes, there has been a long 
recognised relationship between the administration of aspirin and improved survival in 
patients with colorectal cancer (Frouws et al., 2017b).  The basis of the latter relationship is 
not clear.  However, inflammatory mechanisms have been implicated in the beneficial 
effect.  From the results of the present study it is clear that aspirin has a modest or little 
effect on the systemic inflammatory response.  This would therefore implicate a direct 
effect of aspirin on the tumour or its microenvironment as a plausible mechanism.  For 
example, aspirin not only down regulates the cyclo-oxygenase enzyme in the tumour and 
stromal cells but also in platelets, preventing production of thromboxane A2 and hence 
preventing normal activation of the platelet (Sanchez et al., 2012).  Indeed, consistent with 
this concept, recent work suggests that aspirin, given prior to or following diagnosis, 
improves survival in a number of gastrointestinal malignancies (Frouws et al., 2017a).  
Nevertheless, compared with other anti-inflammatory agents such as dexamethasone 
(McSorley et al., 2017) the effect of aspirin and statins on post-operative systemic 
inflammation and outcomes is much less. 
It was of interest in the present study that patients on both aspirin and statin had an even 
greater reduction in the post-operative systemic inflammatory response. It has been 
previously reported that aspirin and statins appear to act synergistically, resulting in 
reduced concentrations of CRP (Fisher et al., 2008) and reduced rates of severe sepsis 
(O’Neal et al., 2011). To date there have been no studies examining the effect of aspitrin 
and statins on post-operative systemic inflammation or on outcomes following elective 
surgery. It would be of interest to see whether the reduction in systemic inflammation in 
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the present study in patients prescribed aspirin and statins resulted in improved short term 
outcomes. 
Aspirin and statin use was significantly associated with the development of any type of 
post-operative complication. Statins were significantly associated with development of 
non-infective complications. This may represent the fact that patients who developed 
complications were also those patients with existing medical co-morbidities that put them 
at increased risk of developing complications. In particular with non-infective 
complications, many of which tend to be cardiovascular in nature, the fact that patients on 
statins were more likely to develop these types of complications highlighted the 
importance that existing medical co-morbidities plays on the nature of the post-operative 
course and may not be directly related to usage of the drug at all.  
One potential limitation of the present study was the small sample size. Whilst the study 
included 446 patients, only 100 patients were on both aspirin and statins with 120 patients 
on aspirin alone. It may be that the results of this chapter are due to the relatively small 
sample size and that a larger group of patients on aspirin and statins may yield different 
results. It would be of interest to conduct similar work in the future on the back of a larger 
group of patients to see whether the results remained the same or whether aspirin and 
statins did indeed moderate the post-operative systemic inflammatory response.     
In summary, the prescription of aspirin and statin was not associated with moderation of 
the post-operative systemic inflammatory response even when adjusted for the presence of 
systemic inflammation prior to surgery.   
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Table 10.1 Clinicopathological characteristics of patients undergoing surgery for colorectal cancer 
 
  All  Aspirin use   Statin use  
Clinical characteristics  (n=446) 
(%) 
 No aspirin (n=326) 
(%) 
Aspirin (n=120) 
(%) 
P-
value 
 No statin (n=259) 
(%) 
Statin (n=187) 
(%) 
P-
value 
Age  
<65 
65-74 
>74 
  
159 (36) 
170 (38) 
117 (26) 
  
136 (42) 
110 (34) 
80 (24) 
 
23 (19) 
60 (50) 
37 (31) 
<0.001   
114 (44) 
92 (35) 
53 (21) 
 
45 (24) 
78 (42) 
64 (34) 
<0.001 
Sex  
Female 
Male 
  
191 (43) 
255 (57) 
  
151 (46) 
175 (54) 
 
40 (33) 
80 (67) 
0.014   
119 (46) 
140 (54) 
 
72 (38) 
115 (62) 
0.117 
Presentation 
 
 
 
Elective 
Emergency 
  
402 (91) 
42 (9) 
  
292 (90) 
33 (10) 
 
110 (92) 
9 (8) 
0.409   
232 (90) 
26 (10) 
 
170 (91) 
16 (9) 
0.600 
 
mGPS       0.037    0.782 
 0  323 (75)  223 (71) 99 (83)   183 (73) 139 (76)  
 1  42 (10)  33 (11) 9 (8)   25 (10) 17 (9)  
 2  67 (15)  56 (18) 11 (9)   41 (17) 26 (14)  
ASA grade 
 
 
I 
II 
III 
IV 
  
21 (16) 
53 (39) 
54 (40) 
7 (5) 
  
19 (20) 
41 (42) 
33 (34) 
4 (4) 
 
2 (5) 
12 (32) 
21 (55) 
3 (7) 
0.042   
20 (25) 
34 (42) 
22 (28) 
4 (5) 
 
1 (2) 
19 (34) 
32 (58) 
3 (6) 
<0.001 
BMI 
 
 
<25 
  
87 (26) 
  
65 (27) 
 
22 (24) 
0.803   
58 (31) 
 
29 (20) 
0.083 
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25-30 
>30 
141 (43) 
102 (31) 
 
100 (42) 
75 (31) 
41 (46) 
27 (30) 
78 (41) 
52 (28) 
63 (44) 
50 (35) 
Tumour Site 
 
 
 
Colon 
Rectum 
  
268 (64) 
153 (36) 
  
197 (65) 
107 (35) 
 
71 (61) 
46 (39) 
0.431   
149 (61) 
95 (39) 
 
119 (67) 
58 (33) 
0.194 
Tumour 
Location 
      0.366    0.391 
 Right  162 (36)  115 (35) 47 (39)   88 (34) 74 (40)  
 Left  84 (19)  64 (20) 20 (17)   48 (19) 36 (19)  
 Rectum  182 (41)  131 (40) 51 (42)   114 (44) 68 (36)  
 Other  18 (4)  16 (5) 2 (2)   9 (3) 9 (5)  
TNM Stage       0.655    0.219 
 I  101 (25)  71 (23) 30 (26)   54 (22) 47 (26)  
 II  170 (39)  124 (39) 46 (39)   99 (39) 71 (39)  
 III  158 (36)  117 (37) 41 (35)   93 (37) 65 (35)  
Laparoscopic       0.256    0.805 
 No  282 (63)  201 (62) 81 (67)   165 (64) 117 (63)  
 Yes  164 (37)  125 (38) 39 (33)   94 (36) 70 (37)  
Corticosteroid 
Use 
      0.618    0.771 
 No  146 (43)  105 (42) 41 (46)   81 (43) 65 (44)  
 Yes  191 (57)  142 (58) 49 (54)   109 (57) 82 (56)  
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Table 10.2 The relationship between aspirin and statin use, the post-operative systemic inflammatory response and post-operative complications in 
patients undergoing potentially curative resection of stage I-III colorectal cancer  
 
  All  Aspirin use   Statin use  
Clinical characteristics 
 
 (n=446) 
(%) 
 No aspirin (n=326) 
(%) 
Aspirin (n=120) 
(%) 
P-
value 
 No statin (n=259) 
(%) 
Statin (n=187) 
(%) 
P-
value 
Day 3 poGPS       0.623    0.338 
 0  206 (50)  145 (49) 61 (53)   111 (47) 95 (54)  
 1  95 (23)  72 (24) 23 (20)   59 (25) 36 (20)  
 2  112 (27)  81 (27) 31 (27)   67 (28) 45 (26)  
Day 4 poGPS       0.303    0.213 
 0  220 (61)  151 (58) 69 (67)   117 (57) 103 (66)  
 1  61 (17)  47 (18) 14 (14)   36 (18) 25 (16)  
 2  81 (22)  61 (24) 20 (19)   52 (25) 29 (18)  
Any Complication       0.040    0.050 
 No  243 (55)  187 (58) 56 (47)   151 (59) 92 (50)  
 Yes  195 (45)  133 (42) 62 (53)   103 (41) 92 (50)  
Infective 
Complications 
      0.159    0.613 
 No  308 (70)  231 (72) 77 (65)   181 (71) 127 (69)  
 Yes  130 (30)  89 (28) 41 (35)   73 (29) 57 (31)  
Non-infective 
Complications 
      0.608    0.034 
 No  345 (79)  254 (79) 91 (77)   209 (82) 136 (74)  
 Yes  93 (21)  66 (21) 27 (23)   45 (18) 48 (26)  
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Table 10.3 The relationship between aspirin and statin use, the post-operative systemic inflammatory response and post-operative complications in 
patients undergoing curative resection of stage I-III colorectal cancer with an mGPS ≥1 
 
  All  Aspirin use   Statin use  
Clinical characteristics 
 
 (n= 109) 
(%) 
 No aspirin (n=89) 
(%) 
Aspirin (n=20) 
(%) 
P-
value 
 No statin (n=66) 
(%) 
Statin (n=43) 
(%) 
P-
value 
Day 3 poGPS       0.142    0.670 
 0  36 (36)  30 (37) 6 (30)   19 (32) 17 (40)  
 1  17 (17)  16 (20) 1 (5)   10 (17) 7 (17)  
 2  48 (47)  35 (43) 13 (65)   30 (51) 18 (43)  
Day 4 poGPS       0.163    0.833 
 0  45 (48)  36 (49) 9 (47)   26 (46) 19 (51)  
 1  17 (18)  16 (22) 1 (5)   10 (18) 7 (19)  
 2  31 (33)  22 (30) 9 (47)   20 (36) 11 (30)  
Any Complication       0.964    0.906 
 No  54 (49)  44 (50) 10 (50)   33 (50) 21 (49)  
 Yes  55 (51)  45 (50) 10 (50)   33 (50) 22 (51)  
Infective 
Complications 
      0.594    0.997 
 No  71 (65)  59 (66) 12 (60)   43 (65) 28 (65)  
 Yes  38 (35)  30 (34) 8 (40)   23 (35) 15 (35)  
Non-infective 
Complications 
      0.108    0.733 
 No  83 (76)  65 (73) 18 (90)   51 (77) 32 (74)  
 Yes  26 (24)  24 (27) 2 (10)   15 (23) 11 (26)  
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Table 10.4 The relationship between aspirin and statin use, clinicopathological characteristics and the day 3 poGPS in patients undergoing potentially 
curative resection of stage I-III colorectal cancer 
 
  poGPS=0 poGPS≥1  Univariate OR 
(95% CI) 
P-
value 
 Multivariate OR 
(95% CI) 
P-
value 
Age (<65/ 65-74/ >74)  76/86/44 68/73/66  1.27 (0.99-1.63) 0.058  1.26 (0.97-1.64) 0.083 
Sex (Female/ Male)  96/110 78/129  1.44 (0.98-2.14) 0.067  1.63 (1.07-2.47) 0.022 
ASA grade (I/ II/ III/ IV)  11/26/21/3 9/24/32/4  1.34 (0.87-2.07) 0.188  - - 
BMI (<25/ 25-30/ >30)  40/76/47 40/54/52  1.07 (0.80-1.44) 0.650  - - 
Presentation (Elective/ 
Emergency) 
 196/8 177/30  4.15 (1.86-9.30) 0.001  3.36 (1.46-7.72) 0.004 
Laparoscopic (No/ Yes)  110/96 159/48  0.35 (0.23-0.53) <0.001  0.39 (0.25-0.61) <0.001 
Tumour site (Colon/ Rectum)  122/77 127/65  0.81 (0.54-1.23) 0.320  - - 
TNM Stage (I/ II/ III)  37/49/49 34/56/54  1.18 (0.89-1.57) 0.257  - - 
Aspirin (No/ Yes)  145/61 153/54  0.84 (0.55-1.29) 0.425  - - 
Statin (No/ Yes)  111/95 126/81  0.75 (0.51-1.11) 0.152  - - 
Aspirin & Statin (No/ Yes)  102/104 116/91  0.77 (0.52-1.13) 0.185  - - 
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Table 10.5 The relationship between aspirin and statin use, clinicopathological characteristics and the day 4 poGPS in patients undergoing potentially 
curative resection of stage I-III colorectal cancer 
 
  poGPS=0 poGPS≥1  Univariate OR 
(95% CI) 
P-
value 
 Multivariate OR 
(95% CI) 
P-
value 
Age (<65/ 65-74/ >74)  70/89/61 52/48/42  0.95 (0.73-1.25) 0.727  - - 
Sex (Female/ Male)  97/123 52/90  1.37 (0.89-2.10) 0.159  - - 
ASA grade (I/ II/ III/ IV)  10/30/30/4 6/15/22/3  1.17 (0.74-1.88) 0.502  - - 
BMI (<25/ 25-30/ >30)  32/84/46 27/34/38  1.05 (0.74-1.47) 0.792  - - 
Presentation (Elective/ 
Emergency) 
 204/15 122/20  2.23 (1.10-4.52) 0.026  - - 
Laparoscopic (No/ Yes)  147/73 106/36  0.68 (0.43-1.10) 0.114  - - 
Tumour site (Colon/ Rectum)  125/89 84/46  0.77 (0.49-1.21) 0.254  - - 
TNM Stage (I/ II/ III)  38/53/53 23/41/39  1.18 (0.86-1.61) 0.303  - - 
Aspirin (No/ Yes)  151/69 108/34  0.69 (0.43-1.11) 0.128  - - 
Statin (No/ Yes)  117/103 88/54  0.70 (0.45-1.07) 0.100  - - 
Aspirin & Statin (No/ Yes)  107/113 80/62  0.73 (0.48-1.12) 0.153  - - 
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11   Conclusions 
Although perhaps underappreciated, the systemic inflammatory response has now been 
established as a key determinant of cancer progression and outcome (Shinko et al., 2017). 
Patients with systemic inflammation have a 50% reduced survival compared to those who 
don’t and make up approximately 30-50% of patients with advanced cancer (Shinko et al., 
2017). Its presence, in a range of common tumour types, prior to treatment whether that be 
surgical or oncological, has been shown to adversely affect outcomes, resulting in 
increased rates of recurrence and poorer long term survival. This thesis sought to gain a 
greater understanding of the role that the systemic inflammatory response plays in the 
development and progression of cancer, specifically colorectal cancer. Work performed 
over the last two decades has demonstrated the importance that pre-operative systemic 
inflammation plays in outcomes for patients with a range of cancers as well as colorectal 
cancer (Guthrie et al., 2013a, McMillan, 2013b). The biology of not only the tumour itself, 
but of the host as well and the complex interaction between the two is thought to drive 
cancer progression (Hanahan and Weinberg, 2011). Whilst the systemic inflammatory 
response has been associated with poorer long term survival, the presence of a local 
inflammatory response has been reported to have beneficial effects on survival (Roxburgh 
and McMillan, 2012, Richards et al., 2012a). These inflammatory changes are generated 
by the innate, adaptive and humoral immune systems. Whilst the majority of previous 
work focussed on the changes relating to the adaptive immune response, more recently it 
has become apparent that components of the innate immune system (neutrophils, 
monocytes/macrophages and myeloid derived suppressor cells) and the humoral response 
(complement, collectins and pentraxins) have complex interactions that can result in an 
exaggerated systemic inflammatory response and are detrimental to the host. 
Chapter 1 describes an overview of colorectal cancer and its current management. Chapter 
2 details the results of a survey of clinicians who have recently published articles related to 
systemic inflammation and cancer. The survey aimed to establish the different opinions of 
worldwide experts on the use of systemic inflammation based scoring systems including 
the 2 most reported ones – the mGPS and the NLR- what their main use was and whether 
they should be incorporated into more into current clinical practice. Despite relatively low 
response rate (25%) we found that the majority of respondents used the GPS/mGPS as 
their score of preference and mainly for research and prognostication purposes. The fact 
that few respondents used these scores in clinical practice was disappointing but perhaps 
not surprising. It is probably unlikely that surgical treatment would be determined by these 
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scores, especially in potentially curable disease. However, the emergence of these scores 
into some clinical trials, in particular oncological trials in patients with advanced disease 
perhaps signals a step in the right direction (e.g. Hurwitz et al., 2015). Further evidence of 
their clinical utility in the context of randomised controlled trials will strengthen the 
argument for incorporation into routine clinical practice. 
Chapter 3 aimed to determine whether any of the components of the pre-operative white 
cell count were associated with survival following surgery for colorectal cancer. It was 
thought important to ascertain whether both components of the NLR were equally 
weighted in terms of their effect on survival. The neutrophil count was the one component 
that was associated with cancer-specific survival. Therefore, the prognostic effect seen 
with the NLR was thought to be mainly driven by the neutrophil count and that further 
prognostic scores utilising the white cell count components should incorporate the 
neutrophil count but not necessarily the lymphocyte count. Indeed, many scores now 
incorporate the neutrophil count such as the optimised Glasgow Prognostic Score (oGPS) 
(Chapter 3) and the systemic immune-inflammation index (Geng et al., 2016).  
In an attempt to utilise the neutrophil count in an optimal innate scoring system, and with 
recent in-vitro work suggesting that both neutrophils and platelets played a key role early 
in the development of the inflammatory process, a new scoring system based on both the 
pre-operative neutrophil and platelet counts was created using existing thresholds. The aim 
of chapter 4 was to determine whether this score, termed the Neutrophil-Platelet score 
(NPS) was capable of predicting long term outcomes in patients with cancer. In patients 
with colorectal cancer, the NPS was associated with cancer-specific survival, particularly 
in those with node negative disease. Moreover, in those patients with a range of common 
cancers, an incremental increase in the NPS was significantly associated with poorer 
cancer-specific survival. These findings further impress the importance of activation of the 
innate immune system in determining long term outcomes in patients with cancer. 
However, validation of these neutrophil-based prognostic scores is required in the context 
of randomised controlled trials in order to confirm their clinical utility. 
Neutrophils are the most common leucocyte found in in blood. They are primarily 
responsible for protecting the host against inflammation and infection and are often 
referred to as the ‘first line of defence’ (Uribe-Querol and Rosales, 2015). Once they reach 
the site of injury or inflammation they destroy micro-organisms by either phagocytosis, 
secretion of anti-microbial substances or formation of neutrophil extracellular traps 
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(NETs). In patients with cancer, neutrophils are often found in abundance in the 
bloodstream. They can display both anti-tumour behaviour or can stimulate cancer 
progression (Coffelt et al., 2016). Which behaviour these neutrophils follow depends on a 
variety of signals received from the tumour itself or from stromal cells within the tumour 
microenvironment. It is possible that tumour production of granulocyte-macrophage 
colony stimulating growth factor (GM-CSF) and other cytokines such as IL-1 and IL-6 
may contribute to increased circulating neutrophil numbers (Uribe-Querol and Rosales, 
2015). Elevated circulating levels of neutrophils are associated with poorer outcomes in 
patients with lung cancer (Atzpodien and Reitz, 2008), melanoma (Schmidt et al., 2005), 
renal cancer (Atzpodien and Reitz, 2008) and in this thesis was shown to be associated 
with poorer survival in patients with colorectal cancer (Chapter 3).  
Neutrophils have therefore emerged as potential therapeutic target in patients with cancer. 
Preventing activation of the neutrophil has been suggested as a possible intervention that 
may improve outcomes. Tumours can secrete chemokines such as IL-8 which attract 
neutrophils. Blockade of this pathway using an IL-8 antagonist has been shown to reduce 
tumour growth and metastasis in lung cancer (Huang et al., 2002). Similarly, blockade of 
chemokine receptors such as CXCR-1 and CXCR-2 would not only block IL-8 but also 
other chemokines responsible for neutrophil recruitment. Trials using a CXCR-2 
antagonist in patients with chronic obstructive pulmonary disease have reported that 
treatment resulted in reduced neutrophil counts, inflammatory markers and symptoms 
(Rennard et al., 2015). Currently clinical trials analysing the effect of and CXCR-1and 
CXCR-2 antagonist are ongoing in breast cancer (USNLM, 2015) and pancreatic cancer 
(USNLM, 2015). The results of these trials are eagerly anticipated and may provide the 
basis for new therapeutic regimens for a variety of cancers.  
Surgery itself is responsible for generating a significant systemic inflammatory response, 
including upregulation of the innate immune response and subsequent downregulation of 
cell mediated immunity (Marik and Flemmer, 2012). This places a great strain on the 
hosts’ anti-tumour defences and can be further compounded by factors that exaggerate the 
systemic inflammatory response such as emergency surgery and the development of 
infective complications (Roxburgh et al., 2013). Surgery for colorectal cancer in the 
presence of both of these factors is associated with very poor outcomes, irrespective of 
tumour stage (Roxburgh and McMillan, 2010). Therefore, modification of the hosts’ 
immune response, by way of downregulating or moderating the innate and humoral 
response may be beneficial in preventing cancer progression and dissemination (Roxburgh 
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and McMillan, 2016). How this is achieved is still unclear, however this thesis sought to 
clarify whether any particular components of the innate immune system are more 
important, how best to monitor the innate immune response and whether modification of 
this response using routine anti-inflammatory medications is of benefit. 
It has long been established that following surgical insult, a stereotypical cascade of mainly 
acute phase and metabolic responses occurs. This is often referred to as the surgical stress 
response but is perhaps better known as the systemic inflammatory response. Whilst it has 
anecdotally been reported that certain markers of the SIR can reflect a degree of surgical 
injury, however there has never been any formal review to analyse this concept in more 
detail. Chapter 5 aimed to identify from 4 common markers of the systemic inflammatory 
response (cortisol, IL-6, CRP and white cell count) whether any of these were indicative of 
the degree of surgical trauma and if so which ones were the most representative of this 
trauma. A systematic review of the literature was performed and for each analyte, surgical 
procedures grouped into minor, moderate and severe. From 164 studies, analysing 14,362 
patients IL-6 and CRP appear to be associated with the magnitude of surgical injury; 
cortisol and white cell count were not. CRP is more readily available in clinical practice 
and perhaps the best marker to use in clinical practice. Furthermore, CRP would appear the 
most useful marker for observing the magnitude of the post-operative SIR. This highly 
cited observation has many potential uses. In particular, it could be used to analyse the 
effect of individual ERAS components and anaesthesia techniques on the systemic 
inflammatory response in order to create the optimal ERAS programme that minimises the 
systemic inflammatory response.  
Given that the WCC itself did not appear to reflect the degree of surgical trauma, Chapter 6 
sought to clarify whether different components of the white cell count responded 
differently to surgical trauma and whether any of these individual components were helpful 
in predicting the development of post-operative complications. In this chapter, the 
neutrophil and monocyte counts were significantly raised following surgery compared to 
pre-operative values whilst eosinophils and basophils fell. When comparing laparoscopic 
and open procedures, laparoscopic surgery was associated with lower neutrophil counts but 
higher lymphocyte and monocyte counts. This would appear to indicate that neutrophils 
and lymphocytes reflect the magnitude of surgical trauma, with this being an inverse 
response in the case of lymphocytes. Regardless of method of surgery, neutrophils were 
associated with the development of infective complications. Therefore, the neutrophil 
count, which composes the majority of the white cell count itself, can be used to monitor 
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both surgical trauma and the development of infective complications. However, when 
compared to markers of the systemic inflammatory response that are already widely used 
such as CRP, it is inferior. Nonetheless, considering that neutrophils are a key component 
of the innate immune system, it provides further evidence of it importance in determining 
short term outcomes following surgery for colorectal cancer.     
As well as having elevated concentrations of neutrophils, patients with cancer often have 
an increased number of immature myeloid cells at earlier stages of differentiation (Uribe-
Querol and Rosales, 2015), collectively referred to as myeloid-derived suppressor cells 
(MDSC). These cells increase in number in pathological conditions such as cancer, 
infection and inflammation and can supress both the innate and adaptive immune responses 
and may contribute to cancer progression (Coffelt et al., 2016, Motallebnezhad et al., 
2016). Multiple studies have found that MDSCs are involved both directly and indirectly in 
tumour progression by stimulating angiogenesis (Murdoch et al., 2008) and metastatic 
potential of cancer cells (Alizadeh et al., 2014). Therefore, by directly targeting these cells 
in order to destroy them or limit their function, it may be possible to improve treatment 
efficacy in patients with cancer (Motallebnezhad et al., 2016).  
This can be achieved in a number of ways such as inhibition of MDSC recruitment 
(currently being tested using various antibodies, tyrosine kinase inhibitors and antagonists 
of CXCR2 and CXCR4); by induction of MDSC differentiation (using vitamin D3 and All 
trans-retinoic acid); by inhibiting MDSC suppressive activity (using COX-2 inhibitors or 
phosphodiesterase-5 inhibitors) and by inducing apoptosis in MDSCs (using different 
chemotherapeutic agents such as gemcitabine, doxorubicin and 5-fluoroucil) (Wesolowski 
et al., 2013, Pan et al., 2015, Motallebnezhad et al., 2016). All of these approaches are 
under investigation in animal models and some in early clinical trials. Whilst some have 
shown promise in animal models, MDSCs methods of action are multiple and complex and 
may require multi-targeted therapies to overcome their detrimental effect (Pan et al., 2015). 
However, these trials using animal models have limited clinical utility due to the varied 
functions seen in human MDSCs. As such large, further prospective clinical trials are 
required to establish the effectiveness of MDSCs as therapeutic targets and subsequently 
refine the therapeutic options in an attempt to improve cancer outcomes (Wesolowski et 
al., 2013, Pan et al., 2015).    
It has been well established that the presence of pre-operative systemic inflammation is 
associated with increased rates of post-operative complications and poorer long term 
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survival. Therefore, it is perhaps surprising that investigation of the post-operative 
systemic inflammatory response and its association with both short term and long term 
outcomes following surgery for colorectal cancer would appear not to have been examined. 
In chapter 7, a prognostic scoring system utilising 2 key components of the systemic 
inflammatory response (CRP and albumin) was constructed in a similar way to the mGPS 
in order to determine whether it was capable of predicting outcomes. In a retrospectively 
collected test cohort and a prospectively collected validation cohort, raised CRP and 
reduced albumin concentrations were associated with infective complications. 
Furthermore, this new prognostic scoring system, the poGPS, on post-operative days 3 and 
4 was associated with incremental increases in infective complication rates and 
complication severity. It was also associated with overall survival. This highlights the fact 
that the presence of systemic inflammation, either pre- or post-operatively, was associated 
with poor outcomes in patients undergoing surgery for colorectal cancer. Given that many 
interventions that occur in the peri-operative period may affect the degree of post-operative 
inflammation these findings raise the possibility of the poGPS being used as a therapeutic 
target for medications or peri-operative protocols designed to dampen this inflammatory 
response and potentially improve outcomes following colorectal cancer surgery. Further 
work is required with regards to this. 
Enhanced Recovery after Surgery (ERAS) programmes have revolutionised peri-operative 
care and are promoted as reducing the surgical stress response or systemic inflammatory 
response. However the objective evidence of this reduced SIR was very limited and it was 
also not clear which specific components of these ERAS programmes were most valuable 
in terms of reducing the SIR. Therefore, Chapter 8 sought to establish which of the ERAS 
components reduced the systemic inflammatory response using objective markers of this 
response such as CRP or IL-6. A systematic review incorporating 19 studies and 1,898 
patients established that only laparoscopic surgery objectively reduced the systemic 
inflammatory response. Further research into this area is warranted and may identify other 
components that also reduce the systemic inflammatory response, thus creating a more 
streamlined ERAS programme that provides maximal benefit to patients in improving 
outcomes following surgery. 
Given the importance of the post-operative systemic inflammatory response, Chapter 9 
aimed to determine which of the common clinicopathological factors are associated with 
the magnitude of this post-operative response. This has potential future benefit as some of 
these factors may be modifiable and therefore could act as possible therapeutic targets. Of 
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the clinicopathological factors assessed, the day 3 poGPS was significantly associated with 
males, ASA grade, BMI, pre-operative systemic inflammation, laparoscopic surgery, rectal 
tumours and T stage whilst the day 4 poGPS was significantly associated with BMI, pre-
operative systemic inflammation and laparoscopic surgery. In binary logistic regression, 
after adjustment for year of surgery, only mGPS, ASA and tumour site were independently 
associated with a greater magnitude of the post-operative systemic inflammatory response. 
These results further strengthen the argument for the majority of colorectal cancer surgery 
to be performed laparoscopically and highlight the importance of pre-operative 
inflammation in outcomes following cancer surgery. It remains to be seen whether 
targeting those patients who are inflamed prior to surgery with anti-inflammatory 
medication will improve outcomes. 
For example, whether pre-operative usage of aspirin and statin have any effect on the 
systemic inflammatory response following surgery for colorectal cancer is not clear. In 
Chapter 10, aspirin and statin prescription was collated retrospectively on patients whom 
had undergone surgery for colorectal cancer. Aspirin prescription was associated with 
increasing age, male sex and comorbidity. Statin prescription was also associated with 
male sex and comorbidity. Patients on either aspirin or a statin had reduced post-operative 
CRP concentrations compared to those on neither. Patients on both an aspirin and a statin 
had even lower post-operative CRP concentrations, suggesting a synergistic effect of these 
drugs. Aspirin use but not statin use was inversely associated with systemic inflammation 
pre-operatively whilst neither aspirin nor statin use was associated with the post-operative 
systemic inflammatory response, as evidenced by the poGPS on either day 3 or 4. Aspirin 
and statin use was also associated with an increase in complications, specifically non-
infective complications. Overall it was concluded that aspirin and statin usage is not 
associated with the post-operative systemic inflammatory response and had no effect on 
infective complications following surgery but may have an effect on the rate of infective 
complications. Randomised controlled trials in larger cohorts of patients may be required 
to establish whether these drugs are of benefit in patients undergoing surgery for colorectal 
cancer.  
The use of pre-operative aspirin and statins results in reduced post-operative CRP 
concentrations but it remains unclear whether it has a beneficial effect on outcomes 
following surgery (Chapter 8). Corticosteroids given at induction of anaesthesia are 
reportedly associated with reduced nausea and vomiting (Karanicolas et al., 2008) with 
dexamethasone now a key component in many ERAS programmes. As well as its anti-
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emetic properties, recent systematic reviews suggest that administration of corticosteroids 
peri-operatively results in reduced length of stay, reduced post-operative complications and 
a reduced post-operative inflammatory response (Srinivasa et al., 2011, McSorley et al., 
2016a). A recent retrospective study reported in 556 patients undergoing surgery for 
colorectal cancer, the effect of pre-operative dexamethasone on the post-operative systemic 
inflammatory response and development of complications. The authors report that 
dexamethasone use was associated with significantly reduced post-operative systemic 
inflammatory response and reduced complications (McSorley et al., 2017). These findings 
raise the unique possibility of a simple pharmacological strategy capable of reducing post-
operative complications, presumably via its effect of dampening the post-operative 
inflammatory response. Importantly, despite long standing concerns regarding 
corticosteroids and their effect on wound healing and anastomotic leak, the authors report 
no increase in either adverse event (McSorley et al., 2017). However, this observation 
would be best tested in a prospective randomised trial.  
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11.1 Future Research 
This thesis highlights the importance of systemic inflammation based prognostic scores, in 
particular those that reflect the innate immune system in patients with colorectal cancer. 
However their use in routine clinical practice remains small, prospective studies utilising 
these scores that demonstrate their prognostic significance may enhance their usage. The 
use of medications in particular corticosteroids has been reported retrospectively to reduce 
the post-operative systemic inflammatory response without increasing complications. A 
prospective RCT analysing their effect on both short term and long term effects would be a 
major step forward in perioperative care as if it demonstrated improved outcomes by 
reducing the post-operative SIR then it would signify a new standard of care in patients 
under-going surgery for colorectal cancer.   
In summary, both the pre-operative systemic inflammatory response (e.g. the mGPS) and 
the post-operative systemic inflammatory response (e.g. the poGPS) are associated with 
poorer short term and long term outcomes in patients with colorectal cancer. As a result the 
systemic inflammatory response has become a therapeutic reference point to which pre- 
and post-operative anti-inflammatory treatments may be compared. In particular, from the 
present work, the magnitude of the post-operative systemic inflammatory response may be 
used to examine the value of different components of ERAS protocols. Such an approach 
will help to rationalise post-operative care in patients undergoing surgery for colorectal 
cancer.  
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